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The scope of the thesis 
 
In a multi-cellular organism, every somatic cell nucleus broadly contains the same 
sequence of DNA, yet clearly most cells are very different to each other. Specific sets of 
genes encoding proteins become activated whereas others are repressed. Within the 
genome, independently regulated genes are often found in close proximity to other 
genes that have different patterns of expression. How specific gene loci are organised in 
nuclear space is only recently emerging. CTCF is a protein that has been strongly 
implicated in mediating many distinct processes of gene regulation, including 
transcription, chromatin structure, and the structural organisation of gene loci. The aim of 
this thesis was to investigate the function of the CTCF protein in vivo, in particular the 
role of CTCF in regulating cellular proliferation, differentiation and the organisation of 
gene loci within the nucleus.  
The introduction aims to give an overview of the information required to 
understand the foundations of studies presented and discussed in this thesis. The 
transcription or activation of genes occurs in the cell nucleus and requires specific 
modifications of chromatin. Chapter 1 describes the formation of chromatin and key 
factors that modify this structure. How transcription is initiated, and influenced by cis-
regulatory elements is also discussed. Since the initial characterisation as a transcription 
factor, many structural and regulatory functions have been attributed to CTCF, as 
detailed in chapter 2, which imply CTCF is a key regulator of development and cell 
viability. The haematopoietic system is used in this thesis as a model for investigating 
the function of CTCF in two distinct lineages. In chapter 3 the development of 
erythrocytes and T-lymphocytes is introduced.  
Chapters 4 and 5 describe the experiments used to address questions regarding 
CTCF function at the β-globin locus and during T-cell differentiation respectively. 
Published data strongly demonstrate the clustering of cis-regulatory elements into an 
active chromatin hub (ACH) facilitates transcriptional activation of the β-globin locus. 
Studies presented in this thesis reveal CTCF is required for normal ACH formation, but 
suggest additional elements may be required to regulate β-globin gene transcription. By 
deleting CTCF in T-cells we show that CTCF is necessary for the expansion of T-cells 
within the thymus. Moreover, CTCF is required for cytokine expression in T-helper type-2 
cells and it is shown that CTCF may mediate T-cell receptor signaling.  
Chapter 6 describes the generation of GFP-CTCF knock-in mice. The data show 
two distinct dynamic populations of CTCF exist within the nucleus, with the majority of 
the protein rendered largely immobile. GFP-CTCF is demonstrated to be a functional 
protein, and can substitute for endogenous CTCF in embryonic stem cells.  
In the concluding chapter 7, the data presented in this thesis and the future 
implications of it will be discussed. 
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Chapter 1: The organisation of genomic DNA. 
 
General introduction 
The DNA of a eukaryotic cell is contained within the nucleus. Essentially, DNA 
can be represented as a linear array of four different nucleotides arranged as a 
sequence. Each nucleotide is known as a base, and the helical double-stranded DNA 
structure in cells is arranged due to coupling of adenine-thymine and cytosine-guanine 
bases on opposite strands of DNA. Functional units of nucleotides that encode proteins 
are called genes. On average, the genome of a mouse contains almost 22,000 genes. It 
is noteworthy that genes only occupy ~5% of the total amount of DNA. One of the most 
remarkable features of DNA in a multi-cellular organism is the scale. If observed as 
linear, the DNA in every cell would measure around two metres in length (Turner 2002). 
These facts immediately suggest that organisation of DNA within a nucleus is very 
important in order to fit into the 3-10μM diameter compartment (Razin et al. 2007). It is 
well documented that DNA adopts a higher-order complex structure together with 
specialised proteins to form chromatin, the sequential compaction of which allows DNA 
to be accommodated within nuclear space. Chromatin is dynamic, the compaction and 
de-condensation of which correlates broadly with areas of inactive and active gene 
expression, respectively, although this relationship is not absolute. 
 
Modifications to chromatin, either the DNA-associated proteins or the DNA itself, 
that do not alter the DNA sequence, are known as epigenetic modifications and these 
can have profound effects on gene expression. Epigenetics is defined as heritable 
changes in phenotype that are not attributable to alterations in DNA sequence. It remains 
debatable how epigenetic modifications are remembered through subsequent cell 
divisions and indeed whether or not epigenetic marks are the cause or consequence of 
memory (Kouzarides 2007). In a multi-cellular organism, every somatic cell nucleus 
broadly contains the same sequence of DNA, yet in each cell specific sets of genes 
encoding proteins required for that particular cell fate and function at that particular stage 
of development and/or differentiation are expressed. Spatial and temporal expression of 
genes is mediated co-ordinately by direct modifications of chromatin, modifications of the 
DNA and interaction of the DNA with numerous general and cell type specific proteins, 
some of which function to remodel the chromatin structure. 
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Chromatin structure and histones 
Chromatin is the DNA-protein complex that exists in the nucleus. The 
fundamental unit of chromatin is the nucleosome, which is organised in repeating arrays. 
A nucleosome is described as a short stretch of 146 ± 2bp of DNA (Noll and Kornberg 
1977) wrapped 1.65 left-handed superhelical turns around a core subunit of specialised 
proteins called histones (Luger et al. 1997). The histone core forms a globular structure 
with an octameric configuration comprising two molecules of each histone protein H2a, 
H2b, H3 and H4. H2A-H2B dimers bind DNA on entry and exit from the nucleosome 
whereas DNA wrapping around the core interacts with the tetrameric H3-H4 structure. 
 
The central part of each histone protein has a histone fold domain comprising 3 
α-helicies and 2 loop structures (Arents et al. 1991) however the amino terminal ends 
consists of 15-30 residues that are apparently unstructured. These ends are called 
histone tails (Kornberg and Lorch 1999). Histone H2a and H2b, in contrast to the other 
histone proteins, also have a carboxy-terminal tail (Turner 2002). Histone tails are key 
sites of modifications that can alter the structure of chromatin (see below). The complex 
of DNA together with the histone core is known as the nucleosome core particle (NCP) 
and migrates with a relative molecular mass of 210 kD (Luger 2006). Histone proteins 
and the configuration of the NCP are among the most conserved structures across 
species. In addition to the canonical core histones, variant histone forms encoded by 
distinct genes are now being recognised to have important structural and functional 
implications (Kamakaka and Biggins 2005, Li, 2007). 
 
Histones require very little sequence specificity to interact with DNA (Oudet et 
al. 1975, Khorasanizadeh, 2004) and are able to package virtually any DNA. One 
notable exception is G-quadruplex or so-called G-DNA or G4-DNA, where sequences of 
guanine bases induce complex folding of the DNA which is not free to wrap around the 
histone octamer (Oganesian and Bryan 2007). The significance of G4-DNA is an 
emerging aspect of gene regulation. Although the association of DNA and histones 
appears to be sequence independent, there is some degree of favouritism regarding 
formation and positioning of nucleosomes on DNA according to rotational preferences 
induced by double stranded nucleotides (Pina et al. 1990). On average there are 14 
points of contact between DNA and the histone core (Luger and Richmond 1998) 
generating over 120 direct atomic interactions (Luger 2003). The interactions between 
histones and DNA are restricted to the phosphodiester backbone of the DNA. The basic 
histone proteins contain many positively charged arginine and lysine residues that are 
tightly attracted to the negatively charged phosphate groups of DNA.  
Chapter 1 
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Packaging of DNA into a nucleosome induces a 5-10 fold compaction of the 
DNA (Weintraub and Groudine 1976). The positioning of histones along the DNA occurs 
with remarkable regularity, spaced approximately at 200 ± 40bp intervals (McGhee and 
Felsenfeld 1980). The regions of DNA separating these structures and not enclosed 
within a nucleosome is known as linker DNA. The length of linker DNA is variable (10-80 
bp) and the variation is thought to be important for regulating gene expression 
(Spadafora et al. 1976, Felsenfeld, 2003). Linker DNA is associated with a fifth histone 
called H1 which helps stabilise subsequent folding of the polynucleosome string through 
a helical configuration into a 30nm fibre resulting in a further 50-fold compaction of the 
DNA. The significance of H1 for inducing compaction to 30nm fibres is unresolved, 
however, linker histones do stabilise pre-existing compact fibres (Schwarz and Hansen 
1994). High mobility group proteins (HMGs) are abundant chromatin-associated proteins 
that compete with linker histones for binding, thereby affecting the structure of chromatin 
(Catez et al. 2004, Bianchi, 2005). 
 
Each region of linker DNA is occupied by a single histone H1 molecule. Histone 
H1 is not required to form the core nucleosome structure but does attract modifications 
that coordinate chromatin structure and regulate gene expression (Fan et al. 2005b). 
Further condensation of the chromatin through 60-130nm fibres known as chromonemas 
(Belmont et al. 1989) generate chromosomes (fig 1.1). In terms of weight, chromosomes 
are comprised of 50% DNA, with histones and other chromatin associated proteins 
accounting for the residual half (Hayes 2002). It is not fully resolved how compaction of 
chromatin is configured nor the exact disposition of chromatin higher order structure. 
Interestingly, the existence of 30nm fibres remains elusive in vivo (Tremethick 2007). 
Analysis of chromatin structure in vitro suggests the chromatin configuration becomes 
less condensed representing the 10nm structure described as ‘beads on a string’ in the 
presence of low-ionic strength buffers. In conditions close to physiological concentrations 
however, compaction of the chromatin into 30nm fibres are visualised (Hansen 2002). 
The greatest degree of chromatin compaction is observed in heterochromatin (see 
below) and mitotic chromosomes. The compaction of interphase chromosomes during 
mitosis results in a 10,000-fold reduction in chromosome length (Li et al. 1998). Despite 
the opinion regarding chromatin compaction as generally inhibitory to transcription and 
other processes that require access to DNA, mitotic chromatin appears to be quite 
dynamic in structure and remains accessible to transcription factors (Chen et al. 2005). 
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Figure 1.1. The organisation of DNA within the chromatin structure 
Chromatin is a complex of the double-stranded DNA helix with proteins called histones. The 
sequential packaging of DNA and proteins to more compact configurations generates the 
distinguishable structure of mitotic chromosomes. Figure taken from (Felsenfeld and Groudine 
2003). 
 
 
Histone variants 
The four core histone proteins as described above are encoded by multiple 
copies of histone gene cassettes that are expressed during S phase of the cell cycle. 
Newly synthesised (H3-H4)2 tetramers carrying specific covalent modifications followed 
by two H2A-H2B dimers are incorporated during replication of DNA behind the 
replication fork (Akey and Luger 2003) (Loyola and Almouzni 2004, Jin, 2005). In 
addition to the major histone proteins, histone variants provide another degree of 
alteration to chromatin that can influence gene expression.  
 
Variant histone forms are encoded by distinct genes and present both structural 
and functional consequences of incorporation to the nucleosome (Suto et al. 2000, 
Chakravarthy, 2005). Genes encoding histone variants are normally single-copy, intron-
Chapter 1 
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containing genes, which are expressed constitutively, unlike core histones, and are 
integrated into nucleosomes in a DNA replication-independent manner (Kamakaka and 
Biggins 2005). Interestingly not all canonical histone proteins seem to have functional 
variants (Akhmanova et al. 1996) whereas others have many variant forms (Li et al. 
2007). Histone variants are usually characteristic features of higher vertebrate genomes, 
however the H2A.Z and H2A.X variants of H2A are widely conserved (Raisner and 
Madhani 2006, Redon, 2002) and essential across eukaryotic species (van Daal and 
Elgin 1992, Liu, 1996, Faast, 2001). There are five predominant H2A-type histones, 
including the core histone H2A and three major histone H3-type histones. Another H2A 
variant (H2AvD) is known in Drosophila (Redon et al. 2002) and mammals possess a 
testis-specific H3 variant H3.4 (Kamakaka and Biggins 2005). 
Incorporation of H2A and H3 variants in the histone octamer affect nucleosomal 
interactions that influence transcriptional competence of specific genes, regulate genome 
stability through chromosome segregation or DNA replication and repair, and 
characterise specific chromosomal regions such as macroH2A1 and H2A-Bbd on the 
inactive and active X chromosomes respectively (Costanzi and Pehrson 1998, 
Chadwick, 2001) and the H3 variant CENP-A at centromeres (Blower et al. 2002). H2A.X 
is a canonical histone protein in yeast (Li et al. 2007) however in mammalian cells, this 
variant is linked to transcriptional repression. Phosphorylation of H2A.X (γ-H2A.X) is a 
recognition site of DNA damage (Fillingham et al. 2006). H2A.Z has reported roles in 
transcriptional activation and repression and is a feature of insulator regions.  Recently 
H2A.Z was identified as a marker of chromatin domain boundaries in human cells (see 
below, (Fan et al. 2002, Barski, 2007). H3 and variant H3.3 diverge only in four amino 
acids, which are not thought to alter the overall structure of the protein or its 
incorporation into the nucleosome. Nevertheless, localisation of H3.3 at transcriptionally 
active regions and enrichment for covalent modifications associated with open chromatin 
is strikingly opposite to that of H3 (McKittrick et al. 2004). 
 
Histones are not confined to chromatin. The details of extra-chromatic histone 
activity are outside the scope of both my research and this thesis, however histones 
seem to be multi-functional in dimensions that exist outside the structure of chromatin, 
even outside the nucleus (Parseghian and Luhrs 2006). 
 
Modifications and remodeling of chromatin 
The histone proteins within the nucleosome complex are considered to be 
general repressors of gene activity (Grunstein 1997, Boeger, 2005). Nucleosomes and 
the higher order packaging of chromatin renders the DNA broadly inaccessible to 
regulatory protein complexes required for processes such as DNA repair, recombination, 
replication and transcription. Nevertheless, all these processes must occur on the 
 17
chromatin template. Nucleosome structure and their interaction with DNA are therefore 
stable but importantly not static. 
Covalent modifications of core histones and DNA generate molecular markers 
distinguishing active, potentially active and inactive chromatin. Eukaryotes have four 
distinct mechanisms for allowing plasticity of nucleosomes within the chromatin template; 
covalent modifications of histone proteins, reorganisation of nucleosome position by 
ATP-dependent chromatin remodeling complexes, incorporation of variant histone 
molecules both into the nucleosome core and linker histone variants and covalent 
modification of DNA itself. Histone modifications and remodeling are widely conserved, 
however the incorporation of variant histones and DNA methylation seem restricted to 
more complicated genomes. 
 
 
Covalent histone modifications 
Covalent modifications of histone proteins occur on both histone tails and the 
globular histone core (Cosgrove et al. 2004, Mersfelder, 2006, Kouzarides, 2007). There 
are currently eleven different classes of identified histone modifications (table 1.1 
(Kouzarides 2007, Hassan, 2006) and many enzymes are known to catalyse post-
translational histone modifications (de la Cruz et al. 2005). Mutations in these enzyme 
complexes are often associated with malignancies in humans (Santos-Rosa and Caldas 
2005), and aberrant patterns of histone modifications have been identified as hallmarks 
of human cancers (Fraga et al. 2005). 
 
Covalent histone modifications enable an otherwise largely regular histone 
octamer to diversify dramatically resulting in profound effects on chromatin both 
structurally and functionally. All known covalent histone modifications with the exception 
of methylation and ubiquitylation influence the interaction of DNA with histones by 
changing the electrostatic charge of nucleosomes (Li et al. 2007). Interestingly, histone 
tails are not thought to be required for the structure of the nucleosome itself as removal 
of histone tails by digestion with trypsin has no effect on the stability of the nucleosome 
(Whitlock and Simpson 1977, Ausio, 1989). However it is increasingly clear that histone 
tail-mediated internucleosome interactions and higher order chromatin structure are 
affected by modifications (Shogren-Knaak et al. 2006, Polach et al. 2000, Tse et al. 
1998). The significance of core histone modifications in mediating DNA interactions with 
the nucleosome remains unclear; however with the increasing number of core histone 
modifications identified it is likely that we will see the importance of these modifications in 
the near future (Xu et al. 2005). 
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Chromatin Modification Residue Modified Functions regulated 
Acetylation H2A  (K5) 
H2B  (K12, K15) 
H3    (K9, K14, K18, K23, K56y) 
H4    (K5, K8, K12, K16) 
Transcription, Repair, 
Replication, 
Condensation 
Methylation (lysine) 
mono/di/tri-me 
H3    (K4, K9, K27, K36, K79) 
H4    (K20) 
Transcription, Repair 
Methylation (arginine) 
Mono/di(active)di(repress) 
H3    (R2, R8, R17, R26) 
H4    (R3) 
Transcription 
Phosphorylation (serine) H2B  (S14) 
H3    (S10, S28) 
H4    (S1) 
Phosphorylation 
(thrionine) 
H3    (T3) 
Transcription, Repair, 
Replication, 
Condensation 
Ubiquitylation H2A  (K119) 
H2B  (K120 h/123 y) 
Transcription, Repair 
ADP ribosylation 
(arginine) 
H2B  (E2 mono-ar) Transcription 
Sumoylation H2A 
H2B 
H4 
Transcription 
Deimination                       
(conversion of argine-
citrulline)                         
mono-me-R not di/tri-me-
R 
H3 
H4 
Transcription 
Proline isomerization            
(distortion of proline 
conformation) 
H3   (P30y, P38y) Transcription 
Biotinylation H2A (K9, K13, K125, K127,K 
129) 
H3   (K4, K9, K18) 
H4   (K8, K12)                               
Gene silencing, 
Mitotic condensation, 
Gene silencing 
 
Table 1.1. An overview of modifications identified on histones and their functions (see 
text for details). Only residue modifications with known modifying enzymes in human and 
yeast (Saccharomyces cerevisiae) are listed, with the exception of biotinylation that is 
dependent on exogenous biotin, based on (Kouzarides 2007, Hassan, 2006).  
 
The function of covalent histone modifications can be broadly categorised as 
active or repressive modifications in the context of transcriptional activity. Acetylation is 
one of the most commonly studied post-translational modifications of histones and was 
first identified over forty years ago to correlate with active transcription (Allfrey et al. 
1964, Grunstein, 1997, Roh et al. 2005). Lysine residues are invariably the substrate for 
histone acetyl transferase (HAT) complexes of which there are two main types; type A 
(nuclear) and type B (cytoplasmic) that function in transcriptional activation and 
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acetylation of newly synthesised histones respectively (Narlikar et al. 2002). There are 
three major acetyl transferase protein families, GCN5-related acetyl-transferase (GNAT), 
MOZ, YBF2/SAS3, SAS2, TIP60 protein family (MYST) and CREB-binding protein/p300 
(CBP/p300) (Sterner and Berger 2000, Ehrenhofer-Murray, 2004, Santos-Rosa, 2005). 
In addition there are also general transcription factor HATs and HATs which are nuclear 
receptor cofactors. HATs are unable to bind DNA directly and therefore operate as 
transcriptional co-activators. In addition to transcriptional activation, histone acetylation 
has been implicated in regulating transcriptional initiation, through the stabilization of 
basal transcription factors to promoters and with transcriptional elongation, DNA 
replication and DNA damage repair. 
 
The extent of acetylated histones throughout the genome is balanced by the 
opposing modification of deacetylation. Specific protein complexes can functionally 
reverse most covalent modifications identified to date, with the exception of methylated 
arginines (see below). Histone deacetylases (HDACs) remove acetyl groups from 
lysines, and hypoactelylation of histones correlates with transcriptional inactivity and 
gene repression. HDACs form parts of multi-subunit protein complexes associated with 
chromatin remodeling (see below). In mammals, three identified groups of HDACs are 
characterised according to homologous corresponding proteins in yeast. Mammalian 
homologues of Rpd3 and Hda1 define HDAC class I and II respectively. Class I HDACs 
are constitutively nuclear and ubiquitously expressed whereas class II HDACs have 
restricted expression patterns and characteristically transfer between the nucleus and 
cytoplasm. The enzymatic component of both groups of HDACs depends on a zinc 
molecule. Class III HDACs, also referred to as SIR-HDACs, are distinguished by a 
functional requirement for nicotinamide adenine dinucleotide (NAD+) for deacetylation 
activity that subsequently reduces NAD+ into O-acetyl-ADP-ribose and nicotinamide 
(NAM) (Blander and Guarente 2004). 
 
Acetylation of lysines and phosphorylation of serines on histones are specifically 
correlated with active chromatin. In contrast, ubiquitylation of lysines and methylation of 
both lysines and arginines can function in either transcriptional activation or repression 
depending on the amino acid modified (Kouzarides 2007). Methylation of histones 
introduces a further level of complexity, as lysines can be mono- di- or tri-methylated, 
although tri-methylation has not been identified on arginines. The regulation of arginine 
methylation is not fully understood; despite characterisation of protein arginine methyl-
transferases (PRMTs), a demethylating complex has not yet been identified. The 
existence of an arginine demethylase is presumed following characterisation of lysine 
demethylases (Kouzarides 2007, Shi et al. 2004).  
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Histone modifications are never single entities, and not every available amino 
acid may be modified nor every histone octamer will be modified in the same way. 
Histone modifications have been shown to function cooperatively and influence each 
other in a manner suggesting a histone code (Strahl and Allis 2000, Jenuwein & Allis 
2001, Iizuka & Smith 2003). The code hypothesis proposes one way of viewing the 
combination of different covalent modifications and how in conjunction with each other, 
recognition motifs are set allowing for interactions with different protein complexes that 
can remodel histone-DNA interactions and/or recruit transcription factors to promoter 
regions. 
 
Chromatin remodeling complexes 
Histone-DNA interactions can also be modified via ATP-hydrolysis. Large multi-
protein complexes that mediate the structure of chromatin in an ATP-dependent manner 
either by physical alteration of nucleosome position and/or attracting different histone 
modification enzymes are known as chromatin remodeling complexes (Ehrenhofer-
Murray 2004). Chromatin remodeling complexes also mediate the complete 
displacement of histones from transcriptionally active genes and exchange of histone 
variants (Kimura and Cook 2001, Clayton et al. 2006). These transient alterations in 
chromatin facilitate transcription factor accessibility and are required for other epigenetic 
modifications such as DNA methylation.  
 
The ATPase subunit is common to all protein complexes that remodel 
chromatin. On the basis of sequence features and identity of the ATPase, three families 
of remodeling complexes are distinguished, SWI/SNF, ISWI and Mi-2. The SWI/SNF 
complex is the prototypical chromatin-remodeling complex, originally identified in 
S.cerevisiae (Cote et al. 1994) after identification of SWI2/SNF2 gene mutations that 
affected multiple gene expression resulting in the mating type switching (swi) and 
sucrose non-fermenting (snf) phenotype. Two Swi.Snf-like complexes are known in 
humans, BAF and PBAF that possess specific ATPase subunits (BRG1 and brm) and 
associated factors (BAFs) (Wang et al. 1996). ISWI is a smaller complex in relation to 
SWI/SNF, however in contrast to SWI/SNF, which requires BRG1, BAF47 and 
BAF155/170 for minimal catalytic activity in vitro, the ATPase of ISWI alone is sufficient 
for chromatin remodeling (Phelan et al. 1999, Langst, 1999). SWI/SNF complexes are 
associated with transcriptional activity and histone acetylation, whereas the ISWI 
complex is considered to be involved in repressive chromatin modifications due to the 
ISWI-mediated induction of nucleosome sliding in cis, which generates inaccessible 
chromatin conformations over neighbouring DNA sequences. The apparent contrasting 
activities of SWI/SNF and ISWI complexes possibly reflect their different substrate 
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specificities; chromatin remodeling by ISWI is dependent on histone tails, whereas 
SWI/SNF is able to remodel tail-less histones (Langst and Becker 2001). 
The ATPase subunit of Mi-2 belongs to the 2 MDa nucleosome remodeling and 
histone deacetylation (NuRD) complex (Xue et al. 1998), and like ISWI has intrinsic 
chromatin remodeling activity. The Mi-2 subunit is distinguished from the other ATPases 
by a pair of chromodomains, designating this group as the chromo-ATPase/helicases-
DNA binding domain (CHD) type. Mi-2 has two isoforms, α (CHD3) and β (CHD4). The 
NuRD complex contains HDAC1 and 2 and is able to deacetylate nucleosomes but not 
free histone proteins (Wade et al. 1999).  
ATPase complexes and histone modifying proteins are unable to bind to DNA, 
and instead depend upon associated transcription factors for targeting to the necessary 
sequences. The differentiation between activating and repressing complexes can not 
simply be viewed according to transcription factor interaction, as transcription factors 
such as GATA-1 can attract both HAT and HDAC-containing complexes (Rodriguez et 
al. 2005). The influence of chromatin remodelling complexes and their associated factors 
can only be acknowledged within a specific context or developmental stage; Mi-2 directly 
interacts with HDACs, implying repressive activity of NuRD, however in T-cells, Mi-2β is 
required for recruiting the p300 histone acetyltransferase to the Cd4 enhancer, directly 
regulating CD4 expression (Williams et al. 2004). 
 
DNA methylation 
Methylated DNA is often considered as refractory to transcriptional activity, 
either by directly inhibiting transcription factor binding or by attracting methyl-binding 
proteins that in turn attract transcriptional repressor complexes such as HDACs and 
chromatin remodeling complexes (Nan et al. 1998, Feng, 2001). DNA methylation mainly 
occurs as a stable, non-random covalent modification of cytosine at position 5 (Geiman 
and Robertson 2002). Methylation of DNA in mammals occurs principally on CpG 
dinucleotides by DNA methyltransferases DNMT1, DNMT3a and DNMT3b. Five DNMTs 
have been identified (DNMT1, DNMT2, DNMT3a, DNMT3b, DNMT3L), however only 
three are known to catalyse the addition of a methyl group to DNA. 
Maintenance of methylated sites following DNA replication is achieved by 
DNMT1, which restores DNA methylation on hemi-methylated CpG dinucleotides and is 
essential for retaining patterns of methylation in proliferating cells (Bestor 1992). 
Following fertilisation, the male pronucleus undergoes demethylation followed by 
widespread demethylation of both maternal and paternal genomes before implantation 
(Howlett and Reik 1991, {Mayer, 2000). Re-establishment of DNA methylation in the 
embryo is the function of de novo methyltransferases DNMT3a and 3b (Okano et al. 
1999). Correct establishment and maintenance of DNA methylation is essential for 
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genomic stability, embryonic development and viability. Interestingly, chromatin 
remodeling complexes, DNA helicases and histone modifications can all influence DNA 
methylation (Li 2002). 
An association between histone methylation and DNA methylation has been 
known for several years based on mutagenesis of defective in methylation-5 (dim-5), a 
H3-K9 methyltransferase in the fungus Neurospora crassa that was shown to be critical 
for DNA methylation (Tamaru and Selker 2001). DNA methylation is known to be both 
necessary and sufficient for establishing chromatin structure and histone modifications 
during development (Hashimshony et al. 2003).  
 
Monoallelic gene expression 
The majority of genes in diploid organisms are expressed from both alleles, 
however in mammals, some of the most important developmental fate decisions are 
made and regulated through the specific preferential expression of genes from one 
allele. Classical examples of such processes include X-chromosome inactivation, 
imprinted gene expression and allelic exclusion, which occurs in B- and T-lymphocytes 
and murine olfactory neurons (Yang and Kuroda 2007). Allelic exclusion is a mechanism 
to generate diversity and specificity of B- and T-lymphocyte antigen receptors (B/TCR) 
(see chapter 3). Strict regulation and timing of allelic exclusion is essential for the 
development of both B- and T-lymphocytes. Receptor diversity is also required in 
olfactory neurons, which have the potential to express any one of more than 1300 
odorant receptor genes (Chess et al. 1994). In contrast, genes that are typically 
‘imprinted’ do not encode receptors, but do regulate growth with many imprinted genes 
being essential for late-embryonic and post-natal development (Hurst and McVean 
1998). Genomic imprinting describes the parental-specific expression of autosomal 
genes. The transcriptional capacity of a given imprinted gene is determined according to 
maternal or paternal inheritance. There are currently over 70 identified imprinted genes 
(Sleutels and Barlow 2001). One of the most outstanding examples of regional gene 
expression occurs in female cells where an entire chromosome is inactivated. X-
inactivation was initially described in mice over 45 years ago as a hypothesis for 
transcriptional dosage compensation between XY males and XX females (Lyon 1961).  
 
The mechanisms and regulation of monoallelic expression are perhaps 
surprisingly similar for each example given both the specificity of genes/genetic regions 
influenced, and the apparent randomness of allelic inactivation choice particularly for X-
inactivation and allelic exclusion. An entire field of research is devoted to elucidating X-
inactivation choice, and the matter of whether or not this is a random process remains 
highly controversial and beyond the scope of this thesis. The signals or characteristic 
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features that determine which Tcr allele should be silenced are also unknown. Epigenetic 
modifications that determine genomic imprinting are the only example of no choice, 
developmental fate is decided in gametes and this is maintained in somatic cells 
throughout life.  
Asynchronous DNA replication, differential DNA methylation and chromatin 
modifications together with non-coding RNAs and even nuclear localisation are common 
themes to all examples of monoallelic expression (reviewed in (Goldmit and Bergman 
2004). X-inactivation is achieved through coordinated and sequential activities of X-
inactive specific transcript (Xist) RNA coating of the chromosome, and RNA polymerase 
II exclusion. Changes in histone modifications including loss of H3K9 acetylation and 
H3K4 hypomethylation occur, which is augmented by polycomb group (PcG) protein 
expression, H3K27 tri-methylation and H3K9 methylation. DNA methylation of CpG 
residues compounds the repressed state (Peters et al. 2003). The contribution of 
different histone methyltransferases to the induction and maintenance of X-inactivation 
indicates the complexity of regulation required in this phenomenon (Ohhata et al. 2004). 
Significantly, not all genes on the designated inactive X are silent, and the mechanisms 
of so-called ‘escape gene’ expression are only recently beginning to be addressed (see 
chapter 2 for details). Differential patterns of DNA methylation are a central feature of 
imprinted gene expression as not only is DNA methylation a stable, heritable 
modification via the action of DNA methyltransferases, but DNA methylation obstructs 
the binding of key transcription factors and other regulatory proteins, reciprocal effects of 
this are observed for example at the Igf2-H19 locus (Hark et al. 2000, Bell et al. 2000). 
Monoallelic expression of olfactory receptor genes depends strongly on interactions 
between genes and the enhancer element H. It remains unclear if promoter-enhancer 
interactions are the defining event to maintain gene expression from that allele and mark 
the other allele for repression (Serizawa et al. 2003, Lomvardas et al. 2006). 
 
Euchromatin and heterochromatin 
A differential distribution of DNA within the nucleus has long been 
acknowledged. Early cytogenetic studies revealed two distinct arrangements of 
chromatin, euchromatin and heterochromatin. Typically, areas of heterochromatin 
contain repetitive sequences of DNA that replicate late in S-phase, and have a low gene 
density. Heterochromatic structures are more compact during interphase and are found 
in discrete areas of the nucleus; the nuclear periphery, at the centromeres and at 
telomeric ends of individual chromosomes. By contrast, euchromatin is gene rich and 
undergoes early S-phase replication. Euchromatin is characterised by an open, 
transcriptionally permissive chromatin structure that is distributed throughout the 
interphase nucleus (table 1.2). It is now recognised that euchromatin and 
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heterochromatin comprise structurally and transcriptionally very different examples of 
chromatin, however there is evidence of transcription and regions of decondensed 
chromatin occurring in otherwise typically heterochromatic areas and also silent or 
repressed genes are found within regions of open chromatin (Gilbert et al. 2004). The 
typical characteristics of heterochromatin have in the past led to the view of 
heterochromatin having little functional significance consisting of ‘junk’ DNA. This idea is 
no longer valid, particularly in light of the fact many vital genes have been mapped to 
heterochromatic regions in Drosophila (Devlin et al. 1990, Dimitri et al. 2003).  
Areas of heterochromatin and euchromatin are not irreversibly stuck with 
respect to transcriptional status, chromatin modifications or nuclear position. The 
formation of heterochromatin outside of constitutively heterochromatic domains such as 
centromeres is important for regulating temporal and spatial expression of certain genes 
during cellular differentiation and in particular is associated with X-inactivation and 
imprinted gene expression in mammals and silencing of homeotic gene loci by the PcG 
proteins (Quina et al. 2006). Recent analysis of histone modifications at centromeric 
domains have determined that chromatin conformation is distinct from that observed in 
both euchromatin and heterochromatin, which may specifically reflect the role of 
centromeres mediating mitosis in the nucleus (Sullivan and Karpen 2004).  
 
Feature Euchromatin Heterochromatin 
Staining after trypsin-
giemsa / packaging in 
interphase 
Isopycnotic / dispersed, 
decondensed 
 
Heteropycnotic/ condensed 
 
DNase sensitivity Sensitive Less sensitive 
Replication timing Early/throughout S-
phase 
Late S-phase 
Presence of genes High/variable density, 
house-keeping genes 
Low density, lack house-
keeping genes 
DNA sequence Predominantly unique Largely repetitive (satellites, 
transposons) 
Transcriptional activity Poised or active Poised or silent 
Meiotic (reciprocal) 
recombination 
Normal frequency Infrequent 
Characteristic modifications Hyperacetylated H3 and 
H4  
Methylated H3K4 
CpG hypomethylation 
Hypoacetylated H3 and H4 
Methylated H3K9, HP-1 
CpG hypermethylation 
         Table 1.2. Adapted from (Richards and Elgin 2002 and Holmquist & Ashley, 2006). 
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Interesting correlations exist between the position of active and inactive gene 
loci within the interphase nucleus and the proximity to heterochromatic regions. The 
location of a gene locus close to or within a heterochromatic domain is associated with 
transcriptional repression. This has been observed using both transgenes and analysis 
of endogenous loci. In T-lymphocytes, the T-helper subsets (Th-1 and Th-2) of naïve 
CD4 cells are distinguished by IGFγ+/IL-4- and IL-4+/IFNγ- expression respectively. 
Progressive polarisation into Th1 or Th2 lineage occurs over several cell divisions. This 
prevents expression of the opposing cytokines (for further discussion, see chapter 3). 
Repositioning of the silenced IL-4 (Th1) and IFNγ (Th2) to centromeric heterochromatin 
is seen only in polarised cells, not in naïve CD4 cells. Increasing evidence shows that 
this is a dynamic process possibly regulated by transcriptional activity, which can 
relocate chromatin domains away from or towards heterochromatin. Transcriptional 
activation may ‘move’ loci to a more transcriptionally permissive nuclear environment 
whereas silencing of an active locus can be achieved by positioning close to 
heterochromatic regions. However repositioning of a locus might also be a consequence, 
not simply a cause of silencing. For example, transcription of the recombination-
activating genes (Rag)-1 and deoxynucleotidyl terminal transferase (Dntt or TdT) genes 
in immature thymocytes is irreversibly repressed upon T-cell receptor engagement in 
CD4 and CD8 T-cells via the acquisition of repressive histone modifications; 
deacetylation of H3K9, hypomethylation of H3K4 and gain of methylation at H3K9. H3K9 
methylation attracts binding of HP-1, a component of silent chromatin. Binding of HP-1 is 
thought to support heterochromatin formation at this locus (Bannister et al. 2001).  The 
timing of transcriptional silencing and relocation of these loci to heterochromatin 
indicated a delay of around twelve hours between silencing and repositioning, 
suggesting the loci are already silent when they become incorporated into 
heterochromatin. 
Movement of active gene loci to a heterochromatic region can be considered as 
one way to negatively regulate gene expression, if binding of specific proteins to the 
DNA regulatory sequences of a given gene, or interacting protein partners can function 
to associate their target genes with heterochromatin. Ikaros is a DNA-binding protein 
specifically expressed in haematopoietic and lymphoid cells and is required for correct 
progression of both B- and T-cell lineages (Wang et al. 1996). Ikaros expression has 
been tightly linked with transcriptional repression, and is a prime candidate for identifying 
factors that can target specific genes to centromeric and pericentromeric 
heterochromatin. Studies by Brown et al revealed Ikaros co-localises with γ-satellite DNA 
in mice, which is a marker for repetitive heterochromatic elements (Brown et al. 2001). 
The ability of Ikaros to bind to both centromeric repetitive DNA as well as cis-regulatory 
elements of lymphoid restricted genes suggests Ikaros may attract gene loci to 
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heterochromatic regions. Interestingly, Ikaros-mediated relocation of silent genes to 
pericentromeric chromatin occurs in mitogen-activated cells, and not resting splenocytes 
(Brown et al. 1997). 
 
The influence of heterochromatin on the expression of genes is seen through 
the phenomena of position effect variegation (PEV). PEV describes the abnormal 
silencing of a gene locus that has been repositioned, for example by translocation, to an 
area of heterochromatin in a population of cells that would usually express the gene. 
Initial studies in Drosophila showed that the proximity of a gene to heterochromatin 
strongly influences the expression of that gene (Ananiev and Gvozdev 1974). Similar 
analyses in mice demonstrated that PEV occurs also in mammals. PEV is thought to 
occur by spreading of repressive histone modifications and binding of transcriptional 
repressors to the active gene, eventually silencing transcription. Interestingly, the β-
globin locus control region (LCR) was the first cis-acting element identified as capable of 
conferring position independent expression on a linked transgene when inserted into 
transcriptionally silent chromatin (Grosveld et al. 1987). This is now a required feature of 
sequences to be called an LCR (see below).  
Insulator sequences (see below) can also block the spread of heterochromatin 
into active gene loci and as such these sequences are thought to function as important 
regulatory boundaries between active and inactive chromatin domains. The properties of 
both LCRs and insulators imply that endogenous genes and linked transgenes may be 
protected from PEV due to looping of chromatin domains away from the surrounding 
heterochromatin. Relocation of a locus away from heterochromatin does not always 
require transcriptional activation. Histone acetylation modifications associated with open 
chromatin are observed on the β-globin locus before expression of the globin genes, 
suggesting the modifications to make transcription possible are enough and that 
transcription itself is not required to move chromatin domains away from a 
heterochromatic state (Ragoczy et al. 2003). Although movement of a gene locus away 
from heterochromatin appears to be a prerequisite for transcription, it is not sufficient to 
initiate gene activation (see below). 
 
DNA loops, nuclear matrix or scaffold, and associated regions 
In the interphase nucleus, topological arrangement of the genome into 
chromatin compacts the chromatin array, but also regulates spatial and temporal 
expression of certain genes. Chromatin is partitioned at 5-200 kb intervals into loops 
(Bode et al. 2003) by elements that may demarcate regions of active and inactive gene 
expression. Factors that organise chromatin loops play a very important role not only in 
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gene regulation but perhaps in the maintenance of the nuclear structure as a whole 
(Earnshaw 1988). 
 
Several proteins involved in gene regulation are known to bind the nuclear 
matrix via specialised DNA sequences, matrix or scaffold associated regions 
(MARs/SARs) (table 1.3). The terms MARs and SARs to describe the attachment points 
of DNA to the nuclear matrix or scaffold are interchangeable and as such are collectively 
addressed as S/MARs. The distinction between SARs and MARs refers to the 
metaphase or interphase cell extraction of these regions respectively. What constitutes 
the nuclear matrix from the nuclear scaffold appears to depend on the method of 
isolation. The nuclear matrix was initially characterised as an insoluble, filamentous 
protein complex, resistant to DNase treatment, detergent and high salt extraction. The 
precise nature and composition of the nuclear matrix is still largely unresolved, and this 
together with technical difficulty in isolating the structure leads to continued debate over 
the existence of a nuclear skeleton. Besides chromatin and related proteins, the nucleus 
is a highly territorial structure comprised of functionally distinct regions such as nucleoli 
(see below). Interestingly, in the absence of any chromatin, the other functional elements 
of the nucleus remain intact, suggesting that a skeleton network or matrix of some 
description remains (Nickerson 2001).  
The nuclear matrix has been defined as a complex of RNA and non-histone 
proteins that forms a network-like base to which chromatin can attach. S/MARs are 
sequences of DNA (200-300bp) that remain attached to the nuclear matrix following 
extraction. There is no definitive consensus sequence defining S/MARs, however they 
have a predominance of A+T base pairs (70%) and frequently contain topoisomerase II 
cleavage sites (Bode et al. 1992). Base unpairing regions (BURs) are key features of 
S/MARs and as such S/MARs have a high unwinding potential which may relieve stress 
in the DNA fibre generated during transcription. S/MARs emerge regularly in the 
genome; on average there is one MAR in every 30-100Kb of DNA (Bode et al. 2003), 
however within the 90Kb that includes the globin locus, eight S/MAR sites have been 
identified and at the 3’end of the Cd8β gene, two MARs are located just 4.5Kb apart 
(Cunningham et al. 1994). 
 
By physically generating chromatin loops, S/MARs have been seen as insulator 
sequences, regions that distinguish chromatin domains into active and inactive gene loci. 
A number of proteins have been identified to associate with S/MARs, including lamins, 
which may be important for the structure of the network (Luderus et al. 1992), Nucleolin, 
a major nucleolar protein (Dickinson and Kohwi-Shigematsu 1995) and Bright, a factor 
primarily expressed in B-cells (Herrscher et al. 1995). S/MARs have been implicated in 
both transcriptional activation and repression (Maya-Mendoza et al. 2003).  
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Table 1.3. S/MAR binding proteins and their expression pattern.  
 
The majority of S/MAR binding proteins currently identified are ubiquitously expressed with 
the exception of tissue-specific proteins found in B- and T-lymphocytes. *Mutated p53 binds 
S/MAR sequences opposed to wt p53 (Gohler et al, 2005; Singh et al, 2007). **CTCF is 
not expressed during certain stages of spermatogenesis (Loukinov et al 2002). 
Scaffold/Matrix 
Attachment Region 
(S/MAR) Binding Proteins 
Expression Pattern Reference 
B-cell regulator of IgH 
transcription (Bright) 
B-cells Herrscher, 1995  
CCAAT displacement protein  
(CDP; Cut/Cux) 
Ubiquitous except terminally 
differentiated cells 
Kaul-Ghanekar, 2004  
CCCTC-binding factor  
(CTCF) 
Ubiquitous** 
 
Dunn, 2003  
Histone H1 Ubiquitous Izaurralde, 1989  
High Mobility Group 1 and 2 
(HMG1/Y) 
Inreased in tumors and cells 
with increased metastatic 
potential 
Liu, 1999  
Ku autoantigen MAR activity identified in 
breast carcinoma cell lines 
Galande, 1999  
Lamins type A and B1 Ubiquitous, MAR studies in 
rat liver 
Luderus, 1992  
Methyl CpG binding protein 
2 (MeCP2) 
Ubiquitous Stratling, 1999  
Nucleolin Major nucleolar protien, 
ubiquitous 
Dickinson, 1995  
Poly (ADP-ribose) 
polymerase (PARP) 
MAR activity identified in 
breast carcinoma cell lines 
Galande, 1999  
p53* Ubiquitous Gohler, 2005,  
Singh, 2007  
Scaffold Attachment Factor 
A and B                                 
(SAF-A/B; p120, hnRNP) 
Ubiquitous Fackelmayer, 1994 
Renz, 1996  
Special AT-rich Binding 
Protein 1 and 2 (SATB1/2) 
Predominantly T-cells Dickinson, 1992  
 
Scaffold/matrix-associated 
region-1-binding protein  
(Smar-1) 
Predominantly T-cells Kaul-Ghanekar, 2004  
Topoisomerase II Ubiquitous Adachi, 1989  
Nuclear Matrix Protein-1/ 
Ying-Yang1 
(NMP1,YY1) 
Ubiquitous Tan, 1998  
Ogino, 2002  
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Significantly, not all S/MARs function as tethering points for chromatin. Selective 
association of S/MARs with the nuclear matrix can therefore alter the structural 
arrangement of chromatin and potentially regulate gene expression. Cell-type specific 
matrix associated proteins may help this regulation. SATB1 (special AT-rich binding 
protein 1) is a S/MAR binding protein predominantly expressed in thymocytes (Dickinson 
et al. 1992). In cells that express SATB1, it has been shown to occupy S/MARs 
positioned at the base of chromatin loops in contrast to non-expressing cells that 
reposition the SATB1 binding S/MARs to the looping chromatin domain. SATB1 appears 
to be sensitive to the base unwinding potential of a S/MAR, a feature that may be 
mediated by its homeodomain. SATB1 has been identified to recruit chromatin-
remodeling complexes, regulating histone modifications and gene expression over long 
distances (Yasui et al. 2002). A characteristic nuclear localisation in T-cells indicates a 
role for SATB1 in maintaining nuclear architecture (Cai et al. 2003). Matrix associated 
regions and their binding proteins are therefore important components of the chromatin 
structure and its plasticity, but also are tightly involved in regulating gene expression.  
 
Transcription and regulation of eukaryotic gene expression 
An open chromatin conformation mediated by covalent modifications of 
nucleosomes together with chromatin-remodeling complexes is necessary but not 
sufficient for genes to become active. In this instance, gene activity refers to 
transcription. Transcriptional regulation is a critical component of cellular function. The 
majority of genes studied encode proteins but many non-coding genes are present in the 
genome and these too have important structural and catalytic roles in the cell.  
 
Basal transcription machinery and transcriptional initiation 
Three RNA polymerases (RNA pol I, II, III) are responsible for transcribing 
nuclear genes. Transcription is the enzymatic process of copying DNA into RNA, which 
in the case of RNA pol II generates messenger RNA (mRNA) that is translated into 
polypeptide templates for functional proteins. Eukaryotic RNA polymerase I synthesises 
ribosomal RNA used in the production of ribosomes. RNA pol I activity is confined to 
specialised areas within the nucleus known as nucleoli (see below). RNA pol III 
transcribes small stable RNAs involved in RNA processing such as transfer RNA (tRNA), 
7SL RNA, U6 small nuclear RNA (snRNA), as well as 5S rRNA (Paule and White 2000). 
All three RNA polymerases are intrinsically unable to identify their respective target 
promoters, and require direction from general transcription factors (GTFs) to guide them.  
 
 Each eukaryotic RNA polymerase is a complex of around twelve subunits whose 
sequences are largely conserved between species, but the composition of subunits 
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varies according to the type of polymerase; five subunits are shared between all three 
polymerases (Martinez 2002). Transcription can be regulated at any of three individual 
stages, initiation, elongation and termination. In the case of RNA pol II, five GTFs (TFIIB, 
-D, -E, -F and -H) are the minimal requirement for promoter recognition and accessibility 
(Conaway and Conaway 1997) together with a large multi-subunit complex called 
Mediator (Conaway et al. 2005). TFIIA is necessary for 5S gene transcription. Specific 
initiation requires recognition of core promoter DNA motifs including the TATA-box, 
initiator (Inr), TFIIB response element (BRE) and upstream promoter elements CCAAT 
and CACC boxes. Experiments in vitro identified the core promoter as the minimal 
sequence required to direct transcription and as such this is referred to as basal 
transcription. TATA-binding protein (TBP) is involved in transcription by all three 
polymerases (Fan et al. 2005a).  
Sequential assembly of GTFs and pol II at core promoter sequences generate a 
pre-initiation complex (PIC). Each of the GTFs with the exception of TFIIB, are multi-
subunit complexes. Binding of TFIID to the core promoter is the first step in transcription. 
TBP is a component of TFIID, which induces a physical change in promoter DNA forcing 
it to bend. TFIIA and –B then assemble and stabilise TFIID interactions. Addition of TFIIF 
functions as a checkpoint ensuring correct promoter complex assembly (Svejstrup 2004). 
A minimal complex of pol II-TFIIB-TFIIF is sufficient to initiate transcription, however, 
TFIIE and TFIIH are important for promoter melting; opening the promoter template 
(Reese 2003). TFIIH in particular is an interesting protein complex involved in at least 
five distinct pathways including transactivation of hormone-responsive genes, DNA 
repair, RNA pol I and II transcription (Rochette-Egly et al. 1997, Schaeffer, 1993, Iben et 
al. 2002). The capacity of TFIIH to open promoters is an ATP-dependent process 
achieved via two DNA helicases subunits XPB and XPD. CDK7 is a kinase catalytic 
subunit of TFIIH that phosphorylates tandem heptapeptide Tyr-Ser-Pro-Thr-Ser-Pro-Ser 
repeats of the carboxy-terminal domain (CTD) of the largest subunit of RNA pol II. 
Phosphorylation of CTD is essential for triggering the transition from transcriptional 
initiation to elongation in vivo (Dahmus 1995).  
 
The transcriptional machinery accompanying each of the RNA polymerases 
must access DNA, which is packaged into chromatin as described above. It is now 
accepted that nucleosomes are removed from activated promoters, allowing transcription 
initiation complexes to assemble on effectively naked DNA in vivo (Boeger et al. 2003; 
Boeger et al. 2005). Genes transcribed by both pol II and III are associated with 
nucleosomes, whereas active rDNA repeats are nucleosome deficient when transcribed 
and repackaged following replication (Paule and White 2000). Large proportions of both 
active and inactive rRNA genes exist which can hamper analysis of chromatin 
conformation of these repeat arrays. 
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Cis-regulatory elements 
 
Promoters as described above are small 100-200bp sequences located directly 
upstream of the transcriptional start site of genes that attract specific transcription factors 
and transcription machinery to position, assemble and initiate correct transcription. 
Mammalian cells are frequently lacking in defining elements of core promoters (TATA-
boxes, Inrs) where the PIC compiles (Smale 2001), instead mammalian core promoters 
are often associated with stretches of G/C rich sequence (CpG islands) that escape 
methylation. DnaseI hypersensitive sites (HSs) are 200-300bp sequences that have an 
increased susceptibility to DnaseI digestion in comparison to the surrounding chromatin. 
These sites frequently encompass binding sites for specific transcription factors, and 
designate areas of chromatin that are potentially active. Sensitivity occurs via multi-
protein interactions on the template that disturb the position of nucleosome. Clusters of 
HSs are indicative of locus control regions (LCRs) (see below). 
 
Enhancer elements are sequences of assorted transcription factor binding sites 
that provide additional specificity and increase the rate of transcriptional activation. 
Structurally, enhancers are similar to promoters, however enhancers are typically longer 
in sequence, can be positioned many kilobases from transcription start sites and their 
activity is orientation independent; enhancers can be found either upstream or 
downstream of their specific genes or even within genes or overlapping promoters 
(Blackwood and Kadonaga 1998). For many years the precise mechanism of how 
enhancer-binding proteins made contact with promoters remained elusive and several 
different models were hypothesised, including tracking of protein complexes along the 
chromatin fibre from enhancers to promoters, and progressive polymerisation of proteins 
that would stretch from enhancers to promoters (Li et al. 2002). It is now widely accepted 
that long-range chromatin interactions between proteins bound to regulatory elements 
and promoters occur via looping out the intervening chromatin (Blanton et al. 2003,  
Tolhuis et al. 2002). Silencer elements configure in much the same way as enhancers, 
however they attract repressive protein complexes and function to inhibit transcription 
from cis-linked promoters. 
 
An additional level of regulating gene expression occurs in the form of locus 
control regions (LCRs). LCRs are specialised regions of chromatin that are similar to 
enhancers in many ways. The structure of LCRs, composed of varying numbers of 
DNase I hypersensitive sites often incorporating enhancers or enhancer 
blocking/insulator elements and its functional definition of a sequence able to drive 
expression of a linked transgene at a level equivalent to its endogenous counterpart from 
any position in the genome (West and Fraser 2005) determines what separates LCRs 
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from other regulatory elements. LCRs were first functionally characterized in transgenic 
mice at the β-globin locus (Grosveld et al. 1987). Many LCRs are now known for different 
genes (Li et al. 2002). Despite the requirement for a linked LCR to confer position-
independent expression of a transgene, protecting against position effect variegation, 
LCRs do not necessarily control the chromatin environment of their target genes; this 
instead most likely is conferred by recruitment of specific transcription factors such as 
GATA1 and erythroid krüppel–like transcription factor EKLF, which attract chromatin 
remodeling complexes to the β-globin locus (Drissen et al. 2004, Vakoc et al. 2005).  
Genes are activated and repressed according to developmental cues, which will 
be specific for each distinct cell type. Different genes are required to express proteins 
constitutively while others have developmental restriction. Within the genome, 
constitutively expressed genes are juxtaposed with genes encoding specialised proteins, 
and frequently the regulatory elements of these genes will overlap. Insulator sequence 
elements were initially defined as boundaries positioned between domains of open and 
condensed chromatin, and were found to have two defining characteristics; the ability to 
inhibit the spread of heterochromatin and the ability to prevent enhancer-promoter 
interactions when placed in between the two (enhancer blocking) (West et al. 2002). 
These defining features of insulators are now revised, and it is accepted that enhancer-
blocking and heterochromatin barrier functions are separable at least in vertebrates 
(Recillas-Targa et al. 2002). The activity of insulator elements is mediated by the 
interacting protein(s). CTCF is the archetypal factor shown to be required for enhancer 
blocking activity in vertebrates (Bell et al. 1999). Increasingly, it is clear that CTCF does 
not directly regulate all known vertebrate enhancer blocking sequences (see chapter 2). 
Interestingly, the transcription factor YY-1 is known to bind to insulator sequences within 
the imprinted Peg3 gene in a methylation-sensitive manner (Kim et al. 2003). 
Differentially regulated insulator types exist; imprinted insulators are regulated in part by 
DNA methylation affecting the binding of proteins as described for CTCF and YY-1. At 
some insulator sequences, CTCF-mediated enhancer blocking activity is influenced by 
CTCF interaction with thyroid hormone receptor (TR) molecules.   CTCF/TR complexes 
retain the capacity to prevent enhancer-promoter interactions, but this is sensitive to the 
presence of thyroid hormone (Lutz et al. 2003).  
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A territorial yet dynamic nucleus 
Immunofluorescence analysis of an interphase eukaryotic nucleus reveals 
distinct nuclear processes such as transcription, ribosomal DNA processing and DNA 
replication each occurs within sub-nuclear structures (fig 1.2) (Stein et al. 2003).  
 
 
       
           
 
Figure 1.2. Taken from (Stein et al. 2003). 
Different domains of the nucleoplasm can be defined as accumulations of specific proteins as 
revealed by indirect immunofluorescence. Abbreviations: chromatin assembly factor-1 (CAF-
1), promyelocytic leukaemia (PML) bodies, transducin-like enhancer (TLE), vitamin D3 
receptor (VDR). For details see (Stein et al. 2003). 
 
All of these structures must continually re-assemble after mitosis. Highly condensed 
mitotic chromosomes begin to expand once again during telophase, and nucleoli 
emerge. Whole-chromosome FISH analysis has revealed individual chromosomes 
occupy a defined space within the interphase nucleus, the chromosome territory (CT) 
(Cremer and Cremer 2001; Cremer et al. 2006). CTs are considered as sub-nuclear 
structures; chromosomes consistently localise in similar positions relative to the center or 
periphery of the nucleus. Interestingly, chromosomes seem to have preferential positions 
with reference to other chromosomes (Parada and Misteli 2002). The relative position of 
gene loci according to their CT as observed by FISH suggests there is a correlation 
between gene activity and nuclear position, where active genes are preferentially found 
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at the exterior of chromatin domains although transcriptionally active genes are also 
located within the CT (Dietzel et al. 1999, Verschure, 1999). The model for CT 
organisation proposes interchromatin domains (ICD) exist and physically separate 
distinct territories. Recently, an alternative FISH protocol (cryo-FISH) was developed, 
allowing fixed sucrose embedded cells to be cut into 150nm thick slices, which are then 
used for standard FISH (Branco and Pombo 2006). The authors reveal CTs in human 
lymphocytes are not as separated from each other as previously proposed, arguing 
against the existence of ICDs.  
 
Live cell analysis using GFP/lac-repressor constructs has revealed the 
interphase chromatin is not static, but is in a state of continual movement (Chubb et al. 
2002). The understanding of nuclear organisation and how nuclear processes actually 
occur has been greatly advanced by the use of (green) fluorescent protein live-cell 
markers. GFP has in the past been the protein marker of choice (Tsien 1998), although 
utilising markers with different excitation wavelengths permits more detailed analysis 
particularly regarding protein-protein interactions. Time-lapse imaging is used to 
understand the behaviour of a protein, for example at different stages of the cell cycle, 
under different growth/stimulation conditions in an attempt to understand the importance 
of localisation and protein dynamics both within the nucleus, and exchanges between 
nucleoplasm and cytoplasm. The dynamics of a (G)FP tagged protein can be analysed in 
time as a measure of the recovery of fluorescent molecules into a previously bleached 
area (FRAP) (Houtsmuller and Vermeulen 2001), indicating the relative mobility of a 
given protein. Additionally, fluorescent correlation spectroscopy (FCS) measures the 
number of actual fluorescent molecules passing through a specified volume. In this way, 
data can be extrapolated to determine the amount of specific protein that is present in 
nuclear/cellular space (Bacia et al. 2006). Importantly, these techniques are only reliable 
if the tagged protein of interest is functional and behaves as the endogenous protein in 
terms of localisation and expression levels.  
 
It is widely believed that most nuclear factors, certainly most transcription factors are 
highly dynamic and in a constant flux between chromatin and the nucleoplasm (Becker 
et al. 2002, Misteli, 2001). Interestingly, although core histone proteins are part of the 
same octameric complex, H3 and H4 were extremely immobile proteins whereas H2A 
and B had a small fraction of molecules that exchanged quickly. In the case of H2B, the 
dynamics of the mobile fraction was transcription-dependent (Kimura and Cook 2001). 
Proteins for the most part are apparently readily mobile throughout the different nuclear 
compartments. Ribosomal RNA (rRNA) synthesis occurs exclusively within the 
nucleolus, however GFP-tagging of essential rRNA factors revealed a rapid exchange of 
these proteins (upstream binding factor (UBF) 1, UBF2, and TAFI48) occurs between the 
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nucleus and sites of rDNA transcription in the nucleolus (Iben et al. 2002). The dynamics 
of proteins both within the interphase nucleus and during mitosis is an emerging aspect 
of our understanding of gene regulation and nuclear architecture. The mechanisms of 
epigenetic regulation of gene expression during interphase are relatively well 
established. The importance of specific protein interactions with mitotic chromosomes 
and how this contributes to cellular memory are currently unknown.  
 36
 
                                                                                                                       
 37
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
What iis CTCF  
and  
what does ii t do? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 38
Chapter 2: What is CTCF and what does it do?  
Maintenance of genetic and epigenetic integrity of the genome is essential. 
Epigenetic control of gene expression as described above regulates how essential 
cellular processes including transcription, proliferation, differentiation, cellular 
senescence, aging and death occur in a multi-cellular system. CTCF has been identified 
at the forefront of many of these processes. CCCTC-binding factor (CTCF) was originally 
identified as a transcription factor that negatively regulates the chicken c-myc gene 
(Lobanenkov et al. 1990). At the same time it was observed that another protein Nep1 
bound to and regulated transcriptional activity of the chicken lysozyme silencer 
(Baniahmad et al. 1990). Nep1, initially thought to be the human homologue of chicken 
CTCF, was later confirmed to be identical to chicken CTCF (Burcin et al. 1997). CTCF is 
now known to mediate the transcription of a number of different genes, both positively 
and negatively, in the classical fashion of a transcription factor, by recognising and 
directly interacting with promoter sequences (Kuzmin et al. 2005, De La Rosa-Velazquez 
et al. 2007, Renaud et al. 2005). Interestingly this includes recognition of the germ cell-
specific TFIIAα/β-like factor (ALF) promoter (Kim et al. 2006). CTCF binds within introns, 
exons and intergenic sequences in humans (Renaud et al. 2005, Vetchinova et al. 2006) 
with the majority of identified CTCF binding sites apparently located far from 
transcriptional start sites (Kim et al. 2007).  
In this chapter I will introduce CTCF and the current knowledge regarding CTCF 
structure and functions will be discussed.  
 
General features of CTCF 
The Ctcf gene has been conserved throughout over 500 million years of 
deviation between vertebrate and invertebrate species; orthologous Ctcf sequences 
have been identified in genomes ranging from mosquito to human (Gray and Coates 
2005). In mice, the gene coding for Ctcf is located on chromosome 8 and consists of at 
least two non-coding exons and 10 coding exons that generate a 728 amino acid protein 
with a predicted relative molecular mass of 82kDa. However, it is well documented that 
CTCF migrates in SDS-PAGE at around 130kDa due to effects from the amino and 
carboxy-terminal domains (Klenova et al. 1997). The genomic structure of CTCF is 
highly conserved particularly in mammals, where the exon-intron junctions in mice and 
humans are identical (Ohlsson et al. 2001). Recent analysis of zebrafish CTCF revealed 
structural similarities to human CTCF genomic organisation, which puts it closer to 
mammalian CTCF than chicken (Pugacheva et al. 2006).  
The CTCF protein in all vertebrates features three distinct regulatory domains, 
of which the central zinc-finger domain consisting of 10 C2H2 and one C2HC-type zinc-
fingers is strictly preserved with 100% amino acid identity between avian and 
mammalian CTCF proteins (Filippova et al. 1996) and 98% identity comparing to 
                                                                                                                       
 39
zebrafish and Xenopus laevis (Burke et al. 2002a). The eleven zinc-finger domain is also 
present in invertebrates, however the conservation of sequence is less consistent. The 
zinc-finger domain mediates CpG methylation-sensitive binding of CTCF to DNA and 
interactions with itself and other proteins. Importantly, CTCF is reported to bind diverse 
DNA sequences, a characteristic feature, which allows interaction between CTCF and 
many different regulatory elements, contributing to the multifunctional nature of the 
protein. The apparent lack of consensus binding site for CTCF has been partially 
explained by deletion analysis of individual zinc-fingers, revealing particular 
combinations of zinc-fingers recognise some target sites while different zinc-finger 
contacts are associated with other target site interactions (Baniahmad et al. 1990, 
Filippova et al. 1996, Quitschke et al. 2000). As such CTCF is considered to be a 
multivalent protein. Ostensibly, the CTCF protein has quite a flexible topology and 
structure. The apparent selective use of zinc-fingers suggests that further control either 
within the 11-zinc-finger domain as a whole, or indeed the entire protein must be present 
to enable conformational plasticity of the CTCF-DNA complex (Pugacheva et al. 2005). 
How this is achieved remains unknown. A wide range of regulatory sequences, some of 
which bear little sequence homology to each other or to comparative regulatory elements 
in related species, have been identified to bind CTCF. Chromatin immunoprecipitation 
followed by detection with genome-tilling microarrays identified 13,804 CTCF binding 
sites in the human genome and a predicted consensus sequence was proposed (Kim et 
al. 2007). Comparisons of conserved sequences in the human genome also led to the 
establishment of a vertebrate consensus sequence (Xie et al. 2007). Recently, a 
proposed consensus binding sequence for CTCF was reported in Drosophila. In this 
study, the authors compared the two consensus sequences of human and drosophila to 
each other, revealing a conserved AGGNGGC consensus sequence (Holohan et al. 
2007). Although no agreed consensus sequence can encompass all established CTCF 
binding sites, within the 50bp DNase footprint of CTCF, a smaller characteristic motif 
occurs (Filippova et al. 2001). The study by Holohan et al hypothesised binding of CTCF 
to specific DNA may be more consistent and conserved than previous analysis suggests. 
Importantly, sequences identified in Drosophila to bind CTCF function as target sites for 
both Drosophila and chicken CTCF proteins, but the Drosophila CTCF protein does not 
interact with all vertebrate target sites (Moon et al. 2005, Klenova et al. 2002) suggesting 
functional evolution of the CTCF protein. 
Consistent with its classification as a transcription factor, CTCF encompasses 
two additional transcriptional regulatory domains, which flank the central zinc-finger 
region. Transcriptional activation and repression activity has been associated with both 
the amino and carboxy-terminal domains, the specificity of action seems to be target 
sequence and cell-type dependent (Drueppel et al. 2004, Vostrov & Quitschke. 1997, 
Lutz et al. 2000).  
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 It is not clear how domains outside of the zinc-finger region influence other 
CTCF functions such as enhancer blocking or mediating chromatin loop formation. CTCF 
is currently known to be phosphorylated and subject to poly(ADP-ribosylation) in vivo (Yu 
et al. 2004, Klenova, 2001), although other as yet unclassified modifications of CTCF 
may also occur (Zhang et al. 2004). Poly(ADP-ribosylation) describes the covalent 
addition of  ADP-ribose polymers onto various target proteins, which in the case of CTCF 
occurs preferentially on the N-terminal domain. Attachment of linear or branched 
poly(ADP-ribose) units is directed almost exclusively  to the γ-carboxyl group of glutamic 
acid residues by poly(ADP-ribose) polymerases such as PARP1. There are at least 
seven PARP family members, which may have redundant functions, complicating 
analysis of PARPs and proteins that are poly(ADP-ribosyl)ated. The balance of 
poly(ADP-ribosylation) is maintained by poly(ADP-ribose) glycohydrolase (PARG), which 
releases free ADP-ribose units by hydrolysing glycosidic bonds of ribose-ribose polymers 
(Soldani and Scovassi 2002, Rouleau, 2004).  Poly(ADP-ribosylation) is a crucial 
modification which occurs on many different proteins from transcription factors to 
histones, and as such is essential for regulating numerous cellular processes including 
DNA repair, apoptosis, transcription, replication, differentiation and has a role in 
chromatin structure (Kraus and Lis 2003, Tulin et al. 2003, Soldani et al. 2001).  
 
Interestingly, accumulation of the CTCF protein to the nucleolus has been 
shown to occur in differentiating cells in a poly(ADP-ribosylation)-dependent manner, 
and is proposed to negatively regulate ribosomal DNA (rDNA) transcription causing an 
arrest in cellular proliferation. Inhibition of poly(ADP-ribosylation) with 3-aminobenzamide 
(3-ABA), a PAR polymerase inhibitor, alleviated  repression of rDNA transcription and 
impedes nucleolar translocation of the protein (Torrano et al. 2006). Poly(ADP-
ribosylation) of CTCF appears to correlate with CTCF interaction with target sites and 
mediates insulator activity of CTCF target sites as shown by H19 ICR insulator sensitivity 
to 3-ABA, (Yu et al. 2004). Detection of the PAR-modified CTCF protein with anti-PAR-
polymer antibody revealed this increased the molecular mass of CTCF to 180kDa. It is 
significant to note that the authors of this study concede only proteins with more than 10 
poly(ADP-ribose) units can be detected with this antibody. It is also possible that polymer 
chains less than 10 units in length attach to CTCF and mediates its function and/or 
structure. The 180kDa form of CTCF is not detectable in all cell types and it remains to 
be seen if other CTCF-dependent insulators also recruit poly(ADP-ribosyl)ated CTCF. 
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Figure 2.1: Schematic representation of the murine CTCF protein. The DNA binding 
domain (mid grey) is composed of 11 zinc fingers. Known casein kinase II (CKII) 
phosphorylation sites, PXXP and AT hook motifs are indicated together with the location of 
the nuclear localisation signal (NLS). Numbers indicate amino acids. See text for details. 
 
 
Within the C-terminal domain, four prominent motifs are present that influence 
CTCF protein function. As a constitutively nuclear protein, CTCF requires import to the 
nucleus from the cytoplasm. Translocation into the nucleus is regulated by importins that 
usually bind to the NLS (Macara 2001). The CTCF NLS is located in the 8th coding exon. 
Mis-localisation of CTCF in the cytoplasm has been described in cases of invasive 
breast carcinoma, however a correlation between this and carcinogenesis remains 
undefined (Rakha et al. 2004) (see below). It remains unknown which importins function 
to locate the CTCF protein within the nucleus.   
As mentioned above, CTCF is a phosphoprotein in vitro and in vivo (Klenova et 
al. 2001). A SKKEDSSDSE motif is unerringly conserved in vertebrates although in 
X.laevis, one aspartic acid (D) residue is replaced by glycine (G) and one serine (S) is 
changed to a threonine (T) (Burke et al. 2002). It is possible the D-G exchange may alter 
the conformation of the protein changing from polar to non-polar side chains that favour 
the outside and inside of proteins respectively.  The serine residues within this motif 
have been identified as substrates for casein kinase II (Klenova et al. 2001).  This study 
revealed by substitution of serines that phosphorylation of CTCF by casein kinase II is 
not required for binding DNA in vitro or the localisation of CTCF within the nucleus, but 
does effect transcriptional repression and cell cycle progression. It has been proposed 
that phosphorylation of CTCF may specify interactions between protein partners or 
regulate the dimerisation potential of CTCF that in turn effects its functional capacity. 
Two further short motifs are located within the C-terminal of CTCF; a potential 
DNA-binding and chromatin-remodelling motif of KRRGRP, known as an AT-hook 
sequence, and a doublet of the PXXP motif distinctive of Src homology 3 (SH3)-domain 
binding proteins. Functionality of the PXXP sequence has been suggested to mediate 
CTCF interaction with BIN-1, a MYC-associated protein, which may regulate repressing 
capabilities of the CTCF C-terminal domain in vitro via essential prolines in this motif 
(Ohlsson et al. 2001).  
NLS         
CKII sites
PXXP  
AT Hook 
NH2 COOH DNA binding domain 
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More than a transcription factor 
 
It is evident that the regulation of gene expression by CTCF extends far beyond 
that of a typical transcription factor. CTCF establishes hormone-responsive 
transcriptional regulatory elements and formation of enhancer-blocking boundary 
elements (Lutz et al. 2003, Burke et al. 2002, Recillas-Targa et al. 2006). Binding sites 
for CTCF are found in several examples to be in close proximity to thyroid hormone 
response elements (TREs) and the location of these composite regulatory elements 
does not necessarily correspond to transcription initiation sites nor is the spacing and 
orientation between CTCF binding sites and TREs consistent (Burke et al. 2002b). In at 
least two cases, the chicken lysozyme gene and human c-myc, CTCF binding sites and 
associated TREs are positioned in between an enhancer and its respective gene 
promoter. Enhancer-blocking activity of CTCF at these sites is mediated by the presence 
of thyroid hormone triiodothyronine (T3) where by the enhancer-blocking capacity of 
CTCF is disrupted in the presence of T3. Further analysis of the chicken lysozyme gene 
revealed CTCF binding per se is not sufficient for enhancer-blocking activity, as CTCF 
remains bound to chromatin even in addition of thyroid hormone and attracts acetylation 
modifications to histone H4 (Lutz et al. 2003). Interestingly, not all TREs function in the 
same manner; TRE 144 coordinates CTCF dependent transcriptional repression in the 
presence of T3 and is therefore considered as a negative TRE (Awad et al. 1999). 
Importantly, it seems that not all nuclear hormone receptor (NHR) binding sites function 
in synergy with CTCF and not all CTCF binding sites require T3 or nuclear hormone 
receptors for CTCF activity (Szabo et al. 2006) (see below).  
 
CTCF, insulators and enhancer blocking 
Chromatin insulators are largely characterised by two separable functions; 
enhancer blocking and protection against chromatin position effects. The ability of 
insulators to shield a transgene against long-term silencing is another important function 
known as silencer-blocking or anti-silencing effects (Pikaart et al. 1998, Yao et al. 2003, 
Hino et al. 2006). CTCF is increasingly linked to the regulation of epigenetics and long-
range chromatin interactions mediating gene expression. The interactions between 
CTCF and diverse insulator sequences have been used to propose a regulatory role for 
CTCF in higher order chromatin organisation and nuclear dynamics.  
 
CTCF was the first and currently only identified vertebrate protein able to 
interact with and regulate enhancer blocking activity of a variety of different insulator 
sequences (Bell et al. 1999). As such it was hypothesised that CTCF may function to 
delineate the genome into regulated functional domains. In complex genomes, the 
spatial and temporal integrity of gene regulation is critical. It is widely believed that 
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shielding neighbouring gene loci from inappropriate regulatory elements is achieved in 
part by insulator sequences and their associated binding proteins However, many genes 
have overlapping regulatory elements or anti-sense transcripts belonging to differentially 
regulated genes, so considering the genome as demarcated into domains is essentially 
misleading. The concept of functional expression modules (de Laat and Grosveld 2003) 
clarifies the genome into a manageable model, which retains the significance of spatial 
and temporal gene regulation.  
Integral to assigning the role of establishing functional expression modules to 
CTCF is the identification of CTCF binding sites and their positions within the genome. 
Analysis of the chicken, mouse and human β-globin locus revealed flanking CTCF 
binding sites, strongly suggesting an archetypal insulator role for CTCF at this locus 
protecting temporal and spatial regulation of β-like globin genes from inappropriate 
activation by distal enhancers (Farrell et al. 2002). CTCF binding sites from the β-globin 
locus have been classified as insulators in vitro although the activity of these insulators 
varies significantly (Bell et al. 1999, Farrell et al. 2002, Bulger et al. 1999, Wai et al. 
2003).  Currently, three CTCF binding sites are known to be located 5’ of the β-globin 
locus and one is positioned at the 3’HS1, all sites correspond to DNase I hypersensitive 
sites shown to cluster into a formation known as the Active Chromatin Hub (ACH) 
(Tolhuis et al. 2002) (see chapter 3 for details). No sites are identified within the β-globin 
domain (Yusufzai et al. 2004). Importantly, formation of the normal ACH is CTCF 
dependent as when one CTCF binding site is mutated, configuration of the ACH is 
disrupted without transcriptional effect on the β-globin genes (chapter 4, Splinter et al. 
2006). Histone H3 acetylation is lost from a mutated 3’HS1 site which can no longer bind 
CTCF and is replaced by repressive histone modifications. This change in chromatin 
conformation occurs at all β-globin CTCF binding sites in the absence of CTCF, but the 
change is specifically local to CTCF binding sites, and does not induce the entire locus 
into a closed state. Questions therefore remain over the function of these CTCF binding 
sites at the β-globin locus and whether CTCF binding sites are indicative of functional 
expression modules (Kim et al. 2007).  
Recent data indicates three previously unknown examples of gene loci that are 
surrounded by CTCF binding sites, α-polypeptide H+/K+ exchanging ATPase (ATP4a), 
myelin-associated glycoprotein (MAG) and NIFIE14 encoding a transmembrane protein 
(Vetchinova et al. 2006), however it is clear that not all loci are regulated by flanking 
CTCF binding sites. The importance of considering functional expression modules rather 
than domains is demonstrated at the α-globin gene locus, which resides in a region of 
open chromatin regardless of transcriptional activation. CTCF dependent enhancer-
blocking elements have been identified in the α-globin locus and CTCF binds to these 
sites in both erythroid and non-erythroid cells (Valadez-Graham et al. 2004).  
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Chromatin structure around the c-myc gene is part of a 160Kb domain flanked 
by MAR sequences that apparently insulate c-myc from the adjacent pvt1 gene. The 
active c-myc gene is associated with acetylated histones, flanked by repressive 
chromatin modifications that comprise no other expressed genes. CTCF interaction with 
the c-myc MARs was not detected. A sequence 5’ to the c-myc gene was identified to 
have insulator activity in vitro and was found to bind CTCF, but no CTCF site 3’ to c-myc 
was identified. The c-myc insulator element (MINE) comprises separable enhancer 
blocking and barrier actions, which are CTCF-dependent and independent respectively 
and does not associate with the nuclear matrix. Importantly, the mechanism of the MINE 
activity seems to be distinct from other insulator elements such as chicken β-globin HS4 
as it does not attract an open chromatin configuration and is located outside of the c-myc 
hyperacetylated domain. Several potential CTCF binding sites have been identified in 
silico and in vitro, but only two are significantly conserved between humans and mice 
and are associated with DNase I hypersensitive sites. Both CTCF binding sites are 5’ to 
c-myc, and CTCF binds constitutively in vivo within the c-myc loop regardless of 
transcriptional activity, suggesting CTCF per se may not directly repress c-myc 
transcription (Lobanenkov et al. 1990, Filippova et al. 1996) and other factors are 
required for the regulation of c-myc (Gombert et al. 2003).  
There are a number of complex loci, which have been identified as having 
CTCF-dependent enhancer blocking elements, however the significance of CTCF 
binding and possible mechanisms of action remain largely elusive. CTCF binding sites 
have been identified within the mouse rDNA locus in between the repeating units of 
ribosomal genes (SvdN unpublished data). In Xenopus, a sequence known as the repeat 
organiser (RO) was shown to have enhancer-blocking activity in vitro using transfected 
K562 cells (Bell et al. 1999, Robinett et al. 1997).This sequence was also identified to 
bind CTCF. Organisation of rDNA transcription is a highly complicated arrangement, as 
not all ribosomal genes will be transcribing at any one time and in a population of cells, 
not all cells will have identical rDNA locus chromatin configurations. Unravelling how 
CTCF functions at this locus will be of great interest.  
Very little is known regarding repetitive sequences as regulated insulator 
elements. It is known that Alu-like repeating sequences flanking the human keratin-18 
(K18) gene function as insulators in transgenic mice (Willoughby et al. 2000), and this 
activity requires RNA polymerase III. Whether there is a CTCF involvement remains 
open to speculation. Alu-like repeating sequences have been identified within CTCF 
binding sites (Vetchinova et al. 2006). 
 
CTCF-mediated enhancer blocking activity seems to be largely conserved from 
Drosophila to human (Moon et al. 2005). The enhancer blocking capacity of insulators 
has been determined as separable to the action of preventing the aberrant acquisition of 
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repressive chromatin modifications, as CTCF binding is necessary for one function but 
not the other (Recillas-Targa et al. 2002). CTCF does not bind all insulators with 
enhancer blocking activity (Magdinier et al. 2004, Holohan et al. 2007, Gomos-Klein et 
al. 2007), indicating at least in some loci, enhancer-blocking activity is a CTCF-
independent process and some insulators function in a CTCF-independent manner. In 
vitro silencer blocking activity by the chicken β-globin 5’HS4 insulator is CTCF 
independent (Yao et al. 2003), however in vivo silencer-blocking activity of CTCF has 
been identified to regulate the imprinted expression of alternative Wilms’ tumour 
suppressor gene-1 (AWT1) and Wilms’ tumour suppressor gene anti-sense transcripts 
(WT1-AS) (Hancock et al. 2007). Interesting connections have been made between the 
enhancer blocking capacity of insulator sequences and their interaction with the nuclear 
matrix. Several insulator sequences including the chicken β-globin HS4 and the 
Drosophila insulator gypsy are known to link chromatin to the nuclear matrix (Yusufzai 
and Felsenfeld 2004, Byrd et al. 2003). CTCF itself has been identified as a MAR-
binding protein (Dunn et al. 2003) and association of CTCF with the nuclear matrix 
correlates with enhancer-blocking activity of insulators although this relationship is not 
absolute (Gombert et al. 2003). It has been proposed that insulators cannot contact the 
nuclear matrix in the absence of CTCF binding, which in turn leads to loss of enhancer-
blocking activity, but again this can not be considered as a general rule. Significantly, the 
anti-silencing capacity of insulators may not require either CTCF or linking to the nuclear 
matrix (Hino et al. 2006).  
 
With the exceptions of the mouse β-globin locus and imprinted gene loci, 
insulator activity is most commonly studied using in vitro cell culture systems. 
Importantly, this does not always reflect the in vivo function as CTCF-binding insulator 
sequences as defined in vitro can activate transcription in vivo (Vostrov and Quitschke 
1997). The identification of new vertebrate proteins that interact with and regulate 
insulator activity will help to enhance our understanding of both how long-range gene 
regulation occurs, and may uncover mechanisms of CTCF-mediated insulator activity. 
 
 
CTCF, enhancer-blocking and imprinted gene expression 
The ability of CTCF to mediate the formation of chromatin loops in cis and 
interact with DNA in a CpG methylation-sensitive manner has been used as a model for 
the regulation of imprinted gene expression. The majority of genes in somatic cells are 
expressed from both maternally and paternally inherited alleles; genomic imprinting 
describes the inheritance of monoallelic gene expression in male and female cells where 
expression of a gene occurs exclusively from one allele depending on the parental origin, 
therefore imprinted genes have haploid expression despite the diploid nature of the 
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locus. In female cells, loci on one X chromosome are completely silenced (X-inactivation, 
see below). About seventy mammalian genes are known to be imprinted (Yoon et al. 
2005). DNA methylation is an integral feature of imprinted gene regulation (Li et al. 1993) 
and until recently it was unclear how differential methylation patterns on these loci were 
maintained.  
 
In mice, the most well characterised study of CTCF-mediated imprinted gene 
expression has come from analysis of the Igf2/H19 imprinted locus. Insulin-like growth 
factor type 2 (Igf2) is an embryonic mitogen and H19 generates a non-coding RNA of 
undefined function. A considerable proportion of imprinted genes produce non-coding 
RNAs, which may have important roles in the regulation of gene expression in cis 
(Sleutels and Barlow 2002). Igf2 is positioned approximately 80Kb upstream of the H19 
on mouse chromosome 7. These factors are expressed solely from the paternal and 
maternal allele respectively (Murrell et al. 2004). Transcription at this locus is known to 
be dependent on two distinct regulatory elements; enhancers located downstream of 
H19 are used to activate both H19 and Igf2 and a region of intervening sequence located 
2.4Kb upstream of the H19 transcriptional start site is critical for regulating imprinted 
expression of these genes. This element was termed the imprinting control region (ICR) 
or differentially methylated domain (DMD) and was later shown to bind CTCF in a 
methylation-sensitive manner (Leighton et al. 1995, Thorvaldsen et al. 1998, Hark et al. 
2000, Bell et al. 2000). Importantly, binding of CTCF to the DMD occurs only on the 
maternal allele where this region is unmethylated and H19 is transcribed. Co-ordinately, 
the Igf2 gene is silenced on the maternal allele. CTCF interaction with the maternal DMD 
prevents the downstream enhancers activating Igf2, as such this element was proposed 
to be an insulator and was shown to have enhancer-blocking activity in vitro and in vivo 
(Hark et al. 2000, Bell et al. 2000). The H19 DMD is an example of an enhancer-blocking 
element that does not associate with the nuclear matrix but matrix attachment of this 
locus does occur in a cell-type and parent-of-origin specific manner (Weber et al. 2003). 
Recent analysis of this locus has revealed CTCF interaction with the maternal ICR 
mediates clustering of the ICR with matrix attachment region (MAR) 3 (Kurukuti et al. 
2006). On the paternal allele the DMD is hypermethylated and CpG methylation is 
incompatible to CTCF binding. Methylation of the paternal DMD coincides with silencing 
of H19 by spreading of methylation repressive chromatin modifications onto the H19 
promoter. Activation of Igf2 by the downstream enhancers apparently occurs by default.  
Using 3C technology, it has been shown that the Igf2/H19 locus forms chromatin 
loops that are in part mediated by CTCF (Murrell et al. 2004). Two distinct loops occur on 
the paternal and maternal alleles where differentially methylated regions (DMR) 1 and 2 
interact with the unmethylated maternal and methylated paternal ICR respectively. The 
DMR1-ICR interaction positions Igf2 into a silent loop where as on the paternal allele, 
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DMR2-ICR interactions bring the enhancers in close proximity to the Igf2 promoter 
allowing transcriptional activation. It is unclear if CTCF binds to DMR2 but binding of 
CTCF to DMR1 has been shown by ChIP (Kurukuti et al. 2006). The importance of 
CTCF in mediating the imprinted expression patterns of these genes is demonstrated 
when the ICR binding CTCF is deleted. Deletion of the maternal ICR induces biallelic 
expression of Igf2, and this is not observed if the paternal ICR is absent.  Loss of Igf2 
imprinting is also observed when levels of CTCF are reduced using RNA interference 
(RNAi) (Ling et al. 2006).  
The loss of CTCF binding to the ICR either by mutation, deletion or knockdown 
correlates with a gain of methylation, which raised the question of whether DNA 
methylation is dependent on the absence of CTCF binding and if CTCF protects 
sequences from acquiring methylation. Two independent and apparently contradictory 
studies have addressed this issue.  Reduction of CTCF in oocytes using RNAi revealed 
a requirement for CTCF in both the establishment and maintenance of differential 
methylation patterns of the Igf2/H19 locus (Fedoriw et al. 2004). However, mutation of 
the four CTCF binding sites within the ICR in female and male germ lines did not result in 
a gain of methylation or indeed any change in methylation status of either paternal 
(hypermethylated) or maternal (hypomethylated) mutated alleles (Szabo et al. 2004). 
This study indicated that establishment of imprinting could be CTCF-independent but 
importantly, after fertilisation, the absence of CTCF binding led to acquisition of 
methylation on the maternal allele, linking CTCF to a role in methylation inhibition. 
Significantly, by mutating the CTCF binding sites, Szabó et al suggested that other 
proteins, which might bind CTCF sites such as BORIS, also could not be responsible for 
methylation patterns pre-implantation. This study does not rule out the possibility of other 
CTCF-dependent regulatory elements that may effect the establishment of imprinted 
gene expression of this locus (Cerrato et al. 2003). Likewise, a global loss of CTCF as 
done with RNAi will also affect other CTCF binding sites in the region and may be 
indicative of a more widespread effect of CTCF loss in nuclear organisation.  
 
It is important to consider that not all imprinted gene loci are regulated in the 
same way. Indeed, even for a single imprinted locus, the pattern of expression can 
change depending on the developmental stage or particular tissue analysed. To 
conclude that CTCF regulates imprinted gene expression is an exaggerated 
generalisation of the story. CTCF has at least been implicated in the imprinted 
expression of several loci (Hikichi et al. 2003, Yoon et al. 2005, Hancock et al. 2007, 
Fitzpatrick et al. 2007) but the mechanisms of how CTCF functions and its precise 
involvement are far from being understood. ICRs are common to a number of imprinted 
genes and together with non-coding RNAs are thought to encompass how imprinted 
gene expression is regulated in general (Pauler and Barlow 2006). 
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CTCF and escape genes; X chromosome inactivation 
Female mammalian somatic cells require dosage compensation to balance the 
expression of X-linked genes with that seen in males, and this is achieved by silencing 
one X-chromosome (for details see ch.1) (Lyon 1961). The first evidence for CTCF 
involvement in X-inactivation came from studies identifying CTCF binding sites in a 
region known as the choice/imprinting center located 5’ of Tsix (Chao et al. 2002). Using 
chromatin immunoprecipitation, CTCF was found to bind to Tsix and it was proposed that 
binding of CTCF indicates the future active X-chromosome (Xa). Interestingly, CTCF 
binding sites also flank the promoter region of Xist. Silencing of the Xist promoter is 
mediated by full length Tsix as truncations impede hetrochromatinisation of the Xist 
promoter (Navarro et al. 2006). This implies a dual role for CTCF, as an activator of Tsix, 
but also required for Xist transcription that generates the Xist nuclear RNA, which 
initiates X-inactivation. Recent data reveal that binding sites for YY1 are in close 
proximity to CTCF binding sites within the X inactivation center and that YY1 is a 
necessary co-factor for CTCF activity in X-inactivation, particularly the transactivation of 
Tsix (Donohoe et al. 2007). It is not yet known if paired CTCF-YY1 sequences are a 
general element of imprinted or autosomal gene regulation.  
The process of X-inactivation requires choice of which X becomes inactivated in 
female cells, and counting of the number of X chromosomes to ensure that male cells 
which only have one X keep their single X chromosome active. A 1.2Kb region of tandem 
repeats located 750bp downstream of the major Tsix promoter has been identified as 
critical for regulating counting (Vigneau et al. 2006). It was previously revealed that 
CTCF has several binding sites within this DXPas34 element (Chao et al. 2002), 
however the mechanisms and function of DXPas34 and CTCF binding remain unknown.  
Not all X-linked genes on the inactive X are silenced. The proportion of active 
genes on the inactive X chromosome differs significantly between just seven genes in 
mice and 10-20% of genes humans (Cohen and Lee 2002, Carrel et al, 1999). A CTCF-
dependent model for escape genes has recently been proposed as binding sites for 
CTCF are positioned 5’ to three genes, human EIF2S3 and mouse Eif2s2x and Jarid1C 
genes that remain active despite nearby inactive genes (Filippova et al. 2005). However, 
targeted insertion of cHS4, a known CTCF binding site and enhancer-blocker element, 
either side of the mouse Hprt locus in ES cells failed to protect the transgene against 
either random or imprinted X inactivation (Ciavatta et al. 2006). Although this data 
appears contradictory to that by Filippova et al, it is important to remember CTCF activity 
may be target site specific or more likely that additional sequences within the regions of 
the identified escape genes are required to establish transcriptional activity in the context 
of the inactive X chromosome.   
Parallels between X-inactivation and autosomal imprinting are becoming 
increasingly apparent. As CTCF is known to mediate the imprinted gene expression of 
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some loci in a methylation-sensitive manner and differentially methylated regions within 
X chromosomes are now being identified, comparisons are intriguing (Boumil et al. 
2006). Monoallelic expression is a characteristic feature of both X-inactivation and 
autosomal imprinting, however other loci including immunoglobulin genes, T-cell and 
olfactory receptors undergo allelic exclusion (Goldmit and Bergman 2004). The function 
of CTCF in mediating allelic exclusion and locus contraction is currently being 
investigated. Asynchronous replication timing is a feature of all monallelically expressed 
loci. Recent data suggest CTCF is involved in regulating the replication timing of the 
Igf2/H19 locus, however it is not clear if CTCF-mediated replication timing occurs 
genome wide (Bergstrom et al. 2007). Interesting differences between X-inactivation and 
autosomal imprinting also occur. CpG DNA methylation strongly inhibits CTCF 
interaction with the autosomal imprinted Igf2/H19 locus (Hark et al. 2000, Bell et al, 
2000), however binding of CTCF to Tsix is only partially disrupted by CpG methylation 
(Chao et al. 2002). 
Both X-inactivation and imprinted gene expression are connected to non-coding 
RNA transcripts. The silencing of one X chromosome requires production of a non-
coding RNA, while a number of imprinted genes generate both sense and anti-sense 
non-coding transcripts. Non-coding RNAs are important regulators of gene expression, 
attracting the formation of heterochromatin including DNA methylation. The presence of 
non-coding RNAs is thought to be a key aspect of normal gene regulation (Holohan et al. 
2007). CTCF interaction with intergenic transcripts has been linked to the regulation of 
the DM1 locus associated with myotonic dystrophy (DM). CTG repeat expansion of the 3’ 
non-coding region of the protein kinase DMPK gene and the accompanying 
heterochromatin is constrained by CTCF binding sites (Filippova et al. 2001, Cho et al, 
2005). CTG repeats are a normal feature of this locus, however in pathological 
conditions, this repeat unit expands from between 5-38 repeats up to thousands. Repeat 
expansion carries accompanying heterochromatin modifications over the neighbouring 
Six5 gene suppressing transcription (Otten and Tapscott 1995) and associated DNA 
methylation is thought to prevent CTCF binding thereby disrupting the insulator function 
of CTCF at this locus.  It has been proposed elsewhere that CTCF may function as a 
barrier to non-coding transcription in Drosophila by blocking RNA polymerase II 
progression, and that this may facilitate the differential regulation of transcriptional units 
found in close proximity (Holohan et al. 2007). 
 
 
CTCF and intrachromosomal interactions 
The importance of intrachromosomal interactions has been appreciated for a 
long time. The classical example of functional trans-interactions is the generation of 
nucleoli. Around 400 ribosomal genes are arranged in tandem repeats that cluster at 
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defined positions within five pairs of chromosomes; 13, 14, 15, 21 and 22 in human 
diploid cells. These clusters are called nucleolus organising regions (NORs) and NORs 
on different chromosomes come together during interphase and help initiate formation of 
nucleoli (Anastassova-Kristeva 1977). Despite this, the mechanisms and implications of 
interchromosomal interactions are poorly understood. Techniques such as 3-C that 
enable analysis of chromatin interactions in cis have been adapted into chromatin 
conformation capture-on-chip (4-C) (Simonis et al. 2006), which together with DNA 
immunofluorescence (DNA-FISH) can identify chromatin interactions occurring in trans. 
Intrachromosomal interactions have recently been used to describe the regulated 
monoallelic expression patterns of interferon-γ and interleukin genes in distinct subsets 
of T-helper cells (Spilianakis et al. 2005). CTCF has been shown to mediate 
interchromosomal interactions between the Igf2/H19 locus on mouse chromosome 7 and 
an intergenic sequence between the Wsb1 and Nf1 genes on mouse chromosome 11 
(Ling et al. 2006). It remains to be seen if other loci also interact in trans in a CTCF-
dependent manner. Random X-inactivation involving counting and choice mechanisms 
also requires trans X-X interaction and possibly X-autosome interactions (Bacher et al. 
2006, Xu et al. 2006). CTCF is proposed to mediate the physical association between X-
chromosomes (Xu et al. 2007). A fascinating common theme of known examples of 
trans-interactions with exception of NOR clusters is monoallelic expression. It remains to 
be seen how extensive the relationship between regulating monoallelic expression and 
chromosomal interactions in trans becomes and whether or not CTCF is a common 
factor in both.  
 
 
CTCF; a tumour-suppressor gene? 
In human cells, CTCF maps to the long arm of chromosome 16, in a region 
frequently deleted in sporadic breast and prostate tumours, 16q22.1 (Filippova et al. 
1998). As such CTCF was proposed to be a tumour suppressor gene. CTCF expression 
is closely linked to cell-cycle regulation and there is evidence suggesting CTCF controls 
many genes involved in cell-cycle progression. Identified mutations in CTCF effect the 
zinc-finger region and binding to growth promoting but not growth-neutral promoters 
(Klenova et al. 2002). The precise role for CTCF controlling cellular proliferation is 
unclear, as ectopic expression of CTCF results in cell growth inhibition without apoptosis 
(Rasko et al. 2001, Docquier et al. 2005) and overexpression in K562 cells induces 
erythroid differentiation together with restricting proliferation. In at least two loci, CTCF 
binding is important for protecting promoters of tumour suppressor genes from acquiring 
methylation and repression (De La Rosa-Velazquez et al. 2007, Butcher et al. 2004). 
Current data regarding CTCF as a potential tumour suppressor gene seem to link mis-
regulation of CTCF rather than CTCF mutations to be involved in tumourigenesis. Loss 
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or mutations of CTCF transcripts occur as a very late marker in Wilms’ tumour 
development (Hancock et al. 2007). Interestingly, mutations in CTCF are rare and not 
correlated to loss of imprinting of Igf2 in Wilms’ tumours (Cui et al. 2001). Analysis of 
CTCF mutations in invasive breast carcinomas and familial breast cancer revealed no 
specific correlation and concluded CTCF mutation is not a critical risk factor (Aulmann et 
al. 2003, Zhou et al. 2004). Cytoplasmic accumulation of CTCF was found in the majority 
of invasive breast carcinoma analysed, however this mis-localisation of CTCF did not 
show a relationship to tumour type (Rakha et al. 2004). Clearly, further detailed analysis 
of CTCF deficient cells and tumours are required to understand the complexities linking 
CTCF and tumourigenesis. To date, the effect of post-translational modifications on 
CTCF activity have not been associated with tumours. CTCF is expressed in tumour cell 
lines such as K562 and HeLa cells, suggesting CTCF modifications or mis-targeting 
opposed to loss of CTCF occurs in malignant cells. Expression of the closely related 
CTCF protein BORIS is found to be over-expressed in cancer and is expressed in 
human tumour cell lines (Hong et al. 2005). The significance of BORIS expression in 
cancer is unknown, but may deregulate expression of CTCF target genes by competing 
for CTCF target sites. Loss of CTCF is not enough to induce activation of BORIS in 
somatic cells (this thesis). 
 
Protein partners of CTCF 
Given the numerous roles for CTCF, especially mediating histone modifications 
and chromatin structure, you could expect this to be assisted by many different cell-type 
specific or gene-specific interaction partners. A surprisingly low number of protein 
partners have been identified and characterised as specifically interacting with CTCF. To 
date, known CTCF-interacting proteins are ubiquitously expressed, as is CTCF.  
Y-box binding protein 1 (YB-1) is an RNA/DNA-binding factor that is proposed to 
mediate transcriptional repression in a co-operative manner with CTCF (Chernukhin et 
al. 2000). Functional association of CTCF-YB1 complexes are not fully understood, 
however correct expression of the serotonin transporter gene (5-HHT) requires YB1 
binding to an intronic variable number tandem repeat (VNTR) motif, and this binding is 
disrupted by CTCF (Klenova et al. 2004).  
Kaiso is a zinc-finger transcription factor of the POZ (pox virus and zinc-finger) 
family. Target sites for Kaiso have been identified close to CTCF binding sites. 
Significantly, Kaiso interactions with DNA are not CpG methylation sensitive. Within the 
human β-globin locus, one unmethylated Kaiso site is present near the CTCF-mediated 
insulator 5’HS5, and binding of Kaiso prevents enhancer-blocking activity by CTCF 
possibly by disrupting binding of CTCF to its target site (Defossez et al. 2005). 
Interestingly, evidence suggests that Kaiso is able to recognise aberrantly CpG 
methylated CTCF binding sites in the promoter of the human retinoblastoma  (Rb) gene, 
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leading to epigenetic silencing of the promoter (De La Rosa-Velazquez et al. 2007). It is 
not clear if Kaiso interaction is a general repressor of transcriptional activation or 
enhancer-blocking activity by CTCF or if this is restricted to modify the functions of CTCF 
in a temporal or cell-type specific manner.  
CTCF has been shown to co-purify with nucleophosmin (B23), which is a protein 
associated with the granular component of the nucleolus (Yusufzai et al. 2004). 
Localisation of CTCF in nucleoli is observed in cells stimulated to go into terminal 
differentiation or growth arrest and apoptosis (Torrano et al. 2006). Both CTCF and B23 
are associated with insulator sites in vivo, and these sites can be tethered to the 
nucleolus via CTCF (Yusufzai et al. 2004).  
Eukaryotic RNA polymerase II is a multi-subunit complex responsible for 
transcription of all protein coding genes and some non-coding RNAs. The largest subunit 
has been shown to interact with CTCF in vivo (Chernukhin et al. 2007). Differential 
phosphorylation, either hypophosphorylation (IIa) or hyperphosphorylation (IIo) of the pol 
II large subunit occurs depending on whether pol II is associated with initiation (IIa) or 
elongating (IIo) transcripts. Co-immunoprecipitations (CoIP) revealed CTCF interacts 
with both IIa and IIo types, although a slightly improved affinity was observed for IIa, but 
this may be cell-type or cell cycle dependent. Similar CoIP experiments in this study 
suggested CTCF is not precipitated from nuclear extracts of HeLa cells using antibodies 
to histone H2A and H3, p53, Sp1, TBP or Rb1. CTCF also does not form a complex with 
TFIIH or MYC (Chernukhin et al. 2000). 
SNF2-like chromodomain helicase protein CHD8 is a member of the CHD 
chromatin remodeling family of proteins that include Mi-2β (CHD4). Pull-down analysis 
showed direct interactions between CTCF and CHD8 in vitro and in vivo and both factors 
are required for enhancer-blocking activity of H19 DMD in transfection assays (Ishihara 
et al. 2006). Importantly, when CHD8 levels are reduced by knockdown, CTCF remains 
bound to the H19 DMD indicating that imprinted expression of Igf2/H19 is dependent on 
both CTCF and CHD8, revealing the first direct mechanistic association between 
imprinting and chromatin remodeling. Knockdown of CHD8 also induced changes in 
DNA methylation and hypoacetylation of histones around CTCF binding sites.  
YY1 is the first protein shown to interact with CTCF and mediate the function of 
CTCF in X-inactivation, co-operating in the transcriptional activation of Tsix (Donohoe et 
al. 2007) (see above).  
 
One particular class of potential CTCF-interacting proteins is conspicuous by its 
absence, histone acetyltransferases (HAT). The 3’HS1 CTCF binding site of the mouse 
β-globin locus is positioned within a region of condensed chromatin, but is itself a site of 
histone acetylation (Bulger et al. 2003). Local gains of repressive histone modifications 
occurred at all known CTCF binding sites within the mouse β-globin locus when CTCF 
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was depleted (Splinter et al. 2006). This suggests CTCF can attract HAT complexes, 
which maintain an open chromatin structure, however no direct evidence for CTCF and 
HAT interactions have been identified. The loss of CTCF may have disrupted other as 
yet unknown protein interactions either directly linked to CTCF or protein complexes that 
bind close to CTCF such as USF (West et al. 2004), causing the gain of histone 
methylation at CTCF binding sites. Considering loss of CTCF induces conformational 
changes to the β-globin locus, it is possible that CTCF-mediated looping brings elements 
with HAT activity into the region of CTCF binding sites. It has been reported previously 
that CTCF interacts with the transcriptional co-repressor protein complex Sin3A, 
contributing to the transcriptional repressive action of CTCF by associated HDAC 
activities (Lutz et al. 2000). However, independent analysis to identify CTCF-HDAC 
interactions by co-immunoprecipitation using breast cancer cells failed to confirm specific 
CTCF interactions with either HDAC1 or HDAC2, but did not exclude the possibility of 
CTCF interaction with other co-repressor complexes harbouring HDAC3 such as N-
CoR/SMRT (Dunn et al. 2003). N-CoR has been identified as a mediator of DNA 
methylation-dependent transcriptional repression through its interaction with Kaiso (Yoon 
et al. 2003), which provides an interesting mechanistic link between CTCF, Kaiso and 
epigenetic silencing. 
 
One would imagine cell-type specific proteins must also be potential binding 
partners. Using homologous recombination in ES cells, a biotin tag has been engineered 
into the endogenous CTCF locus in mice (SvdN unpublished), which will enable 
identification of specific CTCF-interacting partners to be identified and characterised 
from any cell type or developmental stage. 
 
 
Nuclear localisation and dynamics of CTCF, interphase and mitosis 
CTCF is expressed constitutively as a nuclear protein in the vast majority of 
cells at all stages of development. Localisation of CTCF during interphase appears in a 
distinct pattern, which is largely diffuse throughout the nucleus and excluded from the 
nucleolus, but accumulation patterns can be seen as if CTCF is concentrated in many 
small areas (Kantidze et al. 2007). As CTCF is known to mediate chromosomal 
interactions and transcriptional activity in trans, it is tempting to speculate that clusters of 
CTCF binding sites accumulate in the nucleus to regulate nuclear architecture as has 
been proposed for the gypsy insulator in Drosophila (Yusufzai et al. 2004). It is not yet 
known if CTCF functionally clusters in this way, indications from CTCF deficient cells 
suggest no obvious structural abnormality based on DAPI signals, but this is not to 
suggest a more detailed analysis would not find impairments.  
 
Chapter 2 
 54
The subnuclear localisation of CTCF is not effected by phosphorylation (Klenova 
et al, 2001) although localisation of CTCF to the nucleolus is observed in a 
poly(ADP)ribosylation dependent manner (Torrano et al. 2006). Nucleolar accumulation 
of CTCF was observed when cells are induced to differentiate in vitro and this is 
dependent on both poly(ADP)ribosylation, ongoing rDNA transcription and protein 
synthesis, implying a dynamic regulation of CTCF in and out of the nucleolus. The in vivo 
functional significance of nucleolar CTCF remain questionable. In UR61 rat neuron-like 
cells, transfection of GFP-CTCF revealed specific localisation of CTCF within the 
nucleolus. CTCF has been shown to co-localise and co-purify with nucleophosmin 
(Yusufzai et al. 2004), a component of the granular compartment. Significantly, CTCF 
can specifically interact with UBF in vitro and in vivo (SvdN unpublished), but no co-
localisation with UBF was observed in UR61 cells, indicating this interaction may reflect 
the type of cells analysed. Chicken erythrocytes do not enucleate as mammalian red 
blood cells do, but genome wide silencing does occur, as such they are an interesting 
model for chromatin structure and nuclear organisation during differentiation. Kantidze et 
al (Kantidze et al. 2007) describe compartmentalisation of CTCF in both embryonic 
erythroblast and mature erythrocyte nuclei, but not nucleoli. Comparisons between these 
studies ( Kantidze et al. 2007, Torrano et al, 2006), highlight the important difference of 
transformed cancer cell lines and normal cells in culture. The physiological and 
epigenetic distinctions between terminally differentiating cells that stop proliferation and 
differentiation and differentiating cells, which remain transcriptionally active, should also 
be considered. CTCF and other transcription factors become dissociated from DNA in 
terminally differentiated erythrocytes, whereas in proliferating erythroblasts, the majority 
of CTCF is bound to DNA (Kantidze et al. 2007). 
 
Transcriptional activity is not a requirement for CTCF binding to all target sites. 
During mitosis, a proportion of CTCF remains bound to particular target sites despite 
transcriptional inactivity (Burke et al. 2005). The localisation and dynamics of CTCF 
during mitosis is of considerable interest given the growth arrest phenotype in both 
CTCF over-expressing and deficient cells. CTCF associates with mitotic chromosomes 
throughout mitosis, and by immunofluorescent analysis and biochemical fractionation 
shown to co-localise with centrosomes and the midbody (Zhang et al. 2004). The 
function of CTCF binding to mitotic chromosomes is unclear; CTCF may remain bound to 
enforce a memory pattern of epigenetic modifications. Alternatively, CTCF might have a 
structural role, mediating the tight condensation of chromosomes or their correct 
alignment required for mitosis to occur. Interestingly, the association of CTCF with 
mitotic centrosomes is microtubule independent, as treatment with nocodazol, a 
microtubule depolymerising factor, does not disturb CTCF-centrosomal interactions 
(Zhang et al. 2004). The precise role of CTCF during mitosis needs careful consideration 
                                                                                                                       
 55
as under certain cell culturing conditions, CTCF deficient cells can divide (this thesis). 
Importantly a significant amount of GFP-CTCF is released from chromatin as 
chromosomes align at the start of metaphase, and this ‘free’ GFP-CTCF is divided 
between the two daughter cells and the newly formed nuclei (this thesis).  
 
The number and location of potential CTCF binding sites is becoming a topic of 
great speculation and significance. Identification of CTCF binding sites in the genome 
has previously been perturbed by the lack of a primary structure consensus sequence for 
CTCF, however, through combinations of two-dimensional electrophoretic mobility shift 
assays (2D-EMSA), chromatin immunoprecipitation (ChIP) and microarrays (ChIP-on 
chip), there is increasing information which maps CTCF binding sites in humans 
(Mukhopadhyay et al. 2004, Vetchinova et al. 2006, Kim et al. 2007). Ascertaining a 
figure for the number of CTCF binding sites present in the genome is useful to assess 
the possible function of CTCF in organising higher order chromatin interactions. To date, 
estimations range between 4000 and 30,000 CTCF binding sites in humans 
(Mukhopadhyay et al. 2004, Vetchinova et al. 2006, Kim et al. 2007). According to an 
average chromatin domain size estimation of 80-300Kb, this would equate to 10,000-
40,000 insulator boundary elements in the human genome (Heng et al. 2001, Vetchinova 
et al. 2006).  
 
Functionally related proteins? 
To date, only one CTCF-like protein has been identified in mammals. Brother of 
the Regulator of Imprinted Sites (BORIS) is homologous to CTCF only in the zinc-finger 
DNA-binding domain, the remaining sequences shares very little identity to CTCF 
(Loukinov et al. 2002). BORIS is able to bind to CTCF target sequences in tumour cells 
(Vatolin et al. 2005), and is expressed at a stage during spermatogenesis where CTCF 
expression is reduced. This stage coincides with the erasure and re-establishment of 
methylation patterns. As such, BORIS has been implicated in mediating reprogramming 
of epigenetic modifications, notably erasure of methylation in male germ cells (Loukinov 
et al. 2002). However, the role of BORIS or CTCF in regulating imprinted methylation 
patterns in germ cells is controversial (Szabo et al. 2004). BORIS is also implicated in 
demethylation of cancer-testis genes in somatic cells and the de novo methylation of 
imprinted genes in the male germ line (Vatolin et al. 2005, Jelinic et al. 2006). To date, 
BORIS is known to have a highly restricted pattern of expression, confined to 5-
methylcytosine-deficient adult male germ cells, human tumour cell lines and CTCF 
negative cells (Vatolin et al. 2005). The reciprocal pattern of expression with CTCF in 
spermatocytes is interesting, no known BORIS-specific target sites have been identified 
implying some sort of regulation or feedback between the two proteins exist. 
Significantly, there is no direct correlation to CTCF absence and BORIS expression in 
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somatic cells; CTCF deficient T-cells both in the thymus and periphery do not aberrantly 
express BORIS (this thesis). 
 
What actually regulates CTCF? 
During the cell cycle, Ctcf mRNA levels increase at S-G2. However, ectopic 
expression of Ctcf leads to arrest at apparently indiscriminate points of the cell cycle 
(Rasko et al. 2001, Klenova et al. 1998). Loss of CTCF effects the G1-S transition, 
resulting in an extended G1 phase in T-lymphocytes (this thesis). The factors and 
modifications of CTCF protein that determine its regulation are not fully understood. 
Determining specific regulatory factors that control the transcription of Ctcf is 
complicated by the fact CTCF is an essential protein required for cell viability; analysis 
such as chromatin immunoprecipitation can identify protein complexes that associate 
with the Ctcf promoter and other regulatory regions, but the follow up mutational analysis 
can be problematic. A number of potential binding sites have been identified in the Ctcf 
promoter, which are conserved in vertebrates, including potential binding sites for YY-1, 
GATA-1 and p53 (Pugacheva et al. 2006) although direct evidence for the functional 
interaction of any of these proteins with Ctcf regulatory elements is lacking. The YY-1 
element is strictly conserved from zebrafish to humans and is associated with activation 
of Ctcf.  
Few cells have been identified as or modified to be CTCF deficient in vivo. 
Absence of CTCF results in global impairment of cell regulatory systems leading to cell 
death, as such very little is known about factors that influence the expression of CTCF in 
vivo. Expression levels of CTCF require strict regulation; studies indicate severe 
impairment of cellular functions, which are not necessarily different, depending on 
overexpression or knockdown/knockout (Qi et al. 2003, Li. 2007). CTCF function and 
activity may differ depending on the cell type and stage in differentiation you analyse. 
Down-regulation of CTCF is required for differentiation of human monocyte-derived 
dendritic cells (DCs), and enforced expression in bone marrow-derived DCs in irradiated 
mice impairs proliferation and promotes apoptosis. However, enforced CTCF expression 
also resulted in an increase of plasmacytoid DCs, suggesting CTCF is specifically 
involved in regulating differentiation of dendritic cells. The mechanisms of this are 
currently unknown (Koesters et al. 2007). Ctcf knockdown inhibits differentiation of 
human myeloid leukaemia cells (Torrano et al. 2005). However, conditional deletion of 
CTCF as described in this thesis has revealed under specific conditions, T-lymphocytes 
can undergo TCR rearrangements, divide and differentiate in the absence of CTCF (this 
thesis). The indication that CTCF deficient cells can divide when given appropriate 
signals will be of significant benefit to the understanding of CTCF function and the 
regulation of this protein.  
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Chapter 3: Haematopoiesis; Erythrocytes and T-lymphocytes. 
Introduction to haematopoiesis 
An extensive overview of the haematopoietic system, its origins and regulatory 
factors is beyond the scope of this thesis, however general information is useful for 
understanding the data presented. The haematopoietic system is used in this thesis as a 
model to study the function of CTCF in two distinct cell lineages, erythrocytes and T-
lymphocytes. 
Haematopoiesis is the process of generating all cellular populations and their 
derivatives that are found in blood. Blood is a multifunctional tissue, the cellular 
composition of which can be broadly divided into three categories of cell types, erythroid-
megakaryocytic, lymphoid and myeloid. This categorisation as described by Katsura 
(Katsura, 2002) is controversial. Erythroid-megakaryocytic cells are derived from myeloid 
progenitors, therefore the lymphoid-myeloid distinction of cells is more generally 
considered. At least twelve different functional categories of mature cells and cell 
fragments (fig 3.1) are derived from a single pluripotent self-renewing cell called the 
haematopoietic stem cell (HSC) (Lemischka 1992, Katsura, 2002).  
 
 
                            
 
 
Figure 3.1. Classification of different haematopoietic cell types                                             
Adapted from (Katsura 2002).  
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HSCs are very rare cells (1-10 cells per 100,000 cells) in the bone marrow (BM) 
(Abkowitz et al. 2000). The self-renewing HSC potential is maintained by one daughter 
cell following division of the original pluripotent stem cell, while the other daughter cell 
progresses along a pathway of differentiation.  
The first step of differentiation gives rise to cells that retain the potential to 
become any haematopoietic cell type, but have crucially lost their capacity to self-renew. 
These cells are termed mulit-lineage precursors (MLPs). It is widely documented that 
following MLPs, differentiation proceeds into two separate lineage-defining precursors, 
the common lymphoid progenitor (CLP) or common myeloid progenitor (CMP) (Prohaska 
et al. 2002). CLPs are described as committed precursors with the potential to generate 
all cells of the lymphoid lineage including natural killer (NK) cells in vivo (Kondo et al. 
1997). Further lineage restriction occurs as CLPs differentiate to B/T/NK cells. The 
precise nature of the B/T/NK lineage precursor remains controversial (Zuniga-Pflucker 
and Schmitt 2005). The model of CLPs is not without question and the actual identity of a 
lymphoid progenitor remains a matter of debate. Surprisingly CLPs defined in this 
context represent a very small percentage (0.02%) of BM cells. CMPs by comparison 
comprise 0.2% of total BM cells. They are defined as progenitors able to give rise to 
monocytes, granulocytes, erythrocytes and megakaryocytes based on in vitro colony 
forming unit (CFU) culture and in vivo transplantation assays (Akashi et al. 2000). As 
such they are also referred to as colony forming unit-granulocyte, erythrocyte, monocyte, 
megakaryocyte (CFU-GEMM) cells (Richmond et al. 2005) that differentiate to 
granulocyte/monocytes (GMPs) and megakaryocyte/erythroid (MEPs) cells (Akashi et al. 
2000). The expression of specific transcription factors appear key to several cell fate 
decisions. Studies of a dominant negative form of the Ikaros gene revealed a lack of both 
B- and T-cells, suggesting the existence of a common precursor for both cell types 
(Georgopoulos et al. 1994). The function of Ikaros as a defining feature of CLPs is 
however inaccurate, as T-cells can exist in vivo in the absence of Ikaros expression 
(Wang et al. 1996). The precise differentiation potential of CLPs/CMPs remain under 
question particularly with respect to monocyte differentiation that has been observed 
both from CLPs and CMPs (Kee and Murre 1998). The identity and reality of CLPs as 
lymphoid restricted is challenged by the identification of bipotent myeloid/lymphoid 
precursors, so called common myeloid lymphoid precursors (CMLPs) (Kawamoto et al. 
1997, Katsura, 2002) although these are only present at an early stage of development. 
Differentiation into functional cell types proceeds along an ordered lineage 
pathway, which at a certain points becomes restricted and committed. The self-renewal, 
differentiation and survival potential of stem cells, and the development of subsequent 
progenitors and committed cell types is tightly regulated by cooperative signals from 
surrounding cells, cytokines and intrinsic expression of particular transcription factors. 
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Recent findings have proposed a hierarchical expression of transcription factors that is 
essential for coordinated HSC differentiation into progenitor cells and particular lineage 
fates. Transcription factors such as PU1, GATA-1, -2, and Pax5 have each been shown 
to essentially mediate the lineage direction of given precursor cells (Zhu and Emerson 
2002, Akashi, 2005). Ectopic expression of GATA1 in CLPs is sufficient to redirect 
differentiation towards the megakaryocyte/erythroid lineages (Iwasaki et al. 2003). 
Interestingly, reprogramming of non-haematopoietic HeLa cells to express erythroid-
specific genes is also induced by ectopic expression of GATA-1 (Layon et al. 2007) 
suggesting a significant role for GATA1 in mediating transcription of erythroid-specific 
genes, even in cells that seemingly have no priming potential for red cell expression 
profiles. These studies suggest that transcription factors may be the primary 
determinants of lineage plasticity.  
 
Primitive and definitive haematopoiesis are distinct waves of haematopoietic cell 
production at different stages of development, which occur in several distinct tissues 
throughout life. Primitive haematopoiesis in mice originates from mesodermal precursors 
that form the blood islands in the visceral yolk sac. Blood vessels originating from 
endothelial cells (angioblasts) and haematopoietic cells are proposed to derive from a 
common precursor known as the hemangioblast (Huber et al. 2004). The yolk sac is the 
first site of haematopoiesis in mammalian embryos (Palis et al. 1999). Primitive 
haematopoiesis begins around mouse embryonic day (E) 7.25. The majority of 
haematopoietic cells generated are large, nucleated primitive erythroblasts. Primitive 
macrophages and some megakaryocytes are also generated (Lensch and Daley 2004). 
Primitive pro-erythroblasts circulate to and divide within the newly formed embryonic 
vascular system about a day later. Progressive differentiation is accompanied by gradual 
loss of proliferation, repression of gene expression and reduction in cell size, culminating 
in cell cycle arrest and enucleation (McGrath et al. 2003, {Kingsley, 2004). Primitive 
erythrocytes are known to remain in circulation for a short time after birth. 
Independent to yolk sac-derived haematopoiesis, definitive haematopoiesis 
derives from distinct HSCs located within the embryonic aorta, gonads, mesonephros 
(AGM) around E10.5 (Medvinsky and Dzierzak 1996, Zhu, 2002), where they proliferate 
before migrating to the fetal liver and to a lesser extent the spleen. Interestingly, primitive 
haematopoietic cells are unable to support repopulation of irradiated adult recipient mice 
and thus can not be considered as true HSCs. In contrast, AGM derived HSCs can fully 
repopulate the complete haematopoietic system, demonstrating these stem cells are 
genuinely pluripotent. By E12.5, circulating primitive erythroblasts are accompanied by 
enucleated definitive red blood cells released from the fetal liver, which becomes the 
major site of haematopoiesis until birth, after which the spleen and bone marrow 
permanently function as the sites of definitive haematopoiesis in mice. Interestingly, 
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definitive haematopoietic progenitors are also found within the placenta, and this site 
was recently shown to be a new HSC niche (Alvarez-Silva et al. 2003, Ottersbach, 
2005). T-lymphocytes are the only differentiated haematopoietic cell type not generated 
in the bone marrow. Progenitor cells derived from HSCs migrate to the developing 
thymus during embryogenesis and continue to populate the thymus into adult life. 
Commitment to the T-cell lineage is defined in the thymus (see below). 
 
Haematopoiesis: erythropoiesis 
Erythrocytes constitute the vast majority of cells in the blood and are responsible 
for the transport of oxygen and carbon dioxide around the body. As terminally 
differentiated cells, erythrocytes can not divide, but they also do not persist indefinitely. 
In mice, erythrocytes circulate on average for 60 days before being consumed by 
specialised cells in the spleen and liver. The haemeoglobin-associated iron that 
becomes recycled within the body. A continual production of red blood cells 
(erythropoiesis) is therefore required to maintain the supply of oxygen and exchange of 
carbon dioxide in tissues. The process of erythropoiesis is characterised by progressive 
differentiation of committed erythroid precursor cells towards the enucleated red blood 
cell (fig 3.2 Dessypris 1998).  
 
 
 
 
 
 
 
Figure 3.2. Adapted from (215 Dessypris 1998). 
 
Erythroid/megakaryocyte progenitors (EMP) contribute to both the erythroid and 
megakaryocyte lineages. Erythroid commitment is sealed at the BFU-e and CFU-e stage. 
Proerythroblasts indicate the initiation of terminal differentiation, which concludes with 
enucleated erythrocytes.  
 
 
In vitro assays of bone marrow cells in semi-solid medium revealed distinct colonies 
emerging from different lineage restricted precursor cells according to type of growth 
factor present (Wong et al. 1986). Burst-forming units-erythroid (BFU-e) and colony 
forming units-erythroid (CFU-e) retain substantial proliferative capacity, which 
progressively declines as differentiation occurs. Patterns of gene expression define 
progression of the red cell lineage, in particular the characteristic production of α- and β-
globin proteins that combine to form haemoglobin, which accumulates throughout 
EMP                       BFU-e                          CFU-e              Proerythroblast             Basophillic          Polychromatic      Orthochromatic    Reticulocyte        Erythrocyte  
 Erythroblast          Erythroblast          Erythroblast   
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differentiation. The loss of cellular components such as the endoplasmic reticulum and 
mitochondria occurs and macrophages that accompany red blood cell precursors ingest 
the ejected nucleus, leaving a cell almost entirely composed of haemoglobin. 
Macrophages are also important as supporting cells, regulating correct transcription 
factor expression and lineage commitment during erythropoiesis at the site of 
erythroblast islands, where definitive erythropoiesis occurs within the fetal liver and bone 
marrow (Iavarone et al. 2004).   
 
Haemoglobin, globin gene structure and expression 
Haemoglobin is a hetero-tetrameric protein that consists of two α-like and two β-
like globin chains, each of which is attached to one heme group containing an iron atom 
in the center. Different α- and β-globin genes are expressed at distinct stages of 
mammalian development to coincide with the requirement for haemoglobin with higher 
oxygen affinity in the embryo compared to the adult. Each of the globin gene loci, 
including the specialised muscle-specific globin protein myoglobin, is believed to derive 
from a common ancestral locus around 450 million years ago (Hardison 1996). The 
factors regulating correct temporal and spatial expression of globin genes are of great 
medical significance. Hereditary blood disorders, such as sickle cell anaemia and 
thalassemias are the most common genetically inherited diseases with over 250 million 
people world wide known to carry mutations or deletions within globin loci. Studies of 
such disorders have identified several important cis- and trans-acting factors that 
contribute to transcriptional regulation of these multi-gene loci, in particular the 
identification of the β-globin locus control region (LCR) (Grosveld et al. 1987). The 
functional significance of the β-globin LCR will be discussed later. 
 
In mammals, globin gene structure is highly conserved, especially between humans and 
mice. Interestingly, epigenetic modifications and the chromatin environment around the 
α- and β-globin loci are significantly different, indicating distinct regulatory mechanisms 
are used to maintain the specific temporal yet coordinated expression patterns that occur 
(table 3.1) (Brown et al. 2001). Furthermore, the globin genes positioned 5’ in both loci 
are expressed in the embryo; where the globin genes located 3’ encode the prominent 
adult α- and β-globin proteins (fig 3.3). This led to a model of globin gene switching, 
which initially linked the temporal transition between embryonic and adult globin 
expression with the change from primitive to definitive erythropoiesis 
(Stamatoyannopoulos 1991, Ingram, 1972). However this model is no longer valid as 
primitive enucleated erythrocytes are found as early as E12.5 in mice (Kingsley et al. 
2004). 
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Features of chromatin at the β-
globin locus 
Non-erythroid 
cells 
Erythroid cells 
Hyperacetylation H3 and H4 - + 
DNase hypersensitivity of LCR - + 
Replication timing Late S-phase Early S-phase 
Location in interphase nucleus Heterochromatin Euchromatin 
Transcriptional activity of globin genes Repressed  Active or poised 
 
Table 3.1. Differences between chromatin states of the β-globin locus during 
differentiation. Adapted from (Schubeler et al. 2000, Francastel, 2001). 
 
 
 
Figure 3.3. Developmental patterns of globin gene expression 
 
The developmental regulation of human globin synthesis is shown (top panel). α- and ζ-genes 
are located in the α-globin locus (see text for details). The lower panel shows the expression 
pattern of individual mouse globin genes (solid lines) and human β-globin transgenes when 
expressed in mice (dashed line).  
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Both α- and β-globin gene loci are readily accessible model systems of spatial and 
temporal transcriptional regulation and cellular differentiation in vivo.  
 
α-globin locus 
The mouse α-globin gene locus is positioned in the telomeric region of 
chromosome 11 and consists of three functional developmentally regulated genes: one 
embryonic ζ globin gene, primarily expressed in embryonic blood cells and two 
fetal/adult α (α1, α2) genes, which are also expressed in embryonic blood and maintain 
expression in fetal liver and adult bone marrow. In mouse and human, α-like globin 
genes are expressed in the order of their chromosomal arrangement (5’ζ-α1-α2-3’) 
(Zhou et al. 2006, Leder, 1981) and undergo one switching event, the change from ζ to α 
globin. Interestingly, the α-globin gene cluster is in an open chromatin environment in 
both erythroid and non-erythroid cells, and has overlapping genes that are both 
erythroid-specific and ubiquitously expressed (Sjakste et al. 2000, Litt, 2001).  
 
A pre-existing sub-conformation consisting of tissue-restricted chromatin loops 
has been proposed, where by the ubiquitously expressed genes within the α-globin locus 
are constitutively clustered together in non-erythroid cells. Differentiation towards the 
erythroid lineage changes the configuration of the locus, allowing α-globin genes to 
cluster with the positive regulatory elements of the active housekeeping genes. As such, 
the mouse α-globin locus is proposed to form a transcription factory where highly 
expressed yet distinctly regulated genes co-localise with common regulatory elements 
(Caron et al. 2001). Erythroid-specific transcription factors such as GATA1 and NF-E2 
have been shown to interact with the major regulatory element HS26 and α1/α2 
promoters, which could suggest a role for GATA1 in mediating long-range chromatin 
interactions.  
 
β-globin locus 
In contrast to the α-globin locus, mouse β-globin genes are not expressed in the 
order of their chromosomal arrangement (Kingsley et al. 2006). A similar but not identical 
conservation of the β-globin locus is observed between human and mouse loci. In 
humans, five β-like globin genes are developmentally regulated and expressed in their 
chromatin order 5’ ε-Gγ-Aγ-δ-β 3’. Conversely in mice, the β-globin locus consists of four 
functional genes ordered 5’ εγ-βH1-β1-β2 3’ (Trimborn et al 1999), however βH1 is the 
first transcribed gene, followed by a switch to εγ expression before generation of β1 and 
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β2 transcripts (Kingsley et al. 2006). β1 and β2 are also referred to as β-major and β-
minor respectively.   The surrounding chromatin environment also differs between α- and 
β-globin gene loci. In both mouse and human, the β-globin gene cluster is embedded 
within genes encoding olfactory receptor proteins on chromosome 7. As such, the β-
globin locus provides a mechanism of understanding how chromatin modifications effect 
differential temporal and spatial expression of a multi-gene locus within the context of 
distinctly regulated neighbouring genes in mammals.  
 
Central to the control of β-globin expression in all vertebrates is an array of 
erythroid specific DNase I hypersensitive sites located 5’ to the locus which form the 
Locus Control Region (LCR). Additionally, in mice, two more regions of DNase I 
hypersensitivity are positioned outside of the locus within olfactory receptor genes 
85/84kb and 62/60kb 5’ of the εγ cap site (Farrell et al. 2000, Bulger, 2003). Both human 
and mouse β-globin loci are flanked by 3’ hypersensitive sites. The single 3’HS1 is 
located nearly 70kb downstream of εγ (Tuan et al. 1985). Specific cis regulatory regions, 
such as promoters, enhancers and silencers individually influence transcriptional activity 
of each of the β-globin genes. Individual gene promoters and enhancers are 
characterised by DNase I HSs that are both erythroid and developmentally restricted. 
Binding sites for erythroid specific transcription factors such as GATA1, erythroid 
Krüppel-like factor (EKLF) and NF-E2 are found in the promoter regions, and regulate 
local chromatin structure by attracting histone acetyltransferases such as CREB-binding 
protein (CBP)/p300 (Zhang and Bieker 1998, Hung, 2001, Letting, 2003, Blobel, 1998). 
Interestingly, binding sites for ubiquitously expressed factors such as Yin Yang 1 (YY1) 
and SP1 are also found in the ε- and γ-globin promoters and the LCR. YY1 is a truly 
multifunctional protein that interacts with both transcriptional activator and repressor 
complexes (Affar el et al. 2006). The significance of YY1 in regulating the β-globin locus 
and transcription remains unclear. In contrast, regulation of β-globin expression has 
been linked to the phosphorylation status of SP1 (Feng and Kan 2005). Phosphorylation 
is acquired upon differentiation and the accompanying switch from γ- to β-globin 
expression, furthermore phosphorylated SP1 no longer binds to target HS2, HS3, HS4 
and β-globin promoter sites suggesting that SP1 is required to negatively regulate 
expression of β-like globin genes. 
In humans, intergenic sequences between γ- and δ-globin genes are shown to 
harbour a regulatory element that regulates γA to β-globin switching (Chakalova et al. 
2005). This element is associated with a large protein complex consisting of Ikaros, and 
chromatin remodelling proteins, which may function in a context dependent manner 
(O'Neill et al. 1999, O'Neill, 2000). This data suggests LCR-gene contacts can be 
regulated by conformational changes 5’ to the δ-globin gene, an area currently not 
known to contain CTCF target sites. Analysis of deletions that remove the Ikaros binding 
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element and other flanking regions indicate β-globin gene expression is repressed and γ-
globin expression persists in adults (Chakalova et al. 2005). The timing of globin gene 
switching is disturbed in the absence of Ikaros in both humans and mice (Lopez et al. 
2002).  
 Several matrix attachment regions (MARs) have been identified within the β-
globin locus and have been proposed to mediate globin gene switching (Yan and Qian 
1998, Case, 1999). Special A-T-rich binding protein 1 (SATB1) is predominantly 
expressed in T-cells but is known to interact with a regulatory element 3’ to the γA-globin 
gene (Cunningham et al. 1994). Recently, SATB1 has been shown to bind MARs at LCR 
HS2 and within the ε-globin promoter in human erythroleukemia K562 cells (Wen et al. 
2005). In this context, SATB1 forms a complex with the transcriptional co-activator CBP 
and is a positive regulator of ε-globin expression, attracting H3 and H4 acetylation and 
reducing H3-K9 methylation. Concurrently, γ-globin gene activity is repressed via 
increasing levels of histone methylation with no apparent change in acetylation. 
Reducing SATB1 expression resulted in reciprocal data, suggesting SATB1 and 
associated proteins are key regulators of differential ε- and γ-globin expression.  CTCF is 
known to interact with MAR sequences and currently four identified CTCF binding sites 
(HS-85, HS-62, LCR HS5 and 3’HS1) are present in and around the mouse β-globin 
locus (Farrell et al. 2002, Bulger, 2003). It is of interest to note that sites occupied by 
SATB1 do not associate with CTCF and to date CTCF has no known direct role in 
mediating globin gene switching.  
 
 Understanding the mechanisms of coordinated and developmentally regulated 
expression of both α- and β-like globin gene expression has significant clinical relevance, 
and several studies have identified key cis and trans-regulatory factors. The majority of 
haemoglobinopathies occur due to deletions or mutations in either the α- or β-like globin 
genes or their regulatory elements (Collins and Weissman 1984). Optimally functional 
haemoglobin has a tetrameric configuration invariably of two α-globin chains and either 
two γ- or two β-globin chains depending on the developmental stage, which are linked to 
heme groups. Aberrant expression of γ-globin proteins in humans induces a condition 
called hereditary persistence of fetal haemoglobin (HPFH), which describes a failure to 
down regulate γ-globin proteins in the adult but manifests no negative clinical 
consequences for patients. On the contrary, HFPH patients frequently also present with 
other haemoglobinopathies such as thalassemia or sickle-cell anemia that on their own 
would cause severe medical problems, but the effects are compensated by the HPFH 
phenotype. Mutations that effect GATA1 and NF-E2 interaction with target sites in the γ-
globin promoter stimulates continued γ-globin expression (Berry et al. 1992, 
Cunningham, 1994, Collins, 1985) indicating sequences 5’ and 3’ of γ-globin are critical 
to both γ- and β-globin expression.  
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Sickle cell anemia is characterised by degeneration of erythrocyte structure. The 
distinctive sickle shape occurs as the haemoglobin, which constitutes around 90% of an 
erythrocyte, polymerises in its deoxygenated form. Functional haemoglobin proteins are 
soluble when carrying oxygen or carbon dioxide, however, a single A-T base pair 
substitution in the 6th coding exon of the β-globin gene creates a new glutamine amino 
acid in place of the normal valine, which reduces the solubility of deoxygenated but not 
oxygenated haemoglobin (Ingram 1956, Kaul, 1996). Sickle cells attach to and block 
endothelial blood vessels, inducing varying degrees of anemia and impairing the flow of 
oxygen to the tissues. In turn, the body responds by releasing more oxygen from 
erythrocytes, which paradoxically generates more deoxygenated sickle cells that 
eventually cause necrotic lesions in the peripheral tissues.  
α-/β-Thalassemia describes an anemic disease where an imbalance of either α- 
or β-globin chains occurs because of inadequate protein levels. In the case of β-
thalassemia, large deletions of the β-globin locus including regulatory regions or point 
mutations in the β-globin gene are responsible. Interestingly, β-thalassemic patients are 
not able to compensate for a lack of β-globin with continued γ-globin synthesis despite 
expressing γ-globin during fetal life as normal. The resulting disproportionate expression 
of α-globin still accumulates within red cells and associates with heme, but functional 
haemoglobin is not generated. Subsequent anemia develops in two ways, firstly 
accumulations of α-globin protein triggers cell death disrupting erythropoiesis in the bone 
marrow and secondly, excess α-globin predisposes peripheral erythrocytes to lysis via 
increasing levels of reactive oxygen species (Bank 2005). Analysis of a Dutch patient 
with γδβ-thalassemia, which manifests no expression of any β-like globin genes revealed 
no mutations or deletions of either the β-globin promoter sequence or the β-globin gene. 
However a large 100kb deletion encompassing ε- and γ-globin genes and regulatory 
regions was found (Kioussis et al. 1983, Taramelli, 1986) indicating distal cis regulatory 
DNA elements were necessary for β-globin expression. Identification of clustered 
erythroid-specific DNase I HSs positioned upstream of the β-globin locus led to the 
characterisation of the archetypal locus control region (LCR), which when linked to a β-
globin gene conferred copy number-dependent, position-independent, tissue-specific 
expression in transgenic mice (Grosveld et al. 1987). 
 
β-globin LCR 
The conservation of sequences between human and mouse allowed the 
homologous mouse β-globin LCR to be identified (Moon and Ley 1990). Interestingly, 
several differences in LCR structure and apparent function occur between species. 
Potential links between changes in chromatin structure and modifications with 
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transcriptional activation have been extensively studied in both chicken and mammalian 
species to determine the influence of the LCR on these processes, which are both 
necessary for globin gene expression. Important distinctions between the chicken and 
mammalian β-globin loci are apparent; not least the proportion of acetylated histones 
present. In chicken, the entire locus is marked by histone hyperacetylation and DNase 
hypersensitivity, which is constrained at either end by insulator sequences (Litt et al. 
2001). In contrast, the murine β-globin locus has regions of both hyper- and 
hypoacetylation within the region defined by flanking insulator sequences (Bulger et al. 
2003). Deletion of the murine LCR significantly reduced globin gene transcription. 
However, DNase sensitivity and chromatin modifications were not affected, suggesting 
the LCR is redundant for mediating chromatin structure in mice (Schubeler et al. 2001). 
Chromatin organisation of the β-globin locus is in part mediated by CTCF but 
independently of active LCR-β-globin gene contacts (see below) (Palstra et al. 2003).  
LCR deletion effects vary between human and mouse loci (Schubeler et al. 
2001). Murine erythroleukeamia (MEL) cells harbouring chromosome 11 from humans 
where β-globin genes are situated, can express β-globin genes normally, but unlike the 
endogenous mouse locus, hyperacetylation and promoter remodelling in hybrid cells is 
strictly dependent on the presence of the LCR. This is an important consideration as 
studies using the mouse globin locus and their results should not be extrapolated as 
representative of a general model or applied to humans without careful consideration.  
 
 
 
Regulation of globin gene expression in nuclear space 
Gene expression in eukaryotes is regulated by sequences located tens or 
hundreds of kilobases away from the specific target genes via protein interaction with 
these sequences mediating long-range modifications of the chromatin structure (Ptashne 
1986, Bulger, 2002). The murine β-globin locus spans over 200kb, with the LCR 
positioned over 50kb away from the β-globin gene itself. The locus is surrounded by 
insulator sequences in humans and mice. The flanking insulator sequences are DNase 
HSs that interact with CTCF. These CTCF binding sites were identified to cluster 
specifically in progenitor erythroid cells independently of β-globin gene expression. They 
participate in the regulation of LCR interactions with active β-globin genes, leading to the 
idea of chromatin hub (CH) and active chromatin hub (ACH) formation respectively 
(Tolhuis et al. 2002, Palstra, 2003), whereby intervening sequences are looped out (fig 
3.4).  
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Figure 3.4. A 2-D representation of the 3-D mouse β-globin locus configuration                            
From (Palstra et al. 2003). 
 
The conformation of the chromatin environment around the mouse β-globin locus is modified 
in a dynamic and developmentally regulated manner (see text for details). The β-globin genes 
are flanked by constitutive HSs. In erythroid progenitor cells, these sites cluster together and 
the intervening sequences including the developmentally regulated HSs of the LCR and β-
globin genes are looped out, forming a chromatin hub. Upon differentiation, the proteins 
bound to the LCR and globin genes interact dynamically with each other and the constitutive 
HSs.  
 
The significance of CTCF-mediated (A)CH formation and its role in regulating β-
globin gene transcription is currently unclear (Splinter et al. 2006), but it appears 
transcription is independent to chromatin loop formation, currently identified to be CTCF-
dependent. This is in accordance with previous data suggesting that the 3’HS1, which is 
essential for ACH formation, is not required for LCR-gene contacts, and globin gene 
transcription appears normal in its absence (Strouboulis et al. 1992). It remains to be 
seen if other CTCF-dependent or independent loops are formed at this locus that 
influence transcriptional activity.  
 
Importantly, the erythroid-specific transcription factor erythroid krüppel-like factor 
(EKLF) is necessary for β-globin gene transcription but not the establishment of the CH 
(Drissen et al. 2004). Therefore either the transition of the locus into or the stabilisation 
of an active CH is EKLF-dependent. Interestingly, in erythroid progenitor cells when the 
CH is initially formed, EKLF is expressed but does not participate in the structure, 
suggesting EKLF is modified either to become involved or to prevent it activating globin 
expression too early. It would be interesting to analyse the binding of EKLF to the β-
5’HS 5’HS 
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globin locus in the absence of CTCF, to ascertain the stabilising role of EKLF and given 
that transcription of β-globin requires EKLF but apparently not CTCF. Other cis-
regulatory elements apart from the LCR and β-globin promoter are proposed to affect 
ACH formation in the human β-globin locus (Patrinos et al. 2004). 
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Leuko/Lymphopoiesis: Generating immunity. 
Leukocytes are classified into three groups (granulocytes, monocytes and 
lymphocytes) by their appearance under the microscope. Leukocytes such as basophils, 
eosinophils and neutrophils characteristically contain a granular cytoplasm and are 
therefore referred to collectively as granulocytes or polymorphonuclear granulocytes 
(PMNs). Mast cells are also granulocytes, but are not present in the circulation despite 
their haematopoietic origin. Monocytes are without granules and found in the circulation. 
Upon leaving the bloodstream, monocytes differentiate into macrophages, one of the 
main phagocytic cell types important for innate immunity (see below). There are two 
major classes of lymphocyte, B- and T-lymphocytes, which emerge from the bone 
marrow and thymus respectively. T-cells undergo further differentiation in peripheral 
lymphoid tissues such as the spleen and lymph nodes upon leaving the thymus, 
generating distinct cell types involved in inflammatory, allergic and cytotoxic responses. 
 
All leukocytes are specialised blood cells involved in the recognition and 
prevention of and response to infections and as a defence protecting the body against 
environmental antigens. A functional protective immune system is critical for survival. 
The immune system can be broadly separated into two categories, innate and acquired 
immunity. These two types of immune response are very different and are performed by 
different sets of cells, but interact very closely generating a robust immune response 
(Fearon and Locksley 1996). The innate arm of the immune system can be considered 
as the first line of defence, involved in initiating inflammation and is dependent upon 
direct recognition of pathogens by phagocytic cells (macrophages, monocytes and 
PMNs).  Eosinophils although considered as phagocytic cells play a major role in the 
defence against larger pathogens that cannot be internalised, such as parasitic worms or 
helminths. The action of eosinophils is also mediated by cytokines secreted by T-helper 
cells (see below). The innate immune response is important during the early stages of 
infection but is a direct, non-specific response and does not change upon repeated 
exposure to pathogens.  
 
B- and T-lymphocytes broadly represent the acquired or adaptive arm of 
immunity, mediating immediate and long-term antigen-specific responses against 
antigens identified by the innate immune response as potentially harmful. However 
subsets of T-cells such as γδ T cells and Th-17 cells also participate in innate immunity 
(see below). Activation and regulation of the acquired immune response is a major role 
of innate immunity. Adaptive immunity requires specific recognition of pathogenic 
antigens, both extracellular and intracellular using antigen receptors, the B-cell receptor 
(BCR) and the T-cell receptor (TCR). Both B- and T-cells have highly specialised and 
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cooperative immunological functions to recognise and protect the body from infection 
and generate memory lymphocytes, which respond rapidly upon re-infection. B-
lymphocytes are antibody-producing cells found circulating in the plasma that eradicate 
pathogens via macrophage-mediated phagocytosis. In contrast, direct interaction 
between cytotoxic T-lymphocytes and pathogens or indirect responses triggered by T-
helper cells function to remove infections. The development of both B- and T-
lymphocytes proceeds through very strict checkpoints. This chapter will focus on the 
development of T-lymphocytes, which requires tight regulation to prevent autoimmune 
diseases such as multiple sclerosis, autoimmune diabetes, asthma and inflammatory 
bowel disease (IBD) such as Crohn’s disease (Norman and Hickey 2005). T-lymphocyte 
differentiation and factors influencing the progression of the T-cell lineage into distinct 
subsets of mature T-cells will be discussed.  
 
T-lymphocyte development:  
T-lineage commitment and differentiation within the thymus 
As with all haematopoietic cells, lymphocytes are ultimately derived from HSCs 
found in the adult bone marrow. T-lymphocytes however are unique to the 
haematopoietic lineage in that they are the only cells not produced in the bone marrow. 
The vast majority of functional T-lymphocytes found in the circulation and peripheral 
lymphoid tissues are derived from cells generated within the thymus, however a minimal 
proportion of the peripheral T-lymphocyte population has been described to originate 
from an extrathymic source (Rocha et al. 1995, Leclercq, 1996). 
 
  Differentiation from HSC to committed T-lymphocyte potentially involves 
several intermediate stages. However, the identity of the T-lymphocyte precursor cell 
remains controversial (Zuniga-Pflucker and Schmitt 2005, Bhandoola, 2007). During 
early embryogenesis, the fetal liver is the preliminary site of T-cell development prior to 
development of the thymus that occurs between embryonic days (E) 10-13.5 (Manley 
and Blackburn 2003). Specific cell types required for initiating thymus formation are 
shown to be present at E10 with organogenesis beginning at E11. The thyroid gland, 
parathyroids and thymic lobes develop in close association until eventual bilateral 
development of the thymus occurs and leads to separation from the parathyroids at 
E13.5 (Miosge and Goodnow 2005).  The earliest thymus colonising cells appear at E11-
12. It has been shown that these cells are not capable of generating B-cells, but do have 
the capacity for T/NK/DC lineage differentiation, suggesting B-lineage potential is 
restricted extrathymically (Harman et al. 2005, {Masuda, 2005). This restriction seems 
not to continue in adults; early lymphocytes in the thymus known as thymic lymphoid 
precursor (TLP) or early thymic progenitor (ETP) cells retain the potential to differentiate 
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along all lines of lymphoid development as B-lymphocytes, T-lymphocytes, lymphoid 
dendritic cells (DC) and natural killer (NK) cells before T-cell specification is set (Zuniga-
Pflucker and Lenardo 1996, Rothenberg, 2005, Bhandoola, 2007).  A number of 
hematopoietic progenitor cells located in the blood, bone marrow and thymus have the 
capacity to differentiate towards the T-cell lineage (Bhandoola et al. 2007). However 
committed T-cell development is not assured until a relatively late stage of differentiation 
when cells have resided in the thymus for several days. The thymic microenvironment 
strongly supports the potential of multipotent progenitors developing along the T-lineage, 
as direct transfer of HSCs into the thymus allows efficient generation of T-cells. In 
contrast, HSCs injected into the circulation is much less efficient, requiring differentiation 
and homing of differentiated cells to the thymus. How these circulating progenitor cells 
become targeted to and located within the thymus is regulated in part by expression of 
phagocyte glycoprotein-1 (PGP1; CD44), P-selectin glycoprotein ligand-1 (PSGL1) and 
integrins. Significantly, HSCs do not express the CC chemokine receptor CCR9, shown 
to be important for directing cells to settle in the thymus. The earliest CCR9 expressing 
progenitor cell is the early lymphoid progenitor (ELP). The contributions of ELPs to 
defining specific T-cell progenitors remain unknown (Bhandoola et al. 2007). 
Colonisation of the thymus by progenitor cells occurs at the cortico-medullary junction 
and Notch/Delta-like signals provided by thymic stromal cells within the cortex are 
essential for subsequent T-cell differentiation in vivo (Sambandam et al. 2005, Tan, 
2005).  
Lymphocytes within the thymus are widely and broadly classified according to 
expression of the major histocompatibility (MHC) (Germain 1994) receptor accessory 
molecules CD4 and CD81. Double negative (DN) cells express neither CD4 nor CD8, 
double positive (DP) cells express both, and single positive (SP) cells express either 
CD4 or CD8 specifically. The earliest identified intrathymic cells to have T-cell potential 
are designated double negative 1 (DN1), early thymic progenitors (ETPs) or DN1a-e 
cells (Rothenberg 2007, Porritt, 2004). ETPs can strictly be distinguished from true DN 
cells as some cells that fall under the ETP classification also express low levels of CD4. 
However, as both CD4low and CD4- intrathymic progenitor cells have the same functional 
capacity, these terms may be interchangeable (Bhandoola et al. 2007). A more accurate 
classification of thymic cells and their subsequent differentiated states considers the 
expression of the interleukin 2 receptor alpha chain (IL-2Rα; CD25), CD44, CD3, CD8 
and c-Kit (fig 3.5) (Sebzda et al. 1999).  
                                                 
1 Lymphocytes, like all WBCs, express many different molecules on their cell surface. The CD 
(cluster designation) nomenclature categorises these different molecules based upon clusters 
of monoclonal antibodies that recognise specific markers. This system is now used to indicate 
the molecule recognised by each specific ‘CD’ of monoclonal antibodies (Roitt, I., Brostoff, J., 
Male, D. Immunology. Fourth ed. Mosby. p2.2)  
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Figure 3.5. A schematic overview of T-cell differentiation pathways in the thymus 
Adapted from (Sebzda et al. 1999). 
 
TCRγ rearrangements can be detected at DN2, indicating commitment to the γδ lineage is 
initiated at this point. However TCRδ gene expression, which is absolutely required for the 
generation of γδ T-cells is not detected until DN3. CD3 is a co-receptor molecule expressed 
from DN3 onwards as part of the (pre)-T-cell receptor. In mice, ISP cells express CD8, 
whereas the equivalent stage in human cells express CD4. See text for details. 
     
Commitment to the pro-T-cell DN2 stage from ETPs is dependent on interleukin (IL) 7 
expression by thymic stromal cells and is characterised by up-regulation of CD25 and 
initiation of T-cell receptor gene rearrangements, the earliest detection of which involves 
the Tcrγ gene locus at the DN2 stage (Capone et al. 1998). Fully committed T-cells are 
not generally recognised however until DN3 (Rothenberg 2007) when rearrangements of 
Tcrγ, δ, and β gene loci occur and CD44 expression is lost. A small percentage of DN3 
cells express a TCR composed of γ and δ chains, which differentiate into the γδ T-cell 
lineage (see below). The vast majority of cells rearrange Tcrβ genes that are expressed 
on the cell surface forming a complex with the surrogate pre-Tα chain and the CD3 
complex generating the pre-TCR. Signalling from the pre-TCR through Zap-70, calcium 
mobilisation and subsequent activation of NFAT and NFκB inhibits further recombination 
of the TCRβ allele, induces proliferation and down-regulation of CD25 to give DN4 
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(CD44- CD25-) cells and actuates CD4/CD8 expression (Wiest et al. 1999). Aspects of 
pre-TCR expression are significantly different to both αβ and γδ TCRs; functional 
expression of the pre-TCR results in apparently spontaneous inclusion in lipid rafts, 
microdomains enriched in glycolipids (Saint-Ruf et al. 2000). Pre-TCR signalling in 
contrast to αβ and γδ TCRs occurs constitutively and does not require ligand interactions 
mediated by thymic stromal cells (Irving et al. 1998). Failure to develop a functional pre-
TCR leads to apoptosis (von Boehmer et al. 1999). This process is known as β-selection.  
T-cell development in the thymus is dependent on Tcr gene loci rearrangements 
that strictly occur in a developmental stage-specific manner. Rearrangement of Tcrβ 
genes is a critical check-point for T-cell differentiation as only cells that have undergone 
functional β-gene rearrangement will down-regulate CD25, proliferate and continue 
differentiation towards the mature T-cell stage, initiating expression of the Cd4 and Cd8 
co-receptor genes. Antigen receptor genes in both B- and T-cells are composed of 
separate variable (V), diversity (D), and joining (J) gene segments which rearrange by 
somatic recombination via the actions of recombination-activating genes (Rag).  
Recombination signal sequences (RSS) flank the V, D and J genes, and recombination 
is restricted between RSS of differing lengths (Tonegawa 1983). Two RAG proteins 
(RAG-1 and RAG-2) function co-ordinately, inducing site-specific double-strand breaks at 
the coding sequence/RSS border in both Tcr and Bcr loci (van Gent et al. 1996), which 
are repaired by non-homologous-end-joining DNA repair machinery (Weaver 1995). Tcrγ 
gene recombination can be detected as early as DN2, indicating functional Rag genes 
are expressed at this stage, however Tcrβ gene rearrangement does not normally occur 
until DN3. Tcrβ genes rearrange in a highly ordered process, Dβ-to-Jβ rearrangements 
precede Vβ-to-DJβ, which are mediated in part by the Tcrβ enhancer (Eβ) and Dβ1 
promoter (Mathieu et al. 2000). Activation of the Dβ1 promoter (PDβ1) by Eβ is necessary 
for initial Dβ-to-Jβ rearrangements whereby Eβ is proposed to mediate the formation of 
open chromatin modifications across the Dβ, Jβ and Cβ domain. In contrast, 
rearrangements of the TCRβ variable (Vβ) genes are thought to occur in an Eβ-
independent manner (Ryu et al. 2004). Interestingly, Eβ and PDβ1 have been shown by 3-
C to functionally interact with each other at Dβ1 but not at Jβ by forming chromatin loops 
(Oestreich et al. 2006). 
The regulation of chromatin structure and changes in histone modifications are 
proposed to facilitate accessibility of RAG proteins to specific Tcr gene sites.  Particular 
attention has been given to the role of histone H3 acetylation and the requirement of 
ATP-dependent chromatin remodelling complexes in mediating Tcr gene 
rearrangements.   Hyperacetylation of H3 in both Tcrβ and Tcrα genes is strongly 
correlated with the stage at which rearrangements of these loci occur (McMurry and 
Krangel 2000, Winandy, 2005). Stringent control of both the initiation and termination of 
Tcr gene rearrangements is required as this determines cellular developmental potential. 
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The mechanisms by which the timing of Tcr gene rearrangements are mediated and 
coordinated with developmental transition are not yet fully understood.  The cessation of 
VDJβ recombination, which coincides with a loss of Vβ transcriptional activity and 
repressive chromatin formation, is required for progression from the DN to DP stage. It is 
of interest to note that forced transcriptional activity and modification of chromatin 
structure was not sufficient to re-induce Vβ rearrangements, suggesting regulatory 
(transcriptional) factors or other epigenetic modifications were not present to fully 
recapitulate the developmentally appropriate gene regulatory network or cellular 
environment required (Jackson and Krangel 2006). 
 
Progression though the DN stages also requires the regulated expression of 
specific transcription factors, notably GATA3 (Ting et al. 1996, Pai et al. 2003). In mice, 
T-cells differentiate from the DN stage through an intermediate CD8+ expressing cell type 
known as immature single positive (ISP), a transient stage that is largely overlooked in 
most articles. Intense cellular proliferation occurs at this stage in order to generate the 
large numbers of DP cells required in the thymus. The transition between ISP and DP 
cells requires the down-regulation of cell-cycle regulators such as p21 and p27 
(Tsukiyama et al. 2001, Wolfraim, 2004). Sequential up-regulation of Cd4 gene 
expression defines the DP stage, at which point Tcrα Vα–to-Jα gene rearrangements 
begin. Histone acetylation and H3K4 methylation is found at promoter sequences 
important for regulating Tcrα recombination events initiated by the Tcrα enhancer (Eα), 
which affects long-range chromatin modifications and structure of the locus (Hawwari 
and Krangel 2005). It remains to be seen if CTCF participates in the long-range 
chromatin modifications of the Tcrα locus, however there is currently no evidence 
suggesting CTCF directly affects Tcrα expression (this thesis). Unlike Tcrβ gene 
recombination, biallelic and multiple rearrangements of Tcrα genes occur, although there 
seems to be a matter of proximity between Vα and Jα genes determining recombination 
timing (Krangel 2007). 
 
 Functional rearrangement of Tcrα genes and the subsequent formation of 
diverse TCRαβ complexes initiate selective pressure on the developing T-cells based 
upon TCRαβ signalling and the capacity of specific TCRs to recognise antigens. Mature 
T-cells are distinguished according to their ability to recognise infected cells displaying 
peptides from the infecting pathogen on their cell surface. These peptides are distinct for 
each pathogen and accordingly are recognised specifically by the diverse TCR repertoire 
generated by TCR recombination. Cell surface antigen presentation is achieved by 
interactions between pathogen peptides and specific membrane glycoproteins, the major 
histocompatability complex (MHC) (Germain 1994). Antigen/MHC complexes are 
recognised by the TCRαβ, and this triggers the termination of RAG expression and Tcrα 
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gene recombination. Subsequently, expression of TCRαβ increases and cells initiate 
expression of CD69 on their surface, which is a marker for activated T- and B-
lymphocytes. DP cells undergo both positive and negative selection at this stage based 
upon the reactivity of the Ag/MHC complex and TCRαβ signalling. DP cells are selected 
against if they do not receive any functional TCRαβ-mediated signal within 3-4 days, and 
as a result they will go into apoptosis by a process termed death by neglect (Sebzda et 
al. 1999). Self-reactive T-cells also undergo negative selection to maintain a population 
of T-lymphocytes designed specifically to recognise MHC complexes presenting non-self 
antigens, which also provides a mechanism of maintaining tolerance (Kappler et al. 
1988). DP CD69+ cells that express a fully functional and non-self reactive TCRαβ are 
positively selected and go forward to further differentiate into mature single positive (SP) 
T-cells. 
 
Two classes of MHC molecules exist; MHC class I molecules are expressed in 
all nucleated cells in the body (Ellmeier et al. 1999). In contrast, expression of MHC 
class II molecules is relatively cell-type restricted. MHC class II molecules recognise 
extracellular pathogenic peptides that have been internalised either specifically (by B-
lymphocytes) or non-specifically by dendritic cells (DC) or macrophages, which 
collectively are referred to as antigen presenting cells (APCs). MHC molecules class I 
and II also differ in their respective co-receptor molecules that in turn classifies the 
eventual cell lineage fate. Differentiation into CD4+ SP and CD8+ SP cells requires the 
expression of one co-receptor molecule to be repressed. T-cells that express an MHC 
class I restricted TCRαβ maintain CD8 expression and differentiate into cytotoxic CD8+ 
SP cells. Conversely, the interaction of TCRαβ with MHC class II molecules corresponds 
with CD4 co-receptor expression and the differentiation of CD4+ SP cells. The 
mechanism by which the TCR has specificity for MHC molecules and how this 
determines subsequent cell lineage direction remains unknown and controversial 
(Taniuchi et al. 2002). Studies by Hernández-Hoyos et al using transgenic mice revealed 
the expression of particular MHC molecules does not seal the fate of T-cell 
differentiation. Changes in expression levels of the src-family protein kinase p56 (LCK) 
during positive selection have been shown to redirect CD4/CD8 lineage determination. 
T-cells with an MHC class II restricted TCR can develop into functional CD8+ cells when 
levels of LCK are reduced. On the other hand, when activity of LCK is increased, cells 
carrying an MHC class I restricted TCR are capable of CD4 differentiation (Hernandez-
Hoyos et al. 2000). The zinc-finger transcription factor cKrox is known to be required and 
sufficient for directing thymocytes undergoing positive selection into CD4 lineage 
differentiation (Sun et al. 2005). The Zfp67 gene encoding cKrox is up-regulated 
specifically during CD4+ T-cell differentiation. Constitutive expression of cKrox 
transgenes effectively induces the same result as increased LCK activity, directing DP 
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cells with MHC class I TCRs to the CD4 cell lineage, whereas in the absence of cKrox, 
MHC class II-restricted DP cells develop into CD8+ cells. The cKrox protein is also known 
as T helper-inducing POZ/Kruppel factor (Th-POK). Helper deficient (HD) mice are 
completely devoid of CD4 cells. This phenotype occurs from a spontaneous single 
nucleotide mutation in the DNA-binding domain of Zfp67, which functionally inactivates 
the cKrox/Th-POK protein (Dave et al. 1998, He, 2005, Sun, 2005). 
The expression of both Cd4 and Cd8 genes is a tightly regulated process, 
requiring coordinated silencing at the DN stage, activity at the DP stage and subsequent 
independent transcriptional control in single positive cells. The Cd8 locus consists of two 
separable genes (Cd8α and Cd8β), whereas the CD4 protein is the product of a single 
gene (Taniuchi et al. 2004). The epigenetic mechanisms behind Cd4 and Cd8 
expression patterns are only recently emerging; interestingly DNA methylation is 
apparently not required for the silencing of Cd4 expression (Lee et al. 2001, Wilson, 
2005). Cd4 expression is mediated in part by a promoter, a proximal enhancer and other 
enhancer-like elements (Krangel 2007), however the expression pattern of Cd4 is 
underlined by an intronic Cd4 silencer element that represses expression in both DN and 
CD8 SP cells (Sawada et al. 1994). Interestingly, the Runx family of transcription factors 
is essential to the function of this silencer element, and studies have revealed specific 
requirements for Runx1 and Runx3 interaction at the DN and SP stage respectively 
(Taniuchi et al. 2002), although some functional redundancy may occur in CD8+ cells 
(Woolf et al. 2003). Changes in chromatin conformation at the Cd4 locus occur via Runx 
interaction recruiting repressive chromatin remodelling complexes including the DNA-
binding component of the SWI/SNF-like BAF complex (BAF57), histone 
methyltransferase Suv39h1 and HDAC1 (Chi et al. 2002, Telfer, 2004, Reed-Inderbitzin, 
2006).  A corresponding silencer for Cd8 expression is unknown, however over-
expression of the transcription factor GATA3 is known to repress development of CD8+ 
SP cells (Nawijn et al. 2001) and this may also involve the recruitment of specific 
chromatin modifications. In conjunction with a role in Cd4 repression, Runx 1 is also an 
activator of Cd8 expression in DP cells via interaction with Cd8 enhancers (Sato et al. 
2005). Activation of Cd4 requires hyperacetylation of histone H3 at the Cd4 enhancer. 
Surprisingly, this is dependent upon Mi-2β (CHD4), a component of the nucleosome 
remodeling deacetylase (NuRD) complex (Williams et al. 2004), which in the context of 
T-cell development is required for attracting both the HeLa E-box binding protein (HEB) 
transcription factor and the p300 HAT to the enhancer.    
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Transcription factors required for T-lineage development 
The development of T-cells is tightly regulated by the activity of multiple 
transcription factors at every stage from specifying precursor cells with T-lineage 
potential, through to mediating functions of definitive effector cells. A few of the key 
factors will be highlighted here.  
 
Before T-lineage fate is committed, lymphocyte precursor cells strictly require 
the expression of Ikaros, a krüppel-like zinc-finger transcription factor, and PU.1 for the 
development of all lymphoid cells (Georgopoulos et al. 1994, Spain et al. 1999). PU.1 
expression levels are critical for correct thymocyte development and importantly lineage 
direction. High overexpression of PU.1 can redirect precursor cells towards myeloid 
differentiation, whereas moderately increased levels arrest T-cell development at the 
pro-T stage (Anderson et al. 2002). The differentiation from lymphoid progenitors to early 
DN thymocytes also involves GATA3, the expression of which together with c-myb 
characterises the earliest emergence of distinguishable T-cell progenitors in the thymus 
(Ting et al. 1996, Hendriks et al. 1999, Allen et al. 1999). GATA3 is one of the most 
significant regulators of T-cell development; expressed throughout differentiation, but is 
down regulated at stages of TCR rearrangement when cells are in G1 arrest. 
Significantly, the induction of Gata3 in thymocytes is directly regulated by c-myb and is 
independent of TCR signaling (Maurice et al. 2007). 
 
As described above, Tcr gene rearrangements are initiated at DN2-3, and β-
selection occurs, whereby only T-cells completing functional Tcrβ gene rearrangements 
can proceed towards the TCRαβ lineage. The expression of a number of genes including 
Rag1/2, and components of the pre-TCR are essential. A regulatory cascade involving 
Notch interaction with recombination signal binding protein J (RBP-J) activates 
expression of both the preTα (pTα) chain and HES-1, a basic helix-loop-helix (bHLH) 
transcription factor that is necessary for the expansion of early T-cells during β-selection 
(Tomita et al. 1999). HLH proteins are key regulators of both B- and T-lymphocyte 
development, for review (Murre 2005). Class I bHLH proteins are known as E-proteins or 
E-box binding proteins in reference to their DNA-binding consensus sequence. E12 and 
E47 are E-proteins encoded by a single gene, however different proteins are produced 
by virtue of differential splicing. E47 is important in regulating the β-selection checkpoint 
by initiating cell cycle arrest at DN3 before Tcrβ gene rearrangements begin, and in the 
absence of pre-TCR signaling, maintaining developmental arrest (Engel et al. 2001, 
Petersson et al. 2002). 
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Following β-selection, cell proliferation is induced, and continues until Tcrα 
genes begin rearrangement in DP cells. The progression from DN-DP occurs via an 
intermediate ISP stage. Defective Tcrα gene expression can result in accumulation of 
ISP cells, as observed in the absence of TCF-1, a T-cell specific high-mobility group 
(HMG) transcription factor (Roberts et al. 1997) required for Tcrα expression. HEB, 
another bHLH factor (Barndt et al. 1999, Barndt et al. 2000) also mediates the DN-DP 
transition, however redundancy between different E-proteins rescues the developmental 
block observed in the HEB knock out. Importantly, HEB is functional as a DNA-binding 
protein either as a homodimer or in a heterodimeric complex with the related factor E2A. 
Deficient E2A expression affects early T-lymphocyte development (Bain et al. 1997). 
Interestingly, GATA3 is an activator of E2A, which in turn negatively regulates 
expression of the CD5 glycoprotein in DP cells via binding of E2A to the CD5 promoter 
(Yang et al. 2004, Ling et al. 2007). As αβTCR signaling is repressed by CD5, Ling et al 
suggest GATA3 mediates a positive feedback loop where αβTCR activation induces 
GATA3 expression, leading to an increase of E2A and subsequent repression of CD5, 
which continues activation of the TCR.  
 
Peripheral T-cell development 
The differentiation into either CD4 or CD8 SP cells in the thymus precedes the 
loss of CD69 expression and up-regulation of CD62L, which is required for migration of 
mature SP cells from the thymus to the peripheral lymphoid tissues. Differentiated CD4 
and CD8 T-cells that have undergone stringent selection within the thymus to ensure 
they specifically recognise non-self antigens presented by MHC molecules emigrate via 
the circulation to the spleen and lymph nodes without having previously encountered 
their specific antigen, and as such are referred to as naïve T-cells. Before naïve T-cells 
come across their specific cognate peptide-MHC, they circulate as quiescent cells 
arrested in G0. Prior to activation, IL-2 expression is repressed in naïve T-cells in part by 
DNA methylation of the IL-2 promoter, and repressive chromatin modifications across the 
locus (Fitzpatrick and Wilson 2003). 
Upon initial activation, involving TCR stimulation and recognition of the antigen 
together with co-stimulatory signals from APCs, naïve cells begin production of IL-2 
(Wilson et al. 2002) following remodeling of the IL-2 locus that requires c-rel activity (Rao 
et al. 2003). The expression of IL-2 is known to mediate growth, differentiation and/or 
apoptosis in lymphocytes, dependent upon the composition of the IL-2 receptor (IL-2R) 
(Herblot et al. 1999). At least three subunits (α,β, and γ) make up the IL-2R, however the 
IL-2R α-chain, which is only expressed in peripheral T-cells in the presence of co-
stimulatory signals from APCs, increases the affinity for IL-2 interaction and this initiates 
cell cycle release into G1, progression and subsequent cellular proliferation. IL-2 is 
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known to be necessary for IL-2Rα expression in spleen and lymph nodes, but 
dispensable for expression of IL-2Rα in the thymus and bone marrow (Herblot et al. 
1999). 
Naïve T-cells differentiate into effector cells following 4-5 days of proliferation 
(fig 3.6) (Laurence and O'Shea 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. An overview of T-lineage differentiation in mice                                         
Adapted from (Laurence and O'Shea 2007). 
 
In the presence of APCs and cognate peptides, naïve T-cells differentiate in to distinct 
lineages characterised by their cytokine secretion. An important differential requirement for 
TGFβ in Th-17 development occurs between humans and mice. Inducible T-regulatory cells 
(iT-reg) are anti-inflammatory cells that develop under the influence of IL2. Th-17 cells are 
inflammatory cells directed by STAT3 signaling. For details see text and (Laurence and 
O'Shea 2007).  
 
T-cells expressing the MHC class I molecules and CD8 co-receptor are committed to 
differentiate into cytotoxic T-cells. Importantly, cytotoxic lymphocytes (CTLs) include both 
CD8+ cells together with natural killer (NK) cells and lymphokine-activated killer (LAK) 
cells. CD8+ cells are a specialised cell type involved in the rapid removal of virus-infected 
cells after infection, secreting cytolytic effector molecules such as perforin and granzyme 
B that destroy the infected cell to which the CD8+ cell has bound. Characteristically, 
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CD8+ cells also express interferon-γ (Ifn-γ), and they are sometimes referred to as Tc1 
cells (Asnagli and Murphy 2001), however CD8+ cells can express IL-4, IL-5 and IL-13 
when exogenous IL-4 is present, differentiating into so called Tc2 cells (Cerwenka et al. 
1998). CD4+ T-cells undergo further differentiation into T-helper (Th) cells of which there 
are three main classes, Th-1, Th-2 and Th-17. As mentioned above, activation of naïve 
T-cells involves a two-step signalling event; initial TCR-derived signals and a co-
stimulation via accessory molecules expressed on APCs. Significantly, only activated 
DCs express sufficient levels of the CD80 (B7-1) and CD86 (B7-2) co-stimulators to 
induce effector cell differentiation. CD28 is the main co-stimulatory molecule on Th cells 
that interacts with CD80 and CD86 (Lenschow et al. 1996). 
The characteristics and functions of Th-1 and Th-2 cells have been extensively 
reviewed (Abbas et al. 1996, Glimcher, 2000). Th-1 and Th-2 cells differ in the type of 
immune response elicited, the type of pathogens they respond to, and they are also 
associated with different kinds of immunopathology (table 3.2) (O'Garra and Arai 2000).  
 
 
Features T helper-1 T helper-2 
Characteristic cytokines IFN-γ, IL-2, IL-10, lymphotoxin IL-4, Il-5, IL-10, IL-13 
Characteristic gene 
expression 
T-bet GATA3 
Pathogen eradication Intracellular, bacteria, parasites, 
yeasts, fungi 
Extracellular, parasitic 
worms 
Immune response Cell-mediated immunity, 
production of compliment fixing 
antibodies (IgG2a), NK 
activation, activation of 
cytotoxic CD8+ 
Humoral immunity, 
activation of mast cells 
and eosinophils 
Immunopathology Autoimmune disease* Allergy, atopy 
 
Table 3.2. T-helper cell characteristics  
Adapted from (O'Garra and Arai 2000).  
* The induction of autoimmune disease is now characterised as a Th-17 cell 
immunopathology. It was previously thought that Th-17 cells were derived from Th-1 cells. 
Recent studies demonstrate the emergence of Th-17 cells directly from naïve CD4+ cells 
(Harrington et al. 2005, Park et al. 2005). See text for details.  
 
 
Importantly, T-helper cells are characterised by their cytokine expression profile, which 
under normal conditions is strictly restricted to either Th-1 or Th-2 cells.  
 
Th-17 cells are a recently emerging aspect of CD4+ T-cell biology. Previous 
studies of IL-17 expressing cells suggested they were derived from ‘pre-Th-1’ cells that 
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under certain conditions, possibly in the presence of IL-23 would diverge into Th-17 cells, 
whereas IL-12 stimulation allowed Th-1 differentiation. The expression of IL-17 is now 
known to occur directly from differentiated naïve CD4+ cells, therefore Th-17 cells are a 
completely distinct effector cell type (Harrington et al. 2005, Park et al. 2005). 
Significantly, these studies identified IL-17-producing cells as pathogenic in experimental 
mouse models of inflammatory disease, and development of the disease could be 
impeded in mice deficient for IL-23, which initiates IL-17 expression.  Interestingly, the 
developmental initiating factors, cytokine profile and functions of Th-17 cells are distinct 
between humans and mice. It also remains unclear if Th-17 cells are a terminally 
committed lineage of cells like Th-1 and Th-2 cells (Wilson et al. 2007). 
 
Defining Th-1 and Th-2 cells 
 T-helper effector cell differentiation and their characteristic patterns of effector 
cytokine expression are mediated on several different levels, both intrinsic to the cell 
including chromatin modifications (Shoemaker et al. 2006), DNA methylation (Sanders 
2006), chromatin structure (Agarwal and Rao 1998, Spilianakis et al. 2004, Lee et al. 
2005), chromosomal interactions (Spilianakis et al. 2005), regulation of gene expression 
by transcription factors (Agnello et al. 2003, Yates et al. 2004, Szabo et al. 2000, Zheng 
& Flavell 1997) and nuclear repositioning of factors regulating cytokine expression 
(Hewitt et al. 2004), but also environmental factors such as hormones or nutrients 
(Spilianakis et al. 2005b). None of these processes occurs independently, and in some 
cases single proteins are implicated in many different modes of regulation. 
 
 Differentiation of naïve T-cells to effector Th cells is influenced by the 
concentration and type of antigen presented, the avidity of peptide-MHC interaction and 
the type of co-stimulation received. Importantly, an intricate regulatory system of cytokine 
signalling between APCs and Th cells and chromatin remodelling is central to effector 
cell differentiation and function. Naïve T-cells maintain distinguishing Th cytokines (Ifn-γ 
and IL-4) in a permissive yet inactive condition (Baguet and Bix 2004). Following antigen 
stimulation, specific cytokine signals direct differentiation into Th-1 or Th-2 cells, and 
both Ifn-γ and IL-4 loci are remodelled to enhance transcription from one loci but not the 
other ensuring rapid secretion of cytokines upon subsequent exposure to specific 
antigens.  
IL-12 is necessary for the differentiation of naïve T-cells into the Th-1 lineage. 
APCs are the predominant source of IL-12 and are also the first line response to 
infection, providing a critical link between innate and adaptive immunity. The expression 
of IL-12 by APCs is initiated in response to the uptake of bacterial, viral or protozoal 
infection and also via interactions between CD40 cell surface molecules on APCs and 
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CD40L on activated T-cells (Agnello et al. 2003). Co-operative activity between IL-12 
and an unrelated cytokine IL-18 induces Ifn-γ production from NK and T-cells. A 
feedback mechanism occurs where by IL-12 and Ifn-γ expression promotes Th1 
differentiation, and subsequent Ifn-γ expression in Th-1 cells leads to increased IL-12 
expression in APCs that continues the differentiation of Th-1 cells. Ifn-γ expression is 
imperative for Th-1 differentiation. Many characteristic functions and expression profiles 
are mutually exclusive between Th-1 and Th-2 cells (fig 3.4) (Rao and Avni 2000), 
however in the absence of Ifn-γ expression, the defining features become blurred as Th-
1 cells isolated from Ifn-γ knock out mice express Th-2 cytokines when re-stimulated in 
the presence of IL-4 (Zhang et al. 2001). Ifn-γ expression is also important for expression 
of the IL-12Rβ2 chain (Szabo et al. 1997). The IL-12 receptor (IL-12R) is comprised of 
two subunits (β1 and β2) and is only expressed following T-cell activation, therefore IL-
12R is repressed in naïve T-cells. IL-12Rβ2 is a specific marker of Th-1 cells and the 
component parts of the receptor are each necessary for normal Th-1 differentiation and 
responses in vivo. Further feedback loops occur consisting of Ifn-γ and the transcription 
factor T-box expressed in T-cells (T-bet) (Szabo et al. 2000) where T-bet directly 
regulates Ifn-γ via chromatin remodelling of the Ifn-γ locus together with an accessory 
factor HLX (Zheng et al. 2004) and indirectly promotes IL-12Rβ2 expression. IL-12 
interaction with IL-12Rβ2 triggers tyrosine phosphorylation and Janus kinase-2 (Jak-2) 
activation, which in turn activates signal transducer and activator of transcription (STAT) 
4. Importantly, STAT4 sustains T-bet expression allowing increased Ifn-γ expression 
(Szabo et al. 2003). Ifn-γ signaling also activates STAT1, and regulation of T-bet by IFN-
γ requires IFN-γR signaling that occurs in a STAT1-dependent manner (Lighvani et al. 
2001). 
 
 Extrinsic cytokine signals from DCs and other accessory cells also mediate the 
differentiation of Th-2 cells in a similar fashion to IL-12 for Th-1 cells. Antigen-stimulated 
T-cells are directed towards the Th-2 lineage by OX40, CD28 and IL-4, although IL-4 
expression is the major factor polarising Th-2 differentiation (Yates et al. 2004). 
Transcription factors including nuclear factor of activated T-cells (NF-AT), AP-1 family 
members and cMAF regulate IL-4 expression in response to antigen stimulation via 
binding to the IL-4 proximal promoter (Rooney et al. 1995, Ho, 1996). Similar to IL-12 
signaling, IL-4 binds to the IL-4R, which activates STAT6 via Jak-mediated tyrosine 
phosphorylation (Agnello et al. 2003). STAT6 in turn mediates the regulated expression 
of GATA3 by IL-4. Feedback regulation exists whereby IL-4 mediates GATA3 
expression, which subsequently regulates IL-4 expression. IL-4 signal transduction by 
STAT6 is an integral part of Th-2 differentiation, however IL-2-mediated STAT5 
activation is also important (Cote-Sierra et al. 2004, Zhu, 2003). Stat5 has two isoforms, 
a and b, that are both activated by IL-2. Interestingly, expression of a constitutively active 
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form of Stat5a can induce IL-4 expression in Th-1 cells in a GATA3 independent manner 
(Zhu et al. 2003). GATA3 is essential for Th-2 development, although it appears this is 
mediated in part by IL-4/STAT6 signaling, as STAT5 does not influence GATA3 
expression. It is interesting to note that enforced expression of GATA3 is sufficient to 
induce Th-2 responses independently of IL-4/STAT6 signaling, implying GATA3 itself 
has a key role in Th-2 function (Ouyang et al. 1998). IL-4 production is dependent upon 
STAT5 signaling, and defects in IL-4 expression in the absence of STAT5 are not 
overcome by GATA3 expression (Cote-Sierra et al. 2004) suggesting a GATA3-
independent regulation of IL-4 exists. Indeed, conditional deletion of Gata3 from 
established Th-2 cells reduces but does not completely abolish the expression of IL-4 
(Zhu et al. 2004). The IL-4/STAT6 and IL-2/STAT5 pathways are independent but 
optimal IL-4 production probably requires both pathways to work in conjunction (Zhu et 
al. 2006). Analysis of Stat5a deficient mice also revealed a key role for this signaling 
pathway in the repressive regulation of Th-1 differentiation (Takatori et al. 2005). 
STAT5a directly activates suppressor of cytokine signaling (SOCS) 3 by binding to the 
promoter, resulting in inhibition of STAT4, thereby preferentially directing Th-2 
differentiation. In the absence of STAT5a, levels of SOCS3 are reduced, allowing IL-12-
mediated activation of STAT4 and Th-1 differentiation. 
 
The pathways regulating Th-1 and Th-2 differentiation are both mutually 
exclusive and reciprocally inhibitory. Ectopic retroviral expression of Gata3 in Th-1 cells 
suppresses Th1 development by down-regulation of Stat4, a process that normally 
occurs in Th-2 cells. Interestingly, retroviral expression of STAT4 together with GATA3 in 
Th-1 cells upholds the Th-1 phenotype, suggesting the control of STAT4 signaling is 
critical to determining Th-1/Th-2 fate.  Conversely, retroviral T-bet expression in Th-2 
cells induces Th-1 cytokine expression and represses the expression of Th-2 cytokines 
(Szabo et al. 2002). IL-12Rβ2 expression is however not sufficient to induce Ifn-γ 
expression in committed Th-2 cells, nor restrict the expression of IL-4 (Heath et al. 
2000). Significantly, activation of Ifn-γ and repression of IL-4 by T-bet requires 
expression of Runx3, a transcription factor known to mediate the expression of CD8 in 
thymocytes (Taniuchi et al. 2002, Djuretic, 2007). 
 
Intra- and interchromosomal interactions in T helper cells 
The gene encoding IL-4 is located on mouse chromosome 11 within a multi-
gene locus consisting of two other Th-2 cytokine genes, Il-5 and Il-13 that are expressed 
in a developmentally restricted manner (figure 3.7). The entire Th-2 cytokine locus spans 
over 120kb (Spilianakis and Flavell 2004). Il-5 is transcribed in the opposing direction to 
both Il13 and Il-4 and separated from these genes by the constitutively expressed Rad50 
gene encoding a DNA-repair protein. Th-2 cells are characterised by the expression of 
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IL-4 together with IL-5 and IL-13, however IL-5 is also expressed in eosinophils. The 
coordinated activity of these genes is known to be regulated through chromatin 
modifications resulting in DNase I hypersensitive sites, gains of histone acetylation and 
DNA demethylation (Takemoto et al. 1998, Lee, 2002, Avni, 2002). Using 3-C analysis, 
Spilianakis & Flavell demonstrated that Th-2 cytokine genes are regulated by long-range 
chromatin interactions between the gene promoters and a locus control region (LCR) 
present in the 3’ end of the Rad50 gene and that these interactions are dependent on 
GATA3 and STAT6. Interestingly, GATA3-expressing retrovirus transfection of 3T3 
fibroblasts together with ionomycin was used to analyse the contribution of GATA3 in the 
conformation of this locus, although the authors state that despite detectable chromatin 
interactions, fibroblasts are unable to support cytokine gene expression, suggesting 
within a given locus, chromatin interactions per se are not enough to mediate correct 
gene expression. Never the less, GATA3 was identified by chromatin IP (ChIP) and 
electrophoretic mobility-shift assays (EMSA) to bind Rad50 hypersensitive site 7 (RHS7) 
that is essential for Th-2 cytokine expression and long-range chromatin interactions 
within this locus (Lee et al. 2005). 
 
 
Figure 3.7: Schematic representation of the TH2 cytokine gene locus.  
Adapted from Lee et al 2005. The expression of cytokine genes is influenced by sequences in 
the ubiquitously expressed Rad50 gene. DNase hypersensitive sites are indicated with 
downward arrows.  The TH2 LCR consists of RHS 4-7. Horizontal arrows represent the 
direction of transcription. Abbreviations, Rad50 hypersensitive site (RHS), conserved non-
coding sequence (CNS). See text for details (Lee et al. 2005). 
 
 
The differentiation of Th-1 and Th-2 cells provides an intriguing system for 
analysing how differential gene expression patterns are coordinated. Naïve T-cells 
express low levels of both Ifn-γ and IL-4 from mouse chromosome 10 and 11 
respectively, and differentiation into specific effector cells requires the silencing and 
activation maintenance of reciprocal loci. Spilianakis et al have proposed that this is 
regulated through intrachromosomal interactions between the Ifn-γ promoter and 
regulatory regions (RHS6 and RHS7) of the Th-2 cytokine locus in naïve T-cells based 
on 3-C analysis and fluorescence in situ hybridisation (FISH) (Spilianakis et al. 2005a). 
RHS1 RHS2 RHS3 TH2 LCR CNS1 
  Il5   Rad50   Il13    Il4 
50 kb 100 kb 
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GATA3 was previously identified to bind to RHS7 and mediate interchromosomal 
interactions at the Th-2 locus. Interestingly interchromosomal interactions are reduced in 
cells where RHS7 is deleted. The precise mechanism of these interactions, what 
factor(s) bind RHS6 and the potential role of GATA3 remains unknown.  
 Special AT-rich-binding protein 1 (SATB1) is a multi-functional, nuclear-matrix-
associated protein predominantly expressed in T-cells. SATB1 regulates long-range 
transcriptional activation and repression of many different genes via interaction with 
chromatin remodeling complexes (Yasui et al. 2002). T-cell development is strongly 
impaired in the absence of SATB1, as thymocytes do not develop beyond the DP stage 
(Alvarez et al. 2000). An indication for the importance of SATB1 came from indirect 
immunofluorescence of SATB1 localisation in T-cells where a cage-like distribution 
throughout the nucleus was observed (Cai et al. 2003) and it was suggested SATB1 
tethers chromatin loops to the nuclear matrix. Significantly, SATB1 is implicated in the 
regulation of interchromosomal interactions at the Th-2 locus and mediates Th-2 
cytokine expression (Cai et al. 2006). RNAi depletion of SATB1 suggests both chromatin 
loop formation and cytokine activation are dependent upon SATB1, however in the 
absence of CTCF, activation of Th-2 cytokines is impaired despite SATB1 expression 
(this thesis). It is currently unclear if SATB1 remains functional in CTCF knock out cells, 
or indeed what chromosomal interactions remain or are mediated by CTCF at this locus.  
 
γδ T-cells 
The majority of knowledge regarding T-cell development comes from the 
analysis of TCRαβ cells, however these are not the only representatives in the T-cell 
army of immunological defence. All species known to possess αβ T-cells also have γδ T-
cells (Kaufmann 1996). In both humans and mice, γδ T-cells constitute around 10% of all 
T-cells found in the circulation and peripheral lymphoid tissues, in mice however γδ T-
cells importantly are the major population of T-cells present in skin and mucosal 
epithelium (Havran and Boismenu 1994). Mucosal epithelial tissues, such as the skin, 
tongue, lungs, intestine and genitourinary tract present an important porous barrier that 
regulates the prevention of pathogen invasion while mediating the exchange of nutrients. 
This is frequently the initial site of pathogen encounter, and as such the epithelia has a 
specialised immune cell niche environment, the intraepithelial lymphocyte compartment 
(IEL). Interestingly, despite the relative rarity of IELs in one given location, the mucosal 
epithelium constitutes large areas of the body; as such the total number of IELs is greatly 
in excess of the number of lymphocytes circulating in the blood (Kaufmann 1996). 
 
γδ T-cells develop within the thymus, differentiating from DN1 cells. Developing 
T-cells have 4 TCR genes (α, β, δ, γ) that undergo separate and coordinated 
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rearrangements, the earliest detection of which involves the Tcrγ gene locus at the DN2 
stage (Capone et al. 1998). Rearrangement of the Tcrγ locus is regulated by E2A 
proteins and commits T-cell differentiation to the γδ-cell lineage (Bain et al. 1999). 
Interestingly, the fate of pro-T cells (CD25+CD44+c-kit-CD3-CD4-CD8-) to differentiate as 
either αβ or γδ cells, is regulated by interleukin receptor-7 (IL-7R) expression levels 
(Kang et al. 2001). Understanding of γδ-T-cell developmental regulation is lacking, 
although subsequent rearrangement of Tcrδ genes is critical, as demonstrated by mice 
deficient for this locus (Girardi 2006). Very little is known regarding proteins expressed 
on the cell surface of γδ-cells and the γδ-TCR itself is currently the only distinguishing 
marker for these cells. Most γδ-cells are CD4-CD8-, however some express a CD8αα 
phenotype. Normal repression of CD8α and β genes in γδ-cells is mediated by DNA 
methylation (Lee et al. 2001). The γδ-Tcr loci undergo rearrangements by V(D)J 
recombination like αβ genes, and although lower numbers of variable gene segments 
are available, γδ-TCRs have higher potential for diversity due to the use of δ-chains with 
variable  lengths and sequences at V/D/J joining sites that can accommodate multiple 
nucleotide insertions known as complimentary determining region 3 (CDR3) (Kaufmann 
1996, Rock et al. 1994). In mice, six subsets of γδ-T-cell exist characterized by TCRs 
composed of differential variable chains (Girardi 2006). γδ Vγ5Vδ1+ cells initiate a wave 
of migration from the fetal thymus, settling in epidermal tissues. These cells have almost 
no further capacity for TCR diversity. Other TCR-restricted γδ-cell subsets migrate from 
the neonatal and adult thymus in a developmentally regulated manner. The expression 
of particular variable chains is thought to direct specific γδ-cells to particular mucosal 
areas, Vγ5+ cells are located in the skin, whereas Vγ6+ and Vγ7+ T-cells reside in the 
genitourinary tract and intestines respectively. Vγ1+ is the predominant re-circulating γδ-
cell type found in the blood and lymphatic system.  
 
Immunosurveillance by γδ cells is critical to controlling infections of bacterial and 
protozoal origin demonstrated by mouse mutants and treatment of mice with anti-TCRγδ 
monoclonal antibodies. The functional capacity γδ-T-cells classifies them as part of the 
innate immune system; rapid antigen recognition by restricted γδ-TCRs occurs for the 
most part independently of MHC molecules and does not require previous exposure to 
antigen, although differentiation into cells with a memory phenotype, characteristic of 
adaptive immunity also occurs with γδ cells (Holtmeier and Kabelitz 2005). Interestingly, 
the population of γδ cells increases significantly in αβ-T-cell deficient mice; suggesting γδ 
cell development is sensitive to the presence of αβ cells (Viney et al. 1994). Importantly, 
γδ cells are able to express ‘characteristic’ αβ CD4+ Th-1 and Th-2 cytokines (Ifn-γ and 
IL-4) when activated by bacterial and helminth antigens accordingly (Ferrick et al. 1995). 
An emerging aspect of γδ T-cells is their anti-tumour effect and the potential use 
of γδ cells in immunotherapy.  The predominant site of γδ cells is the skin. Girardi et al 
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analysed the development of cutaneous malignancies in mice deficient for γδ cells by 
intradermal injections of carcinogenic mutagens and transformed cells (Girardi et al. 
2001). This study revealed γδ cells impede the onset and progression of tumours and are 
important for cytolytic clearance of tumour cells. Furthermore, γδ cells are frequently 
found associated with a variety of tumours in humans. The possible clinical application of 
γδ cells in tumour immunosurveillance and protection against graft-versus-host disease is 
reviewed in (Lamb and Lopez 2005). 
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Summary 
 
CTCF (CCCTC-binding factor) binds sites around the mouse β-globin locus that spatially 
cluster in the erythroid cell nucleus. We show that both conditional deletion of CTCF and 
targeted disruption of a DNA-binding site destabilize these long-range interactions and 
cause local loss of histone acetylation and gain of histone methylation, apparently 
without affecting transcription at the locus. Our data demonstrate that CTCF is directly 
involved in chromatin architecture and regulates local balance between active and 
repressive chromatin marks. We postulate that throughout the genome, relative position 
and stability of CTCF-mediated loops determine their effect on enhancer-promoter 
interactions, with gene insulation as one possible outcome.     
 
 
Introduction 
 
Chromatin insulators are DNA sequences that confer autonomous expression on genes 
by protecting them against inadvertent signals coming from neighbouring chromatin. 
CTCF (CCCTC-binding factor) is the prototype vertebrate protein exhibiting insulator 
activity (West et al.  2002) that can  act as an enhancer-blocker or as a barrier against 
repressive forces from nearby  heterochromatin (Defossez and Gilson 2002; Recillas-
Targa et al. 2002). In vivo, CTCF binds to the imprinting control region of the H19/insulin-
like growth factor (Igf2) locus, where it is thought to act as a methylation-sensitive 
enhancer blocker (Bell and Felsenfeld 2000; Hark et al. 2000). Moreover, CTCF binding 
sites have been found - and its insulator activity has been anticipated- at the imprinting 
center that determines choice of X inactivation (Chao  et al. 2002), at boundaries of 
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domains that escape X inactivation (Filippova et al. 2005) and  at sites flanking 
CTG/CAG repeats at the DM1 locus (Filippova et al. 2001). CTCF was first defined as an 
insulator protein when it was found to be required for the enhancer-blocking activity of a 
hypersensitive site 5’ of the chicken β-globin locus (5’ HS4) (Bell et al. 1999). A similar 
CTCF-dependent insulator site was subsequently found at the 3’ end of the locus and 
both sites coincide with erythroid-specific transitions in DNase I sensitivity of chromatin 
(Saitoh et al. 2000). Such observations suggested that CTCF partitions the genome in 
physically distinct domains of  gene expression. The molecular mechanism underlying 
CTCF’s insulating activity is still unknown.   
CTCF-binding sites also flank the human and mouse β-globin locus (Fig. 1A), 
which contain a number of developmentally regulated, erythroid-specific β-globin genes 
and an upstream locus control region (LCR) required for high β-globin expression levels. 
In mice, three CTCF-binding sites have been identified upstream (HS-85, HS-62 and 
HS5) and one downstream (3’ HS1) of the locus (Farrell et al. 2002; Bulger et al. 2003).  
Previously we have applied chromosome conformation capture (3C) technology (Dekker 
et al. 2002) to study long-range DNA interactions between these and other sites in the β-
globin locus.  In erythroid cells, the CTCF-binding sites  (including HS-85, see below) 
participate in spatial interactions between the LCR and the active β-globin genes, and 
collectively form an Active Chromatin Hub (ACH) (Tolhuis et al. 2002). No such long-
range DNA interactions were detected in non-erythroid cells.  However, in established 
I/11 erythroid progenitor cells that do not yet show activated β-globin gene expression, 
contacts between the LCR and the genes are absent, but long-range DNA interactions 
already exist between the hypersensitive sites that contain CTCF-binding sites (Palstra 
et al. 2003). Here, we investigated the involvement of CTCF in the formation of these 
loops. 
 
Results and Discussion 
 
β-globin locus conformation in erythroid cells with reduced levels of CTCF protein    
 
To investigate the role of CTCF in the formation of chromatin loops, we analyzed β-
globin DNA contacts in cells lacking the CTCF protein. Analysis was focused on E12.5 
erythroid progenitor cells because they can be expanded ex vivo (Dolznig et al. 2001) 
and lack stable LCR-gene contacts, therefore best reveal the interactions between outer 
hypersensitive sites. Chromatin immunoprecipitation (ChIP) experiments revealed that 
CTCF was bound in vivo to cognate sites in the ®-globin locus in these cells (Fig. 1F), 
while the protein was absent from HS5 and 3’ HS1 in brain cells not showing these loops  
(Supplemental Figure 1). Since CTCF-null mice die early during embryogenesis, a 
conditional knock-out mouse model was generated by inserting two lox sites upstream 
and downstream of the first and last coding exon of CTCF, respectively. To delete CTCF, 
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fetal liver cells were isolated from lox/lox E12.5 embryos, cultured under conditions that 
select erythroid progenitors, and infected with a replication-deficient lentivirus expressing 
Cre recombinase (Fig. 1B). Heterozygous (lox/wt) cells from littermate embryos 
underwent the same treatment and served as controls. Cre recombination resulted in 
nearly 100% deletion of targeted CTCF alleles, with a reduction in mRNA and protein 
levels to 2-3% and 10-25%, respectively in lox/lox as compared to wild-type  (Fig. 1C-E). 
CTCF binding to cognate sites in the β-globin locus was reduced but not completely 
abolished in lox/lox cells, as demonstrated by ChIP (Fig. 1F). To investigate β-globin 
locus conformation in these cells by 3C technology, we used a novel taqman probe-
based quantitative polymerase chain reaction (Q-PCR) strategy to accurately quantify 3C 
ligation efficiencies (Supplementary Fig. 2).  
 
We found that the structure of the β-globin locus in wild-type and lox/wt E12.5 
progenitor cells was essentially the same as previously observed in I/11 progenitor cells 
(data not shown), with long-range interactions between the CTCF-binding sites HS-85, 
HS-62/60, HS4/5 and 3’ HS1 (Fig.  1G). In lox/lox cells containing lower levels of CTCF 
protein, however, clearly reduced DNA-DNA interaction frequencies were observed 
specifically between the sites that normally bind CTCF (Fig. 1G-H). This is true for all 
combinations of binding sites, except for the interaction between 3 HS1 and HS-62 (but 
see below). The results demonstrated that CTCF is required for long-range DNA-DNA 
interactions between cognate binding sites in the β-globin locus. Gene expression 
analysis revealed the same low levels of expression for all β-globin genes in wild-type 
versus lox/lox progenitor cells (Supplementary Fig. 3). Moreover, we did not find 
activation of any of the mouse olfactory genes immediately surrounding the β-globin 
locus (MOR5B1-3 and MOR3B14) (data not shown). Hence, the reduction of CTCF 
protein to low levels had no appreciable effect on gene expression at, or around, the β-
globin locus in erythroid cells representing a differentiation stage prior to LCR-mediated 
gene activation.     
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Figure 1. Deleting CTCF in primary erythroid progenitors reduces the frequency of 
interactions between cognate binding sites in the β-globin locus 
 
(A) Schematic presentation of the mouse β-globin locus. DNase I hypersensitive sites 
(arrows) and CTCF-binding sites (red) are indicated.  
(B) Strategy to delete Ctcf. The conditional knock-out allele is composed of two lox sites 
(triangles) flanking the coding part of the Ctcf gene (yellow rectangle). Cells containing lox/lox 
or wt/lox Ctcf loci are infected with a Cre recombinase expressing lentivirus to delete the 
CTCF gene leaving a single lox site. The cellular size distribution is the same for homozygous 
and heterozygous conditional knock-out cells 4 days after infection.  
(C) Southern blot analysis showing complete deletion of Ctcf conditional knock-out alleles in 
lox/wt and lox/lox cells, 3  and 4 days after infection.  
(D) CTCF mRNA levels (as determined by quantitative RT-PCR) in untreated wild-type (level 
set to 1) and Cre-recombined lox/wt and lox/lox cells, 4 days after infection. Expression was 
normalized to HPRT. Standard deviation is indicated.  
(E) Western blot analysis of CTCF protein and GATA-1 protein (control, stripped and re-
hybridized blot), showing strongly reduced amounts of CTCF protein in lox/lox cells, 3 and 4 
days after infection. (F) CTCF ChIP analysis, showing reduced CTCF-binding to cognate sites 
in the β-globin locus in lox/lox (orange) versus control cells (blue) (4 days after infection). 
Values were normalized to input signals and expressed as enrichment over necdin.  
(G) 3C analysis, demonstrating reduced interaction frequencies between 3 HS1, HS4/5 and 
HS-85 in lox/lox cells (orange), as compared to control cells (blue) (4 days after virus 
infection). (H) 3C analysis, demonstrating reduced interaction frequencies in lox/lox cells 
between the other CTCF-binding sites in the β-globin locus.    
 
 
 
 
Long-range interactions of 3’ HS1 containing nucleotide changes that disrupt 
CTCF binding    
 
The structural changes in the β-globin locus that we observed in cells with deleted CTCF 
may be a direct consequence of reduced protein-binding to the locus, or could be caused 
by secondary pathways that fail to act on the locus in the absence of sufficient CTCF. To 
investigate this, we disrupted CTCF-binding locally by changing four conserved 
nucleotides in the core CTCF-binding site of the endogenous 3’HS1 (Supplementary Fig. 
4).  Band-shift assays confirmed that these alterations completely abolished CTCF-
binding in vitro (Supplementary Fig. 5). Targeting was performed in embryonic stem (ES) 
cells that were established from a cross between the two inbred strains 129 and 
C57BL/6 (B6); because of the genetic origin of the construct, targeting was directed to 
the B6 allele. Two additional, non-conserved, nucleotides were changed 70 base pairs 
downstream of the core CTCF-binding site to allow allele-specific analysis of CTCF-
binding to 3’HS1 by chromatin immunoprecipitation (ChIP). Moreover, an extra HindIII 
restriction site was introduced  ~850bp downstream of the CTCF-binding site, which 
enabled us to exclusively analyse DNA interactions of the targeted 3’HS1 by 3C. An 
independent control ES line was generated containing the extra HindIII site with the 
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normal 3’HS1. In each cell line the neomycin selection cassette was removed by 
transient expression of Cre recombinase, leaving behind a single lox site immediately 
downstream of the newly introduced HindIII site (Supplementary Fig. 4).   
 
Definitive erythroid progenitors were generated from the ES cells in vitro to 
analyse the consequences of the targeted nucleotide changes in erythroid cells.  We 
established two such ES-EP cell lines, ES-EP (∆3’HS1) (or ‘∆’) and the control line ES-
EP(c) (or ‘c’) (Fig. 2A). After validation of the cells as a model system for erythroid 
differentiation (Supplimentary fig. 6; Carotta et al. 2004), we analysed CTCF-binding to 
mutated and wild-type 3’ HS1 in vivo. In the control line ES-EP(c), CTCF bound strongly 
and equally well to 3’ HS1 on both alleles. In ES-EP (∆3’ HS1) however, binding to 3’ 
HS1 on the non-targeted 129 allele was the same as in ES-EP(c), but binding to the 
mutated 3’ HS1 on the targeted B6 allele was completely abolished  (Fig. 2B). Thus, the 
change of 4 nucleotides (nt) in the core CTCF-binding site prevented binding of CTCF to 
3’ HS1 also in vivo. Next we analysed whether disruption of CTCF binding at 3’ HS1 
affected its long-range DNA interactions in the β-globin locus. The extra HindIII 
restriction site introduced downstream of 3’ HS1 was used to focus 3C analysis 
exclusively on the targeted B6 allele. In undifferentiated ES-EP(c), the wild-type β-globin 
B6 allele formed a chromatin hub typically observed in normal erythroid progenitor cells, 
with 3’ HS1 interacting with HS4/5, HS-62 and HS-85 (Fig. 2C). In undifferentiated ES-
EP (∆3’ HS1) however, the mutated 3’ HS1 showed a dramatic drop in interaction 
frequencies with all these DNA elements, to levels similar to those observed in non-
expressing fetal brain cells (Fig. 2C). Thus, disruption of CTCF binding to 3’ HS1 
severely destabilized the large chromatin loop containing the LCR and the globin genes 
in erythroid progenitor cells. The fact that the interaction with HS-62 was lost upon 
targeted disruption of CTCF-binding to 3’ HS1, but not in our conditional CTCF knock- 
out experiments suggests that this interaction is more resistant than others to the 
reduction of levels of CTCF protein.  
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Figure 2. Targeted nucleotide changes in 3 HS1 disrupt CTCF-binding and reduce  frequency 
of long-range 3 HS1 interactions 
 
(A) Erythroid progenitor cell lines derived in vitro from ES cells. ES-EP("3 HS1) harbours 4 
targeted nucleotide changes in the core  CTCF-binding site of 3 HS1 on the B6 allele 
(orange). ES-EP(c) contains wild-type 3’ HS1 on the B6 allele (blue). The non-targeted, intact, 
129 allele is in grey. For ChIP, each 3 HS1 CTCF-binding site can be analysed with a unique 
primer pair (#1-4). An extra HindIII site targeted downstream of 3 HS1 allows exclusive 3C 
analysis of B6 allele (with 3C-primer b).  
(B) Absence of CTCF-binding to mutated 3 HS1 in vivo.   ChIP on undifferentiated ES-EP cell 
lines, with antibody against CTCF. Enrichment over necdin (normalized to input) was plotted; 
highest value set to 1. Left: 3 HS1 alleles in the two ES-EP lines (" and c); right: positive (HS-
85) and negative (β-major) controls.  
(C) 3C analysis with primer b to exclusively analyse 3 HS1-DNA interactions on the targeted 
B6 allele in undifferentiated ES-EP(c) (blue) and ES-EP ("3 HS1) cells (orange). Note that 
interaction frequencies with mutated 3 HS1 (orange) are reduced compared to wild type 3 
HS1 (blue). Black hatched line: 3 HS1 interactions in fetal brain, analysed with primer a and 
plotted for comparison.  
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Expression of β-globin and surrounding olfactory receptor genes in the absence of  
CTCF-mediated chromatin loops   
 
Since the large, CTCF-dependent, loops are formed only in human or mouse cells that 
are committed to, or highly express the β-globin genes (Palstra et al. 2003), we 
investigated the relationship between these loops and transcriptional regulation in detail.  
First, we analysed whether CTCF at 3’ HS1 serves as an enhancer-blocker that prevents 
the inappropriate activation of downstream mouse olfactory receptor genes (MORs) by 
the β-globin LCR in erythroid cells, as suggested previously (Farrell et al. 2002). For this, 
we compared mRNA levels of the MOR3’B1-4 genes between differentiated ES-EP(c) 
and ES-EP (∆3’ HS1) cells when the LCR is fully active. We found no inappropriate 
activation of any of the downstream MORs, nor of MOR5’B3, in the differentiated ES-EP 
(∆3’ HS1) cells (data not shown) and we concluded that insulator activity of CTCF at 3’ 
HS1 is not required for blocking LCR-mediated activation of downstream MOR genes in 
ES-EP cells. Noteworthy, previously it was found that deletion of the complete HS5 from 
the endogenous locus also had no effect on expression of the surrounding MOR genes 
(Bulger et al. 2003). We envision that the transcription factor environment in erythroid 
cells does not support the activation of olfactory receptor genes. Next, we analysed 
whether the CTCF-dependent loops influence β-globin gene expression. Upon erythroid 
differentiation, the LCR forms stable contacts with the active β-globin genes and strongly 
up-regulates their transcription rate (Carter et al. 2002; Tolhuis et al. 2002).  We 
reasoned that a shared presence on one chromatin loop anchored by CTCF in 
progenitor cells would decrease the spatial distance between LCR and genes, which 
may facilitate their productive interaction later during differentiation. If true, absence of 
such a pre-existing loop could possibly result in a delay of full β-globin gene activation. 
To test this, we compared the kinetics of LCR-mediated gene activation between the 
individual alleles of differentiating ES-EP(c) and ES-EP (∆3’ HS1) cells. Two sets of β-
major intron primers were designed that allowed independent analysis of ongoing 
transcription from the B6 allele and 129 allele (Supplementary Fig. 7). ES-EP(c) and ES-
EP (∆3’HS1) cells were induced to undergo synchronous differentiation and RNA was 
collected at various time intervals. As expected, β-major transcription rates increased 
strongly upon differentiation. However, at each given stage of differentiation, we detected 
the same gene activity between the 129 and B6 allele, both in ES-EP(c) and ES-EP 
(∆3’HS1) cells  (Fig. 3A). Thus, the CTCF-dependent chromatin loop with 3’ HS1 that 
topologically defines the β-globin locus in erythroid cells does not detectably influence 
the expression kinetics or levels of the β-globin and nearby MOR genes. This was also 
true for the embryonic β-globin genes εγ and βH1, which were off in both cell lines before 
and after differentiation (data not shown).     
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Figure 3. Targeted nucleotide changes in 3 HS1 do not affect ≤-globin gene expression  
 
(A) Expression kinetics are the same between mutated B6 allele and intact 129 allele.  
Ongoing ≤major transcription was measured by quantitative RT-PCR, using 129 and B6 
specific primers against intron 2 of the ≤major gene. Expression was normalized against 
HPRT expression levels. LCR-mediated up-regulation of β-major was not delayed in the 
absence of a pre-existing CTCF-dependent chromatin loop (compare B6 and 129 alleles in 
ES-EP ("3 HS1). X-axis: hours after induction of differentiation. Error bars represent standard-
error of mean.  
(B) Locus-wide, B6-specific, analysis of interaction frequencies with HS4/5 after 
differentiation. Graphs show that HS4/5 interactions with β-major and rest of the locus are not 
affected in ES-EP ("3 HS1) after differentiation. Note that primer a was used near 3 HS1, 
which on the B6 allele analyses a small (0.5 kb) fragment downstream of (i.e. not containing) 
3 HS1, whereas on the 129 allele this primer would analyse an ~8kb fragment encompassing 
3 HS1. The dramatic drop in interaction frequencies reassuringly shows that analysis is 
restricted to the B6 allele. 
 
 
Establishment of LCR-gene contacts in the absence of a pre-existing loop with 3’ 
HS1   
 
The unaltered β-globin gene expression patterns from the targeted allele in ES-EP (∆3’ 
HS1) cells suggested that in the absence of a pre-existing chromatin loop, LCR-gene 
contacts can still be established normally upon erythroid differentiation. To test this, we 
searched for 129/B6 polymorphisms near restriction sites in the LCR that would allow 
allele-specific 3C analysis. This resulted in the design of a TaqmMan probe for a HindIII 
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fragment encompassing HS4 and HS5 that signals exclusively from the B6 allele  
(Supplementary Fig. 8). Although HS4 and HS5 are not prime candidates in the LCR to 
directly contact the genes, this relatively large HindIII fragment was previously shown to 
be representative of the complete LCR, since it displayed a prominent peak of interaction 
with the β-major gene upon erythroid differentiation (Tolhuis et al. 2002). In both 
differentiated ES-EP(c) and ES-EP (∆3’ HS1) cell lines, we found identical locus-wide 
interaction frequencies for HS4/5 between the B6 alleles containing either wild-type or 
mutated 3’ HS1, and both showed a strong peak of interaction with the β-major gene 
(Fig.  3B). This demonstrated indeed that a pre-existing loop between upstream sites 
and 3’ HS1 is dispensable for the establishment of stable LCR-gene contacts later during 
erythroid differentiation. Such a conclusion is in agreement with transgenic experiments 
showing full β-globin expression from constructs lacking 3’ HS1 (Strouboulis et al. 1992).      
 
Histone modifications in the absence of CTCF binding   
 
3’ HS1 was previously shown to be present in, and close to the 3’ border of an open 
chromatin domain spanning ~145 kb around the β-globin locus in erythroid cells (Bulger 
et al. 2003). Within this domain, a large (~15kb) region of highly repetitive DNA is 
present approximately 3kb upstream of 3’ HS1, that cannot be analysed for nuclease 
sensitivity, but likely is packed into compact chromatin. To further investigate this, we 
analysed histone modifications at and directly around 3’ HS1 in ES-EP cells. Using an 
antibody that recognizes both di-methyl H3K9 and di-methyl H3K27, we found that these 
repressive marks were abundantly present on both sides of 3’ HS1, but not inside the 3’ 
HS1 (Fig. 4A). Conversely, acetylation of histone H3, a mark for open chromatin, was 
clearly enriched at 3’ HS1 but not, or much less, at sites surrounding the hypersensitive 
site (Fig. 4C). These data argued against the existence of a large open chromatin 
domain extending across 3’ HS1 and suggested that 3’ HS1 forms an isolated entity of 
open chromatin. To address whether CTCF plays a role in the establishment of this 
pattern, we performed ChIP on ES-EP(c) and ES-EP (∆3’ HS1) cells and used allele-
specific primer pairs to compare modifications at 3’ HS1 on targeted, versus non-
targeted alleles. In the control cell line, we found identical levels of di-meH3K9/K27 at 3’ 
HS1 on the two alleles. In ES-EP (∆3’ HS1) however, loss of CTCF binding was 
accompanied by an increase of di-meH3K9/K27 and concomitant decrease of AcH3 at 3’ 
HS1 (Fig. 4B-C).  We found no indication for spreading of the methyl mark into the locus, 
either locally  (Fig. 4, compare levels of enrichment between A and B), or at the β-major 
gene, which locates more inside the locus (Fig.4B, analysed by allele-specific primers). 
In fact, AcH3 levels at β-major were also similar for the targeted and non-targeted allele 
in ES-EP (∆3’ HS1) cells - two observations that were fully in agreement with our finding 
that β-major gene expression was not affected by disrupted CTCF binding to 3’HS1 (Fig. 
3A).    
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Figure 4. Histone modifications in the absence of CTCF binding 
(A) ChIP enrichment for di-meH3K9/K27 2.8kb upstream, 1.2kb downstream and at 3 HS1 in 
undifferentiated control ES-EP (c) cells. White bars: non-allele-specific primers; grey bar: 129-
allelespecific primer pair; blue bar: B6-allele specific primer pair. Values in 4A-C were 
normalized to input (therefore expressed per allele) and enrichment expressed relative to 
levels observed at inactive necdin (set to 1).   
(B) ChIP enrichment for di-meH3K9/K27 at and around 3 HS1 and at ≤major in 
undifferentiated ES-EP ("3 HS1) cells. White bars:  non-allele-specific primers; grey bars: 
129-allele-specific primer pairs; orange bars: B6allele specific primer pairs. Note increased 
methylation only at mutated 3 HS1 (C) ChIP enrichment for acetylated histone H3 at and 
around 3 HS1 and at ≤major in undifferentiated ES-EP ("3 HS1) cells. Note decreased 
acetylation only at mutated 3 HS1  
(D) ChIP enrichment for di-meH3K9/K27 at the β-globin locus in control (blue) and conditional 
CTCF knock-out (lox/lox) (orange) E12.5 erythroid progenitors cells. Note that reduced levels 
of CTCF cause a drop in di-meH3K9/K27 at the CTCF-binding sites HS-85, HS-62, HS5 and 
3 HS1 (indicated by red arrows), but not elsewhere in the locus.   
 
We considered the possibility that spreading of di-meH3K9/K27 into the locus 
requires disruption of CTCF binding to more sites than just 3’ HS1. To investigate this, 
we compared di-meH3K9/K27 levels in E12.5 wild-type versus lox/lox conditional CTCF 
knock-out progenitor cells, the latter containing reduced amounts of CTCF (Fig. 1). We 
found that loss of CTCF binding to 3’ HS1, HS5, HS-62 and HS-85 coincided with locally 
increased amounts of di-meH3K9/K27, while modification levels elsewhere in the locus 
appeared unaffected (Fig. 4D). Since CTCF-binding to β-globin sites was reduced but 
not absent in lox/lox cells, this leaves open the possibility that residual CTCF amounts 
prevent spreading of di-meH3K9/K27 into the locus. We concluded that CTCF regulates 
the balance between active and repressive chromatin modifications at its binding sites 
and we propose that CTCF-mediated acetylation of histones prevents their methylation. 
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Mechanistically, CTCF may directly attract histone acetyl-transferases (HATs), although 
current evidence for this interaction is lacking. Alternatively, CTCF mediated chromatin 
looping brings binding sites into spatial proximity with HATs bound elsewhere to the DNA 
(de Laat and Grosveld 2003). The observation that CTCF-binding was required for 
histone acetylation is interesting because previously these two events were previously 
claimed to be uncoupled (Recillas-Targa et al. 2002). Our data do not support the 
generality of boundaries demarcating expression domains, but fit better with the concept 
that genes maintain autonomous expression profiles mostly through their unique ability 
to productively interact with positive regulatory elements (Dillon and Sabbattini 2000; de  
Laat and Grosveld 2003).   
 
CTCF organises higher-order chromatin structure   
 
We have presented two independent lines of evidence that together firmly establish that 
CTCF functions in the formation of chromatin loops; removal of most CTCF protein, as 
well as targeted disruption of a CTCF-binding site, resulted in destabilization of long 
range contacts between cognate binding sites in the β-globin locus. CTCF is critical for 
the looped conformation present in erythroid progenitor cells, but is dispensable for LCR- 
gene contacts established later during differentiation. We, and others, previously have 
shown that the latter contacts depend on the transcription factors EKLF and GATA-1  
(Drissen et al. 2004; Vakoc et al. 2005). Together, these studies begin to delineate the 
factors that act sequentially to form a functional β-globin ACH in differentiated erythroid 
cells where β-globin genes are fully expressed. Based on the observations that CTCF 
dependent chromatin loops are tissue-specific and evolutionary conserved between 
mouse and man, it seemed reasonable to expect that these loops would play a role in 
gene expression. Such function may exist but is beyond our current detection limits. An 
alternative view is that evolutionary selection against sites forming chromatin loops within 
a gene locus positions them outside the β-globin locus, without necessarily being 
selected to act, positively or negatively, on gene expression (Dillon and Sabbattini 2000).    
We hypothesize that CTCF also organizes higher-order chromatin structure at 
other gene loci and we predict that such chromatin loops facilitate communication 
between genes and regulatory elements but can also lead to the exclusion of interactions 
between elements. In terms of transcriptional regulation, the final outcome of such 
chromatin loops will depend on the position of CTCF-binding sites relative to other 
regulatory elements and the genes, the concentration of the trans-acting factors 
involved, and the affinities of the (long-range) interactions. In Drosophila, a limited 3C 
analysis previously provided indications for a loop between the scs and scs’ enhancer 
blocking elements  (Blanton et al. 2003). Moreover, insulator proteins like suppressor of 
Hairy-wing (Su[Hw]) and Modifier of mdg4 2.2 (Mod[mdg4]2.2) have been found to 
coalesce into  large foci, called insulator bodies. These bodies preferentially localize at 
Chapter 4 
 104
the nuclear periphery and are hypothesized to bring together distant insulator sites, with 
intervening chromatin fibres looped out to form isolated expression domains 
(Gerasimova et al.  2000). Our observations made on the CTCF protein provide high-
resolution insight into the nature of such loops in mammals. It will be interesting to see if 
CTCF forms chromatin loops through multimerization of CTCF molecules bound to 
distinct DNA elements (Yusufzai et al. 2004), or whether this loop formation also involves 
other factors. Similarly, future experiments should provide insight whether CTCF-
dependent chromatin looping occurs at a defined physical structure in the nucleus (Dunn 
et al. 2003; Yusufzai and Felsenfeld 2004; Yusufzai et al. 2004) or whether the base of 
such loops has a more fluid nature. 
 
 
 
Materials and Methods   
 
Generation of conditional CTCF knock-out mice and CTCF antibody   
 
Targeting constructs and strategy for the generation of conditional Ctcf knock-out mice  
as well as the polyclonal antibody generated against CTCF will be described in detail as  
part of a study that addresses the role of CTCF in T cell development (H. Heath,  
manuscript in preparation).  
    
Lentivirus production   
 
Cre-lentivirus was produced by transient transfection of 293T cells according to standard  
protocols (Zufferey et al. 1997). Briefly, 293T cells were transfected with a 3:1:4 mixture  
of psPAX-2, pMD2G-VSVG (kind gifts of D. Trono, University of Geneva) and a  transfer 
vector construct that is essentially as pRRLsin.sPPT.CMV.GFP.Wpre (Follenzi  et al. 
2002) but with CMV-Cre instead of CMV-GFP, using poly(ethylenimine) (PEI). After 24 
hours medium was refreshed and virus-containing medium was harvested 48 and 72 
hours after transfection. After filtration through a 0.45μm cellulose acetate filter, the virus 
stock was concentrated 1000 times by centrifugation at 19.4K rpm for 2 hours at  10ºC in 
a SW28 rotor. Virus stocks were stored at  -80ºC. Virus activity/functionality was tested 
by serial dilutions on primary mouse embryonic fibroblasts (MEFs) containing loxP sites, 
which were scored for recombination after 4 days of infection by Southern  blotting.     
 
Culturing primary E12.5 fetal liver cells and lentiviral infection   
 
Fetal livers were isolated from E12.5 embryos, resuspended in FCS with 10% DMSO by 
repeated pipetting and stored in liquid nitrogen until genotyping of embryos was 
completed. Per experiment, cells from three fetal livers of the same genotype were 
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pooled and cultured as described (Dolznig et al. 2001). After 2 days of culturing, cells 
were infected by adding Cre-lentivirus to medium and centrifugation of cell culture plates 
for  55 minutes at 2.5K rpm (37ºC). Cre-mediated recombination efficiency was analysed 
3 and 4 days after infection by standard Southern and western blotting techniques 
(antibody used to detect GATA-1: #N6, Santa-Cruz). CTCF RNA levels were analysed 
by quantitative RT-PCR (see below).    
 
 3C Analysis, Chromatin Immunoprecipitation and Analysis of gene expression 
   
These PCR-based techniques were performed according to standard procedures 
(Splinter et al. 2004). For details, probe and primer sequences, see supplemental 
information.   
 
In vitro differentiation of ES cells into ES-EPs and characterization of ES-EPs 
 
Differentiation of ES cells into ES-EPs, expansion of ES-EPs and in vitro differentiation  
of ES-EPs into erythrocytes was performed as described (Carotta et al. 2004), except 
that  embryoid bodies were formed in 4000-6000 hanging drop cultures (~200 ES 
cells/drop)  that were pooled and disrupted after 6 days of culturing to generate ES-EPs. 
After 2 to 3 weeks of cultivation a homogeneous erythroid progenitor population was 
obtained, as determined by FACS analysis (Table S1), cell morphology and the capacity 
to respond massively to physiologically relevant stimuli to terminally differentiate into 
enucleated  erythrocytes within 72 hours. 
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Supplemental Material and Methods 
3C Analysis 
3C analysis was performed essentially as described (Splinter et al. 2004), using HindIII 
as the restriction enzyme. Quantitative real-time PCR (Opticon I, MJ Research) was 
performed with Platinum Taq DNA Polymerase (Invitrogen) and double-dye 
oligonucleotides (5’FAM + 3’TAMRA) as probes, using the following cycling conditions: 
940C for 2 min and 44 cycles of 15 s at 940C and 90 s at 600C. Probe and primer 
sequences are listed in supplementary Table 2. 
 
Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as described in the Upstate protocol (http://www.upstate.com), 
except that cells were cross-linked at 2% formaldehyde for 5 minutes at room 
temperature. Quantitative real-time PCR (Opticon I, MJ Research) was performed using 
SYBR Green (Sigma) and Platinum Taq DNA Polymerase (Invitrogen), under the 
following cycling conditions: 940C for 2 min, 44 cycles of 30 s at 940C, 60 s at 550C, 15 s 
at 720C and 15 s at 750C (during which measurements are taken). Enrichment was 
calculated relative to Necdin and values were normalized to input measurements. Primer 
sequences are listed in supplementary Table 3. Antibodies used: Anti-acetyl-Histone H3 
(#06-599, Upstate); anti-di-methyl Histone H3 K9/K27 (ab7312, Abcam). 
 
Lentivirus production and infection 
Cre-lentivirus was produced by transient transfection of 293T cells according to standard 
protocols (Zufferey et al. 1997). 293T cells were transfected with a 3:1:4 mixture of 
psPAX-2, pMD2G-VSVG (kind gifts of D. Trono, University of Geneva) and a transfer 
vector construct that is essentially as pRRLsin.sPPT.CMV.GFP.Wpre (Follenzi et al. 
2002) but with CMV-Cre instead of CMV-GFP, using poly(ethylenimine) (PEI). After 24 
hours medium was refreshed and virus-containing medium was harvested 48 and 72 
hours after transfection. After filtration through a 0.45μm cellulose acetate filter, the virus 
stock was concentrated 1000 times by centrifugation at 19.4K rpm for 2 hours at 100C in 
a SW28 rotor. Virus stocks were stored at –800C. Virus activity/functionality was tested 
by serial dilutions on primary mouse embryonic fibroblasts (MEFs) containing loxP sites, 
which were scored for recombination after 4 days of infection by Southern blotting. Fetal 
livers were isolated from E12.5 embryos, resuspended in FCS with 10% DMSO by 
repeated pipetting and stored in liquid nitrogen until genotyping of embryos was 
completed. Per experiment, cells from three fetal livers of the same genotype were 
pooled and cultured as described (Dolznig et al. 2001). After 2 days of culturing, cells 
were infected by adding Cre-lentivirus to medium and centrifugation of cell culture plates 
for 55 minutes at 2.5K rpm (370C). Cre-mediated recombination efficiency was analysed 
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by standard Southern en western blotting techniques (antibody used to detect GATA-1: 
#N6, Santa-Cruz). CTCF RNA levels were analysed by quantitative RT-PCR (see 
below). 
 
Analysis of gene expression 
Total RNA was isolated from cultured fetal liver cells or 0.5-1 x 106 of ES-EPs at the 
indicated time points using TRIzol reagent (Invitrogen) according to the manufacturers 
instructions. 1 μg of RNA was treated for 1 hour at room temperature with amplification 
grade DNAseI (Invitrogen) to remove genomic DNA contamination. An aliquot was used 
as a no RT control. cDNA synthesis was performed using Superscript II RNase H- 
Reverse transcriptase (Invitrogen) according to the manufacturers instructions using 
200ng random hexamers as primers. Quantification of primary transcripts was performed 
on Opticon II real-time PCR machines (MJ research) using Platinum Taq (Invitrogen) and 
SYBR Green (Sigma), using the following PCR program: 2 min 940C, 45 cycles of 30 sec 
940C, 1 min 620C, 15 sec 720C and 15 sec 750C (during which measurements are 
taken), followed by 10 minutes chain extension and a melting curve. Expression was 
normalized against HPRT expression levels. Primer sequences are listed in 
supplementary Table 3. 
 
Targeting nucleotide changes to 3’HS1 in ES cells 
The 3’HS1 targeting constructs were based on a 5.6 kb BamHI-EcoRV isolated from 
BAC RP23-370E12 (BACPAC Resources) (Supplementary Fig. 1). Site-directed 
mutagenesis was performed on an internal 683bp NdeI-NdeI fragment (coordinates: 
67033-67716, see Supplementary Fig. 1), using QuikChange® Multi Site-Directed 
Mutagenesis Kit (Stratagene). Oligonucleotide used to change CTCF-binding site: 
CGGAAATCAGCGGAACACTTCTGATATCTACTGGTATGCAACAGG. 
 Oligonucleotide used to change 2 nucleotides 70 bp downstream of the core CTCF-
binding site: CAGTTTATCCCAGTTACGTTTAGTTGACAACCTGAGAC. Before 
reintroduction into the BamHI-EcoRV targeting vector, the complete NdeI fragment was 
sequenced to confirm that only targeted nucleotides were changed. A TK-NEO cassette 
flanked by head-to-tail oriented loxP sites and containing a HindIII site immediately 
upstream one of the loxP sites was inserted as an XbaI-SpeI fragment into the AvrII site 
at position 68251 (Supplementary Fig. 1). For selection against random integration 
events, diphtheria toxin (DTA) (Yu et al. 2000) was cloned outside the region of 
homology. ES cells for targeting were isolated from 129xB6 F1 blastocysts and 
transfected with the SalI linearised targeting construct by electroporation. Clones scored 
positive for homologous recombination at 3’HS1 by Southern blot hybridization were 
transiently transfected with a CMV-Cre construct containing a PGK-puromycin selection 
cassette, followed the next day by a 40 hours selection on medium containing 2 μg/ml of 
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puromycin. Surviving clones were analyzed by Southern blotting for successful Cre-
mediated deletion of the neomycin selection cassette and by PCR analysis for the 
absence of Cre. Positive clones were selected for in vitro differentiation into ES-EP cells. 
 
 
 
 
Supplemental Figures 
 
 
 
 
 
Supplemental Figure 1  
 
ChIP with anti-CTCF antibody on E14.5 fetal liver (black) and brain (white bars).  
Data were normalized against input and expressed as enrichment over necdin (highest level 
set to 1). 
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Supplemental Figure 2  
 
(A) Q-PCR analysis of ligation frequencies obtained by 3C. The approach entails a primer-
probe combination that is specific for a particular restriction fragment (blue), with the probe 
hybridizing to the opposite strand as compared to the PCR primer. A second PCR primer 
hybridizes to the fragment (orange) of which one wants to quantify its interaction. The 
primers/probe configuration guarantees that the probe only signals upon extension of the 
second primer across the ligated junction (# 1), which is important given the great variety of 
junctions (e.g. #2-7) formed with each fragment. f (fluorescent group) and q (quencher).  
(B) Examples of PCR products obtained after 45 cycles of QPCR, analyzed on a 2% agarose 
gel.  
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Supplemental Figure 3 
 
Expression of all β-globin genes in cultured wild-type versus lox/lox progenitor cells. 
Messenger RNA levels were normalized to HPRT mRNA levels. For comparison, levels in 
primitive (E9.5) and definitive red blood cells (E12.5 fetal liver) are indicated and set to 1. ND: 
Not Detectable. 
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Supplemental Figure 4 
 
Targeting strategy. Top: wild-type (non-targeted) allele. Nucleotide polymorphisms between 
129 and B6 used to design allele-specific ChIP-primers #1 (129) and #3 (B6) are shown. Box 
indicates core CTCF-binding site. Coordinates are relative to the start of most upstream β-
globin gene (εy). H: HindIII, B: BamHI, A: AvrII, E: EcoRV. Sequence between 67172 and 
68749 is drawn to scale (see scale bar). 3C primer ‘a’ (is primer +68(3’HS1)) is used to 
analyze the 7.9 kb (60859-68749) wild-type HindIII fragment containing 3’HS1. Middle: 
targeting construct for 3’HS1. Targeted nucleotide changes in core CTCF-binding site 
(CCCC to ATAT) are indicated in orange. Downstream nucleotide changes (GC to CG) allow 
the design of ChIP-primer #4 that is specific for this targeted allele. The extra HindIII site 
upstream of the neomycin selection cassette flanked by two loxP sites is maintained after 
Cre-mediated deletion. This new HindIII site creates an allele-specific HindIII fragment around 
3’HS1 that can be analyzed by primer ‘b’. This fragment is 7.4 kb in size, not much smaller 
than the 7.9 kb fragment analyzed by primer ‘a’ on the non-targeted allele. On the targeted 
allele primer ‘a’ now analyzes a small (0.5kb) HindIII fragment downstream of 3’HS1. Bottom: 
targeting construct for the control ES-EP line (ES-EP(c)). 3’HS1 is untouched, but the extra 
HindIII site is introduced at the same position as before. 
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Supplemental Figure 5 
 
Nucleotide changes in the core binding site of 3’HS1 effectively disrupt CTCF binding in vitro. 
Gel mobility shift assay with nuclear protein extracts from fetal livers (all lanes) (Wall et al. 
1988). 32P-labeled probe used: mutant (lane 1), wild-type (lane 2-16). Lane 3: +1 μl anti-CTCF 
antibody, lane 4: +2 μl anti-CTCF antibody, lane 6-10: competition with increasing amounts of 
unlabeled wild-type probe, lane 12-16: competition with increasing amounts of unlabeled 
mutant probe.  
 
Probe sequences:  
3’HS1-wt-S: CGGAAATCAGTGGAACACTTCTGCCCCCTACTGGTATGCAACAGG,  
3'HS1-wt-AS: TCCTGTTGCATACCAGTAGGGGGCAGAAGTGTTCCACTGATTTCCG,  
3'HS1-mut-S: CGGAAATCAGTGGAACACTTCTGATATCTACTGGTATGCAACAGG,  
3'HS1-mut-AS: TCCTGTTGCATACCAGTAGATATCAGAAGTGTTCCACTGATTTCCG.  
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A. 
Marker ES-EP(3’HS1) ES-EP(c) 
CD117 (%) 74 74 
CD71/Ter119 (%) 98 100 
 
B. 
                 
C. 
                  
 
Supplemental Figure 6.  Characterization of ES-EP cells  
 
(A) ES-EPs express markers characteristic for proerythroblasts.  
(B) Synchronous in vitro differentiation of ES-EP cells. Cell size (μm) was measured at 
various intervals after induction of differentiation. The plots for the Δ and c lines are identical. 
(C) Globin mRNA expression during in vitro differentiation of ES-EP cells. Quantitative RT-
PCR was performed to measure α- and β-globin mRNA levels relative to HPRT. Relative 
expression at t = 0 hours was set to 1. The fact that globin expression levels are higher in 
differentiated EP-EPs than in E14.5 fetal liver is attributed to the fetal liver being composed of 
cells at various stages of differentiation. 
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Supplemental Figure 7 
 
βmajor intron 2 primers for independent analysis of ongoing transcription from the B6 allele 
and the 129 allele. Real-time PCR analysis plots showing the log fluorescence (y-axis) versus 
PCR cycle number (x-axis). Quantitative PCR with SYBR Green was performed on genomic 
DNA from B6 (red and green curve) and 129 cells (blue and yellow curve). Top: primers 
GGTTGCAAACAAATGTCTTTA (βmaj-in2-f (B6)) and CCAGGAGCTGTGGGAAG (βmaj-in2-r 
(B6)) amplify much more efficiently from B6 DNA than from 129 DNA (Ct = 12, i.e. 129 
contribution is ~ 1/4000). Middle: primers GGTTGCAAACAAATGTCTTTG (βmaj-in2-f (129)) 
and CCAGGAGCTGTGGGAAT (βmaj-in2-r (129)) exclusively amplify βmajor intron 2 from 
129 DNA. Bottom: HPRT primers show that equal amounts of 129 and B6 DNA were used as 
templates.   
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Supplemental Figure 8 
 
B6 allele-specific Taqman probe for HindIII fragment HS4/5. Real-time PCR analysis plots 
showing the log fluorescence (y-axis) versus PCR cycle number (x-axis). Quantitative PCR 
was performed on genomic DNA from B6 (red and green curve) and 129 cells (blue and 
yellow curve).  
Top: taqman probe (HS45-B6) AGGAGGAATTTCTTCCGGTTGAATATGCCACAGCC 
hybridises near the HindIII site directly upstream HS5 and signals exclusively from B6 alleles. 
Primers used: TTCAAGTTCTCATCCTTCACTG (-21(HS4/5)), 
GCTTTGTGTACACTGTGCAG.  
Bottom: A primer/probe combination for the βmajor promoter that works on B6 and 129 DNA 
shows that approximately equal amounts of DNA were analysed.   
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Supplemental Table 1  
Sequences of primers used for 3C analysis  
(names correspond to approximate position (in kb) relative to εy):  
-97:   AACCTGGTAACTTTCTGCTGA  
-85(HS):  AGGTTGCAGTTGGTGTGA 
-79:   CTCATTTGTCAACTCATCCC 
-62(HS):  GGGTGTGGGTATTTGTAAGAG 
–48:  AGCCTAATCTGGTGCTGG 
–42:  ATGAACAAGTTTCATGGGG 
-21(HS4/5): TTCAAGTTCTCATCCTTCACTG 
–17(HS3): CTTGTCCTATGGATGCCA 
-10(HS2):  GCAGCTTCCTCATTTAGCA 
+11(βh1): ATAAGTGTAGCTGCCTGGTG 
+12(βh1): GCTTGTGATAGCTGCCTTC 
+30(βmaj): AATCGCTGCTCCCCCTCACT 
+52:   TTTAATGTCACGCAAAACATCAG 
+68(3’HS1):     TCCTTGCTTTTACTCTTTCTCC (primer ‘a’) 
+88:     CATTCATTGTTCTTCTACCTCG 
Primer for extra HindIII site introduced downstream of 3’HS1: 
(primer ‘b’):         CATCTTTGGACCCTTCTAATCC 
XPB-1    GCCCTCCCTGAAAATAAGGA 
XPB-2    GACTTCTCACCTGGGCCTACA 
Sequences of probes:  
3’HS1:   AGCTTCCTTTGAACATAACTTTGCACTTACTTGTTTCTG (with primer ‘a’);  
HS45-B6:  AGGAGGAATTTCTTCCGGTTGAATATGCCACAGCC (with -21(HS4/5)) 
XPB:  AAAGCTTGCACCCTGCTTTAGTGGCC 
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Supplemental Table 2. Primer sequences used for ChIP 
 
HS-85-f:   GAGACTAAGTAATTCACCATGGG 
HS-85-r:   GGATCTATCTTGATTGTCCTCC 
HS-62-f:   GCACATGCCGTAGTTCTC 
HS-62-r:   TCTGGAGTTCTCAGTTGTATGAC 
HS-62-B6-f:   GAACATGCTGTAGTTCTC 
HS-62-B6-r:   TCTGGAGTTCTCGGTTGTATGGC 
HS5-f:    ATGAGGCGTTTTCACCAC  
HS5-r:    AAGGGGTCTTTTCACCGT 
HS3-f:    TTTCAGAACCAGGAGGC 
HS3-r:    TTTGCTGTTGTTGTTACTGTTC 
HS2-f:    TTCCCTGTGGACTTCCTC 
HS2-r:    GTCATGCTGAGGCTTAGG 
βH1-f:    TGGAAACCTCTCTTCTGCC 
βH1-r:    AAGCCCAAGGATGTCAGC 
βmajor-f:   GGGAGAAATATGCTTGTCATC 
βmajor-r:    CAACTGATCCTACCTCACCTT 
Upstream-3’HS1-f:  TGTGGCTCTGGCTGTATCA  
Upstream-3’HS1-r:  GCCAGGGCAACAGATAAGT 
3’HS1-f:    AATCAGTGGAACACTTCTGC 
3’HS1-r:   GTCTCAGGTTGTCAACTAAAGC 
Downstream-3’HS1-f:  CTGTCTGGGAATGCTAACC 
Downstream-3’HS1-r:  GCAAGGAGATTCTATGAGCC 
Necdin-f:   GGTCCTGCTCTGATCCGAAG 
Necdin-r:   GGGTCGCTCAGGTCCTTACTT 
Allele-specific primers at 3’HS1 (see Fig. 3A):  
1: AGAGGAGGGCGGAAATCAGT 
2: GTCTCAGGTTGTCAACTAAAGC 
3: GGAGGAGGGCGGAAATCAGC  
4: GTCTCAGGTTGTCAACTAAACG 
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Supplemental Table 3. Primer sequences used for gene expression analysis 
HPRT-S:   AGCCTAAGATGAGCGCAAGT 
HPRT-AS:   ATGGCCACAGGACTAGAACA 
εy-f:    GAACTTGTCCTCTGCCTCT 
εy-r:    ATCACCAGCACATTACCCA 
βH1f:    TGGACAACCTCAAGGAGAC 
βH1r:    AGTAGAAAGGACAATCACCAAC 
βmaj-mRNA-S:   ATGCCAAAGTGAAGGCCCAT 
βmaj-mRNA-AS:   CCCAGCACAATCACGATCAT 
βmaj-in2-f (129):   GGTTGCAAACAAATGTCTTTG 
βmaj-in2-r (129):   CCAGGAGCTGTGGGAAT 
βmaj-in2-f (B6):   AGGTTGCAAACAAATGTCTTTA 
βmaj-in2-r (B6):   CCAGGAGCTGTGGGAAG 
βminor-f:   ATCCCAAGGTGAAGGCCCAT 
βminor-r:   CCCAGCACAATCACGATCGC 
CTCF-f:    GACCACAAATCTAGAACCAAAGAAC 
CTCF-r:    GTTGGCTTCGGAGGCTTCATATTACC 
MOR3’B1 (Olfr67)-f:  CCTTTGGTAGTTGTGTGTCC 
MOR3’B1 (Olfr67)-r:  GTGGTGTATCTCAGTGGGT 
MOR3’B2/B3 (Olfr68, 69)-f: TCAAGTTCAATGGCTCAGTC 
MOR3’B2/3 (Olfr68, 69)-r:  ACGATTGAGGAATACAGCCA 
MOR3’B4 (Olfr630)-f:  ATGGTGCTGGAGTTTGAGG 
MOR3’B4 (Olfr630)-r:  ACTGTGGGATTGGATTGAGC 
MOR5’B3 (Olfr64)-f:  CACAGACCTCACAGTTACAC 
MOR5’B3(Olfr64)-r:  CCACAATGGAAAGGGAGTG 
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Summary 
The conserved transcriptional regulator CTCF is involved in imprinting and long-range 
chromatin interactions and is thought to be essential for many nuclear events in all cells.  
We generated mice with a conditional Ctcf allele and tested CTCF function in vivo in the 
T-cell lineage. Deletion of the Ctcf gene in early double-negative thymocytes did not 
hamper T-cell receptor (TCR) gene rearrangement, but impeded the proliferation of β-
selected cells and their differentiation into double-positive thymocytes. In contrast, γδ T 
cell differentiation remained unaffected. CTCF deletion at the double-positive stage 
allowed development of peripheral T cells, but their activation and proliferation upon anti-
CD3 stimulation was severely impaired. Surprisingly, circumventing TCR signaling with 
phorbol ester and ionomycin, allowed substantial proliferation of CTCF-deficient CD4+ 
and CD8+ T cells. In Th1/Th2 polarization cultures CTCF-deficient Th1 effector cells 
produced significant amounts of INF-γ. Expression of IL-4, IL-5 and IL-13 in Th2 cultures 
was severely reduced, despite the induction of two essential transcription factors, GATA 
3 and SATB1. Thus, CTCF plays a major role in GATA 3/SATB1dependent regulation of 
gene expression within the Th2 cytokine locus. Collectively, our findings demonstrate 
that CTCF controls distinct pathways in T-cell development and activation, but is not 
absolutely essential for cell survival or proliferation.  
 
Introduction 
The 11-zinc finger protein CCCTC-binding factor (CTCF) is a widely expressed and 
highly conserved transcriptional regulator implicated in many important processes in the 
nucleus (for reviews, see Ref. 1, 2). In line with this view, murine CTCF is essential at 
very early embryonic stages (3), and expression of CTCF in WEHI231 B lymphoma cells 
results in growth arrest and apoptosis (4). CTCF is the archetypal vertebrate protein that 
binds insulator sequences, DNA elements that have the ability to protect a gene from 
outside influences (5).  Its methylation-sensitive interaction with the imprinting control 
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region of the H19/insulin-like growth factor 2 (Igf2) genes indeed controls enhancer 
access (3, 6, 7). CTCF-mediated insulator activity has been predicted at several other 
sites including the DM1 locus and boundaries of domains that escape X-chromosome 
inactivation (8, 9). We have shown that CTCF mediates long-range chromatin 
interactions and regulates local histone modifications in the β-globin locus (10). Evidence 
has also been presented for a role of CTCF in interchromosomal interactions between 
Igf2 and other loci (11). During mitosis, CTCF remains bound to mitotic chromosomes, 
possibly facilitating reformation of higher order chromatin loops after mitosis (12).  
Genome-wide mapping of CTCF-binding sites revealed ~14,000 sites, the distribution of 
which correlates with genes but not with transcriptional start sites (13). Strikingly, the 20-
bp consensus motif found in the majority of the sites is virtually identical to a consensus 
sequence LM2*, bound by CTCF and found in ~15,000 conserved non-coding elements 
in the human genome (14). High-resolution profiling of histone methylation in the human 
genome showed that CTCF marks boundaries of histone methylation domains (15) 
consistent with a role for CTCF as an insulator protein. Multiple CTCF-binding sites were 
identified near genes displaying extensive alternative promoter usage, including 
protocadherin γ, the immunoglobulin λ light chain and the Tcrα/δ and β chains. In mice, 
CTCF-dependent insulators were found downstream of the Tcrα/δ and the 
immunoglobulin H chain loci (16, 17), suggesting a role for CTCF in the regulation of 
gene transcription or recombination targeting in these complex loci.    
To understand how CTCF regulates proliferation and differentiation in vivo, we 
generated mice with a conditional Ctcf allele (Ctcf f/f), and deleted the gene at sequential 
stages of T cell development. T cell progenitors differentiate in the thymus, where early 
double negative (DN) precursors, expressing neither CD4 nor CD8 co-receptors, begin 
locus-specific recombination of their TCR loci (for review, see Ref. 18). Upon productive 
TCRβ gene rearrangement, the TCRβ chain associates with the invariant pTα chain on 
the cell surface.  Cells that successfully pass this β-selection checkpoint enter the cell 
cycle and acquire CD4 and CD8 co-receptors to become double-positive (DP) 
thymocytes. Upon productive TCRα locus recombination in DP cells, TCRαβ is 
expressed on the cell surface. Positive selection results in the differentiation to CD4 and 
CD8 single positive (SP) cells, which express TCRαβ and recognize peptide antigens 
presented by MHC class II or class I molecules, respectively.  Mature SP cells exit the 
thymus and circulate to the periphery as naive CD4+ and CD8+ T cells. Activation of 
CD4+ T cells triggers differentiation into effector T cells, classically divided into two 
distinct subsets: IFN-γ+ Th1 cells mediating cellular immunity against intracellular 
pathogens and IL-4, IL-5 and IL-13 producing Th2 cells important for the eradication of 
parasitic worms, but also implicated in allergic responses (19, 20). When naive CD4+ T 
cells differentiate into Th1 or Th2 cells, the Ifn-γ and Th2 cytokine loci undergo structural 
and epigenetic changes, thought to be dependent on the transcription factors T-bet and 
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GATA 3, respectively (21-23).  Here we show that CTCF acts as a critical dose-
dependent regulator of cellular proliferation and differentiation following β-selection in the 
thymus. In the absence of the Ctcf gene, peripheral CD4+ and CD8+ TCRαβ T 
lymphocytes survive, but anti-CD3-mediated activation and proliferation is impaired. 
Remarkably, when TCR signaling is bypassed by phorbol ester and ionomycin, CTCF-
deficient T cells show substantial proliferation.  However, lack of CTCF severely affects 
Th2 cytokine production in Th2 cells. Thus, the insulator protein CTCF regulates specific 
pathways in T cell development and effector function, but is not essential for cell survival 
or proliferation per se. 
 
Results 
Generation of a conditional Ctcf allele   
We generated a conditional Ctcf allele (Ctcf f/f) by inserting loxP-sites upstream of exon 3 
and downstream of exon 12 (Fig. 1A, B). Normal amounts of CTCF were expressed in 
Ctcf f/f mice  (unpublished data). Ctcf f/f mice were crossed with mice expressing Cre 
recombinase ubiquitously (24), generating a CTCF-lacZ fusion transcript by removal of 
Ctcf exons 3-12 and inclusion of LacZ sequences (Fig. 1A, B). Ctcf +/- mice appeared 
normal, but we were unable to generate Ctcf-/- offspring from Ctcf +/- crosses 
(Supplemental Table S1), consistent with an essential role for CTCF in early 
development (3). 
 
Conditional deletion of the Ctcf gene in developing T lymphocytes   
CTCF expression was explored using mice carrying a GFP-Ctcf knock-in allele. We used 
flow cytometry with markers for CD3, CD4 and CD8, as well as CD44 and CD25 to 
subdivide DN cells into DN1-DN4 stages. We detected GFP-CTCF throughout T 
lymphocyte development, with higher fluorescence levels in subpopulations associated 
with high proliferation (Supplemental Fig. S1). We subsequently analyzed lacZ 
expression in Ctcf +/- T cells using fluorescein-di-β-D-galactopyranoside (FDG) as a 
substrate. LacZ expression was similar to that of GFP-CTCF  (unpublished data), 
indicating that lacZ is a good marker of Ctcf gene deletion.  T-cell specific deletion of 
Ctcf, was achieved by crossing Ctcf f/f mice with transgenic lines, in which the Cre 
recombinase was either driven by the proximal Lck promoter (LckCre) or by the CD4 
promoter (CD4-Cre) (25, 26). Using lacZ as reporter, we found that the Ctcf gene 
deletion was almost complete from the DN2/DN3 stage onwards for Lck-Cre mice, and 
from the ISP stage onwards for CD4-Cre mice (Supplemental Fig. S2).  
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Figure 1. Conditional targeting of the mouse Ctcf gene 
(A) Murine Ctcf locus and gene targeting constructs. Exons of the Ctcf gene (solid boxes) are 
numbered, scale is in kilo base (K). Exon 1 is embedded in a CpG island. Exon 3 contains the 
start codon and exon 12 the stop codon. Southern blot probes are shown above the Ctcf 
gene. The two targeting constructs, with loxP sites (small triangles), flanking a PMC1-
neomycin cassette (neor) or a PGK-puromycin cassette (puror), are shown with homologous 
regions. TK: thymidine kinase gene, SA-LacZ: Splice acceptor-lacZ cassette (41).  
PCR primers for genotyping (p8563, p8946, p260 and p261, large triangles) are indicated on 
targeting cassettes. Underneath the targeting constructs the deleted Ctcf gene is shown (Ctcf 
-/-), that is generated after complete 
Cre-mediated recombination at the outermost loxP sites. Due to alternative splicing, the splice 
acceptor (SA) site, present at the 5’end of the reporter LacZ cassette, is spliced on to Ctcf 
exon 1 or 2, thereby generating a hybrid Ctcf-lacZ transcript.  
(B) PCR analysis of genomic tail DNA. Genotypes are shown above the lanes (f: targeted 
allele, flanked by loxP sites; +: WT allele).  
(C) Southern blot analysis of Lck-Cre and CD4-Cre recombinase activity. 
Digested genomic DNA from thymus and spleen of mice of the indicated genotypes was 
analyzed by hybridization with the HIII-probe (see panel a). The positions of the WT, Ctcf f/f 
(flox) and Ctcf -/- (del) alleles are indicated (asterisk indicates a polymorphic WT allele from 
the FVB background).  
(D) Western blot analysis of thymus. Total thymus lysates from Lck-Cre Ctcf f/f, CD4-Cre Ctcf 
f/f or WT mice (+ indicates presence of Cre transgene; - indicates absence) were analyzed for 
CTCF, DNMT1 and UBF protein levels.  
(E) Western blot analysis of naïve T cells. Total cell lysates from sorted CD62L+ CD4+ and 
CD8+ T cell fractions from non-transgenic (-) or CD4-Cre transgenic (+) Ctcf f/f mice were 
analyzed for CTCF, DNMT1 and UBF. 
 
 
 
Southern blotting showed efficient deletion of the Ctcf gene in thymus, while in spleen 
deletion was less evident, reflecting the abundance of non-T lineage cells (Fig. 1C).  
Western blotting showed that in thymic nuclear extracts from Lck-Cre Ctcf f/f mice CTCF 
protein levels were reduced to ~8 % of control (Fig. 1D). Despite efficient Ctcf gene 
deletion in the thymus of CD4-Cre Ctcf f/f mice, close to normal amounts of CTCF protein 
(~73  %) were detected in this tissue (Fig. 1D), suggesting that CTCF is remarkably 
stable.  Consistent with this notion, residual CTCF protein was still detectable in highly 
purified fractions of naive peripheral CD4+ and CD8+ T cells (~25 % of control; Fig. 1E).  
To examine whether CTCF deletion affects global nuclear processes we investigated 
DNA methylation and nucleolar organization. Neither DNMT1, a maintenance 
methyltransferase with an important role in T cell development (25), nor UBF, a major 
accessory factor of RNA polymerase I (27), were significantly affected by deletion of 
CTCF  (Fig. 1D, E). Consistently, the methylation status of ribosomal DNA (rDNA) 
repeats was normal in Ctcf knockout cells (Supplemental Fig. S3A) and the appearance, 
amount, and organization of rDNA repeats, analyzed by fluorescent in situ hybridization 
(FISH) with an rDNA probe, were similar in Ctcf knockout and wild-type (WT) CD4+ and 
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CD8+ T cells  (Supplemental Fig. S3B and Table S2). The paralogue of CTCF, named 
CTCF-L or BORIS, can bind the same DNA sequences as CTCF (28) and might 
potentially substitute for the loss of CTCF in T cells. However, CTCF-L was not 
expressed in normal T cells and was not induced in the absence of CTCF (Supplemental 
Fig. S3C), eliminating a possible functional substitution. 
 
 
Defective TCRαβ lineage development in Lck-Cre Ctcf f/f mice   
 
Thymocyte subpopulations in 6-8 week-old mice were analyzed by flow cytometry. Lck-
Cre Ctcf f/f mice displayed reduced thymic cellularity, with a severe decrease in the 
proportions of DP and CD4 SP cells, and a concomitant increase in the proportions of 
DN and CD4-CD8+ cells (Fig. 2A, B). CD4 -CD8+ cells were mainly of the CD3loCD69lo 
type, indicative for ISP cells (Fig. 2A). αβ T cell development was partially arrested at the 
ISP to DP transition, causing accumulation of DN3, DN4 and ISP cells (Fig. 2B). 
Heterozygous Lck-Cre Ctcf +/f mice also displayed a phenotype at the DP stage, showing 
that normal CTCF levels are important for proper T cell development. In CD4-Cre Ctcf f/f 
mice, thymic cellularity was only modestly reduced and no accumulation of ISP cells was 
detected (Fig. 2B). In agreement with impaired thymic SP cell production, the numbers of 
mature CD4+ and CD8+ T cells in spleen and lymph nodes of Lck-Cre Ctcf f/f, 
heterozygous Lck-Cre Ctcf +/f and CD4-Cre Ctcf f/f mice were significantly reduced (Fig. 
2A, B and unpublished data).   
 CTCF-deficiency had no adverse effect on γδ T cell development, since the 
number of CD3+ TCRγδ+ thymocytes in Lck-Cre Ctcf f/f mice were ~2-fold higher than in 
WT littermates  (Fig. 2C, D). The relative proportion of γδ T cells in the spleens of Lck-
Cre Ctcf f/f and CD4Cre Ctcf f/f mice was markedly increased (Fig. 2C), probably due to 
impaired αβ T cell production. Collectively, these findings show a specific role for CTCF 
in αβ T cell development, in particular at the ISP to DP transition.  
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Figure 2. Defective TCRαβ lineage development in CTCF-deficient mice 
(A) Flow cytometric analyses of the indicated cell populations in thymus or spleen from the 
indicated mice. Expression profiles of surface markers are shown as dot plots and the 
percentages of cells within quadrants or gates are given.  
(B) Absolute numbers of the indicated thymic and splenic T cell subpopulations. Each symbol 
represents one individual animal and lines indicate average values. Lck-Cre Ctcf f/f had 
increased numbers of DN3 (p<0.01), DN4 (p=0.0002) and ISP cells (p<0.002). In Lck-Cre Ctcf 
f/f mice, heterozygous Lck-Cre Ctcf f/+ mice and CD4-Cre Ctcf f/f mice DP, CD4 SP and CD8 
SP subsets in the thymus were significantly reduced (p<0.0001). CD4 and CD8 T cells in the 
spleen were significantly reduced in Lck-Cre Ctcf f/f mice (p<0.00001), in heterozygous Lck-
Cre Ctcf f/+ mice (p<0.01) and in CD4-Cre Ctcf f/f mice (p<0.0001).  
(C) Flow cytometric analyses of total thymocytes and CD3+ splenocytes. For the thymus, 
expression profiles of CD3 and TCRγδ surface markers are shown as dot plots and the 
percentages of CD3+TCRγδ+ cells are given. For the spleen, data are displayed as 
histograms and the percentages represent the fractions of CD3+ cells that are TCRγδ+.  
(D) Absolute numbers of TCRγδ+ T cells in thymus and spleen of the indicated mouse 
groups. TCRγδ+ T cells were significantly increased in the thymus of Lck-Cre Ctcf f/f mice 
(p<0.05) and in the spleen of CD4-Cre Ctcf f/f mice (p<0.05). Data shown are representative of 
10-20 animals per group. 
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Impaired proliferation of β-selected cells in Lck-Cre Ctcf f/f mice   
TCR≤ rearrangement is generally initiated and completed in DN3. This stage consists of 
early small cells that have not yet productively rearranged the Tcrβ locus and more 
mature large, proliferating cells expressing TCRβ (29). Remarkably, in Lck-Cre Ctcf f/f 
mice a significant population of large cells containing intracellular TCRβ+ was present in 
DN2 fractions (Fig.  3A). In DN3 cells the proportion of large TCRβ+ cells were still 
elevated. When compared to WT cells, differentiation into DN4 and ISP cells resulted in 
smaller cells (Fig. 3A; quantified in Supplemental Fig. S4A). The CTCF-deficient ISP 
population also contained less cycling cells: 29% ± 1 in S/G2/M phase, compared to 53% 
± 8 in WT (Fig. 3B). Differentiation was further analyzed by the expression of important T 
cell factors in sorted CTCF-deficient T cell fractions. C-myc was not affected in CTCF-
deficient cells (Fig. 3C), even though CTCF was reported as a negative transcriptional 
regulator of c-myc (4, 30). GATA3 is critically involved in β-selection and development of 
CD4 SP cells (31), while SATB1 organizes cell type specific nuclear architecture (32). 
Expression levels of these transcription factors were somewhat reduced in Lck-Cre Ctcf 
knockout cells. Interestingly, preTα was up-regulated rather than down-regulated in DP 
cells, in the absence of CTCF (Fig. 3C). The expression of GIMAP4, which is strongly 
induced by pre-TCR signaling and accelerates T-cell death (33), was also increased in 
CTCF-deficient T cells (Fig. 3C). Finally, Ctcf knockout cells showed significantly 
increased p21 and p27 expression, consistent with a cell cycle arrest and defective 
proliferation of CTCF-deficient β-selected cells.  
 The accumulation of CTCF-deficient ISP cells could result from a developmental 
arrest or alternatively reflect defective up-regulation of CD4 expression in CD3+TCR+ 
cells  (i.e. DP cells), similar to thymocytes deficient for the chromatin remodeler Mi-2β 
(34). To distinguish between these possibilities, we assessed expression of various 
surface markers on CTCF-deficient ISP cells. CD3 and TCRβ expression was very low, 
suggesting that these were true ISP cells (Fig. 3D; Supplemental Fig. S4B). Consistently, 
CTCF-deficient ISP cells expressed low levels of CD5, which is normally present on DN 
and ISP cells and is up regulated on DP cells (35), and of CD69, which is normally 
induced in a sub-fraction of DP cells, reflecting TCR-mediated activation (36) 
(Supplemental Fig. S4). Expression of CD24  (HSA), which is normally high on DN and 
ISP cells and down-regulated at the ISP to DP transition (34), was reduced in CTCF-
deficient cells throughout thymocyte differentiation. 
 Lck-Cre Ctcf f/f DP cells manifested consistently low levels of CD3/TCR 
expression, but normal levels were present in SP cells (Fig. 3D; Supplemental Fig. S4B). 
The severe reduction of DP cell numbers and low surface CD3/TCR expression on 
CTCF-deficient DP cells, together with the reported presence of CTCF-bindings sites in 
the Tcrα gene locus (13, 16), suggested that the arrest of CTCF-deficient thymocytes 
may result from defective TCRα V(D)J recombination. We therefore crossed Lck-Cre 
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Ctcf f/f mice with transgenic mice expressing pre-rearranged TCRαβ transgenes that 
normally drive thymocytes into the CD4 or CD8 lineage, respectively. However the 
impaired developmental progression of CTCF deficient ISP into DP cells was not 
rescued (Supplemental Fig. S5). Thus, the developmental block in Ctcf knockout T cells 
is independent of TCRα rearrangement. Consistent with this, in vivo induction of DP cells 
by stimulation with anti-CD3ε mimicking pre-TCR signaling (35) was reduced in CTCF-
deficient Rag2 -/- DN cells, compared to CTCF-expressing Rag2 -/- DN cells 
(Supplemental Fig. S6).   
Figure 3. Impaired proliferation and differentiation of β-selected cells in Lck-Cre Ctcf f/f 
mice.  
 
(A) Flow cytometric analyses of intracellular TCRβ protein expression in the indicated thymic 
subsets from WT and Lck-Cre Ctcf f/f mice. TCRβ/forward scatter (FSC) profiles are shown as 
dot plots and the percentages of TCRβ+ cells are shown. 
(B) Cell cycle status of DN, ISP and DP cells, using 7-AAD.  
(C) Quantitative RT-PCR analysis in sorted DN, ISP and DP cell fractions from WT and Lck-
Cre Ctcf f/f mice. The DP fraction also contained CD4SP cells.  
(D) Surface TCRβ expression in the indicated thymic subsets. Results are displayed 
as histogram overlays of Lck-Cre Ctcf f/f mice (bold lines) on top of profiles of wild-type mice 
(gray). Data shown are representative of 6 mice per group. 
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In summary, in the absence of CTCF, the Tcrβ locus can undergo functional V(D)J  
recombination in DN3, and apparently even in DN2 cells. This results in the initiation of 
β-selection, as evidenced by cell size increase and differentiation into DN4 and ISP cells.  
However, CTCF is essential to drive proliferation and maturation of β-selected cells and 
to efficiently up-regulate CD3/TCR surface expression in DP cells. The arrest of CTCF-
deficient DP cells cannot be explained by impaired TCRα gene rearrangement.  
 
Defective TCR/CD3-mediated proliferation in CTCF-deficient TCRαβ cells   
The role of CTCF in T cell activation was investigated using in vitro cultures. 
Remarkably, anti-CD3/CD28 antibody stimulation of purified peripheral T cell fractions 
from Lck-Cre Ctcf f/f mice resulted in a selective outgrowth of TCRγδ T cells 
(Supplemental Fig. S7A). CTCF is expressed in both TCRαβ and TCRγδ T cells 
(Supplemental Fig. S1) and was absent in a mixed population of in vitro activated 
TCRαβ and TCRγδ T cells from Lck-Cre Ctcf f/f mice (Supplemental Fig. S7B, C). We 
therefore conclude that CTCF is essential for TCR mediated activation and proliferative 
expansion of TCRαβ but not of TCRγδ T cells.  
 To investigate cellular activation of CTCF-deficient αβ T cells, we performed in 
vitro stimulation experiments with highly purified naive CD62L+ CD4+ and CD8+ T cells 
from WT and CD4-Cre Ctcf f/f spleen and lymph nodes. We evaluated the ability of T 
cells to go through sequential cell divisions by carboxy-fluorescein succinimidyl ester 
(CFSE)-labeling and observed severely reduced proliferation of anti-CD3/CD28-activated 
CTCF-deficient CD4+ T cells at day 3 (Fig. 4A). A similar proliferation defect was also 
present in CTCF-deficient OTII transgenic CD4+ T cells after a more physiological, 
antigen-specific, activation by OVA peptide 323-339-pulsed APC (Fig. 4A). In contrast, 
anti-CD3/CD28-activated CTCF-deficient CD8+ T cells were able to undergo cell division, 
although they lagged behind WT cells by approximately one cell cycle, and cell recovery 
was reduced when compared to WT cells.  
 Phorbol-12-myristate-13-acetate (PMA) bypasses proximal TCR signaling 
events and directly activates protein kinase C signaling (37). Under conditions where 
PMA was added as a co-stimulatory signal with anti-CD3, CTCF-deficient cells were 
defective in proliferation.  However, when T cells were stimulated by PMA and the 
calcium ionophore ionomycin, we observed significant proliferation of CTCF-deficient 
CD4+ and CD8+ T cells (Fig. 4B). These data indicate that under specific conditions 
CTCF is not required for cell proliferation. 
 Anti-CD3/CD28-stimulated CTCF-deficient CD4+ T cell cultures at day 3 showed 
diminished cell recovery and an almost complete lack of cells in S/G2/M phase of the cell 
cycle (Fig. 4B). This is consistent with the limited cell division observed in CFSE 
experiments. Although CTCF-deficient PMA/ionomycin-stimulated CD4+ or CD8+ T cell 
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cultures exhibited lower expansion rates, their cell cycle profiles at day 3 were similar to 
WT cells (Fig. 4B).  
 
Figure 4. Impaired anti-CD3ε-mediated proliferation of CTCF-deficient CD4+ and CD8+ 
T cells.  
 
(A) CFSE profiles of T cell cultures of sorted CD62L+ CD4+ and CD8+ T cell populations from 
WT mice (gray filled histogram) in comparison with cultures from CD4-CreCtcf f/f mice (black 
line). Cells were activated by the indicated stimuli and cultured for 3 days (or 4 days for OT-II 
CD4+ T cells). Dotted lines indicate the fluorescence intensity of un-stimulated cells.  
(B) Cellular expansion in 3d cultures upon anti-CD3/CD28 or PMA/ionomycin stimulation 
(upper part). Symbols represent the expansion values of cultures from individual mice, 
whereby cell numbers at the start of the culture were set to one; lines indicate average values. 
The lower part shows the cell cycle status of the indicated cultures, whereby DNA content 
was examined by propidium iodide (PI) staining. The percentages of cycling cells (S/G2/M 
phase) are shown.  
(C) Phenotypic characteristics of anti-CD3/CD28 or PMA/ionomycin-stimulated CD4+ and 
CD8+ T cells. CD25, CD69, and FSC profiles are displayed as histogram overlays of WT (gray 
filled histograms) and CD4-Cre Ctcf f/f cultures (bold lines). The percentages shown represent 
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the fractions of the cells within the indicated marker, in WT (gray) or CD4-Cre Ctcf f/f  (black, 
bold) cultures. Data shown are representative of 4-6 animals per group. 
 
 
The proliferation defect in anti-CD3/CD28-stimulated CTCF-deficient T cells was not due 
to defective IL-2 production (Supplemental Fig. S8). Nevertheless, induction of the IL-2 
receptor CD25 on CD4+ and CD8+ T cells was severely impaired (Fig. 4C).  Activation-
induced up-regulation of CD69 and cell size increase was particularly affected in CD4+ T 
cells. When activated by PMA/ionomycin, CTCF-deficient CD4+ T cells displayed a 
partial defect in CD25 up regulation and cell size increase, while CD69 induction was 
normal.  PMA/ionomycin-stimulated CTCF-deficient CD8+ T cells showed normal CD25, 
CD69 and cell size up-regulation at day 3 (Fig. 4C), close to WT expansion rates, but 
reduced production of IFN-γ and granzyme B at day 7 (Supplemental Fig. S9).   
 Thus, anti-CD3/CD28 treatment does not elicit the proper activation and 
proliferation of CTCF-deficient peripheral TCRαβ cells, whereby CD4+ T cells are more 
affected than CD8+ T cells. CTCF deficiency does not inhibit TCRγδ T cell proliferation. 
When TCR signaling was bypassed by PMA and ionomycin, CTCF-deficient CD4+ and 
CD8+ T cells showed substantial activation and proliferation. These findings point to a 
specific function of CTCF in the regulation of proximal components of TCR signaling 
pathways. Unexpectedly, CTCF is not essential for cellular proliferation in vitro.    
 
Th2 cytokine defect in CD4-Cre Ctcf f/f mice   
 
Consistent with the severe reduction of peripheral CD4 + T cell numbers in Lck-Cre Ctcf 
f/f mice, the levels of all serum Ig subclasses, except the T cell-independent isotypes IgM 
and IgG3, were dramatically reduced (Fig. 5A). Interestingly, total serum Ig levels in 
CD4-Cre Ctcf f/f mice exhibited a different profile, as the levels of the IL-4-dependent 
isotype IgG1 were more affected than those of INF-γ-dependent IgG2a (~10% and ~60% 
of wild-type, respectively). We also observed low serum levels of the IL-4-dependent 
isotype IgE (Fig.  5B). Th2-mediated responses in vivo were tested by injection of TNP-
KLH, which boosted serum IgE levels in WT mice, but not in CD4-Cre Ctcf f/f animals 
(Fig. 5B). Thus, in CD4-Cre Ctcf f/f mice the Th2-dependent subclasses IgG1 and IgE 
were severely reduced, while the Th1-dependent isotype IgG2a was only moderately 
affected. 
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Figure 5. Serum Ig analysis in CTCF-deficient mice 
(A) Serum concentrations of Ig isotypes, displayed as average values plus SD. Mice were 2 
months of age.  
(B) Total IgE serum concentrations in non-immunized mice (left) and in immunized mice 7 
days after i.p. injection with 10 µg TNP-KLH (right). 
 
 
Whether CTCF is specifically required for Th2 differentiation was tested by in vitro 
polarization cultures. Sorted naive CD62L+ CD4+ T cells from spleen and lymph nodes 
were stimulated with PMA/ionomycin under Th0 conditions (without additional cytokines 
or antibodies), Th1-polarizing conditions (with IL-12 and anti-IL-4) or Th2-polarizing 
conditions (with IL-4, anti-IL-12 and anti-IFN-γ) for 7 days. CTCF-deficient CD4+ T cells 
showed substantial expansion (~5-10 times; Fig. 6A), but when compared to WT cells 
they produced moderately reduced levels of IFN-γ in Th1-polarized cultures and 
significantly decreased amounts of IL-4 in Th2-polarized cultures, as determined by 
intracellular FACS  (Fig. 6B). Both frequency of IL-4+ cells and intracellular IL-4 signals 
per cell were reduced  (Fig. 6B). Moreover, quantitative RT-PCR analysis of Th2 cultures 
showed that in CTCF deficient Th2 cultures transcription of the Th2 locus cytokines Il-4, 
Il-5 and Il-13, as well as of Il-10 was strongly reduced (Fig. 6C).   
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Figure 6. Th2 cytokine production defect in CTCF-deficient mice 
(A) Expansion of Th0, Th1 and Th2 cultures 7 days after stimulation with PMA/ionomycin. 
Symbols represent the expansion values of cultures from individual mice, whereby cell 
numbers at the start of the culture were set to one. Lines indicate average values.  
(B) Flow cytometric analysis for intracellular expression of IFNγ and IL-4 in the indicated T cell 
cultures after stimulation with PMA/ionomycin. CD4+ T cells were gated and expression 
profiles are displayed as dot plots. The percentages of cells within the quadrants are given. 
Mean fluorescence values for IL-4 were 138 and 75 for WT and CD4-Cre Ctcf f/f IL-4+ Th2 
cells, respectively.  
(C) Quantitative RT-PCR analysis of expression of the indicated cytokines in different T cell 
cultures. Expression levels were normalized for GAPDH and are expressed as arbitrary units, 
whereby the values in WT Th2 cells were set to one. Mean values and SD are given for 4 
mice analyzed per group. 
 
 
As Th2 cytokine production depends on the transcription factor GATA 3 (22), we 
evaluated its expression in the T cell cultures. GATA 3 expression appeared unaffected 
in CTCF-deficient Th2 cultures (Fig. 7A), excluding the possibility that Th2 cytokine 
production was impaired due to defective GATA3 induction. Furthermore, the CTCF 
deficient Th2 cultures displayed clear features of Th2- polarized cells, including low 
mRNA levels of T-bet and Stat4 (Fig. 7B). As GATA 3 has the capacity to inhibit Stat4 
transcription  (38), the finding of low Stat4 expression levels suggest that in the absence 
of CTCF GATA 3 still operated as a negative regulator of Stat4. Like GATA 3, SATB1 is 
important for proper Th2 locus expression (32). SATB1 was specifically induced, both in 
WT and CTCF-deficient Th2 cultures (Fig. 7C). In CTCF-deficient Th1 cultures, T-bet 
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expression was reduced when compared to WT (Fig. 7B), which is consistent with the 
observed moderate reduction in IFN-γ expression (Fig. 6B).  
 
 
 
Figure 7. GATA3 and SATB1 are induced in PMA/ionomycin-stimulated CTCF deficient 
Th2 cultures 
(A) Flow cytometric analysis for intracellular GATA3 protein expression in PMA/ionomycin 
stimulated T cell cultures. CD4+ T cells were gated and for the indicated mice expression 
profiles are displayed as histograms overlays of Th1 (gray filled histograms) and Th2 cultures 
(bold lines). (B) Quantitative RT-PCR analysis of GATA3, T-bet and STAT4 expression in 
different T cell cultures. Expression levels were normalized for GAPDH and are expressed as 
arbitrary units, whereby expression in WT Th1 cells (T-bet, STAT4) or Th2 cells (GATA 3) 
was set to 1. Mean values and SD are given for 4 mice analyzed per group.  
(C) Western blotting analysis of SATB1 and CTCF protein levels in PMA/ionomycin-stimulated 
T effector cell cultures at day 7. Fibrillarin was used as a loading control. 
 
 
 
As a result of defective TCR/CD3-mediated proliferation, sorted CTCF-deficient 
CD62L+ CD4+ peripheral T cells did not show expansion in 7-day Th1/Th2 polarization 
cultures when stimulated with anti-CD3/CD28 (Supplemental Fig. S10A). Moreover, we 
found a severe Th2-cytokine defect and an absence of GATA 3 induction (Supplemental 
Fig.  S10).   
 139
Taken together, our data indicate that CTCF-deficiency affects Th2 cytokine 
production in multiple ways. CTCF is required for the induction of proliferation and GATA 
3 expression upon TCR stimulation. When bypassed with PMA/ionomycin, proliferation is 
induced and differentiating CTCF-deficient Th2 cells express GATA 3 and activate 
SATB1.  However expression of the Th2 cytokines IL-4, IL-5 and IL-13 remains strongly 
inhibited. 
 
Discussion    
 
Here we report on the in vivo function of CTCF, a protein involved in chromatin 
organization and epigenetic regulation of gene expression. Consistent with previous 
studies (3), a knockout of Ctcf in early embryonic development is lethal, while 
heterozygous Ctcf knockout mice are viable and fertile. No evidence was found for an 
increased tumor incidence in heterozygous knockout animals, or T lymphoid 
malignancies in the CTCF-deficient T-cell lineage, arguing against a role for CTCF as a 
crucial tumor suppressor. Furthermore, we did not observe a more severe phenotype in 
CTCF-deficient female thymocytes compared to male cells suggesting that absence of 
CTCF does not cause mis-expression of genes on the inactive X chromosome. 
 Within the T-cell lineage, we found that CTCF is not required for V(D)J  
recombination at the TCRα locus. Importantly, our findings show that CTCF is essential 
for the efficient proliferation of β-selected cells, for their maturation from ISP to DP cells, 
and for TCR up-regulation at the cell surface of DP cells. In line with the proliferative 
block, we detected a strongly increased expression of two major cell cycle inhibitors, p21 
and p27. The developmental progression of CTCF-deficient ISP into DP cells was not 
rescued when we crossed Lck-Cre Ctcf f/f mice with transgenic mice expressing a pre-
rearranged αβ TCR.  Therefore, the arrest of CTCF-deficient DP cells cannot result from 
impaired TCRα gene rearrangement. Because also the TCRβ, δ and γ loci could undergo 
functional V(D)J  recombination in the absence of CTCF, we conclude that the multiple 
CTCF-binding sites  reported to be present in TCR loci (15, 17) are not essential for the 
process of V(D)J  recombination, which involves complex long-range DNA interactions.   
 The impaired generation of SP cells in the thymus of CTCF-deficient mice can 
be explained by the reduced size of the DP compartment. Thus CTCF appears not 
required for the substantial epigenetic and regulatory changes (18) that accompany 
commitment and maturation of CD4 or CD8 SP cells. Like DNMT1 and the RNase III 
enzyme Dicer (39), CTCF was not essential for γδ T cell development or anti-CD3-
mediated proliferation of these T cells. Apparently, cell division and the regulation of 
chromatin structure and gene expression in γδ T cells are very different from αβ T cells, 
and do not depend on proteins like CTCF, DNMT1 or Dicer.   
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 We found that CD4-Cre Ctcf f/f mice contained substantial numbers of CD4+ and 
CD8+ T cells in which the expression of CTCF protein was significantly reduced. Either 
CTCF is not essential for the survival of resting peripheral T cells, or very low amounts of 
CTCF are enough for cells to survive. When resting naive T cells were activated and 
driven into cell division in vitro, CTCF was no longer detectable. Since activation by PMA 
and ionomycin resulted in proliferation of CTCF-deficient αβ T cells, we conclude that 
CTCF is not essential for cellular proliferation per se. Consistent with this notion, γδ T 
cells, and to a lesser extent also CD8+ T cells show substantial proliferation in the 
absence of CTCF. By contrast, CTCF appeared essential for anti-CD3ε-induced 
activation and proliferation of αβ T cells. It remains to be investigated which pathways 
are specifically affected in αβ T cells by CTCF-deficiency.  
 The in vitro Th1/Th2 polarization cultures showed that CTCF-deficient Th1 
effector cells produced significant amounts of INF-γ. By contrast, CTCF-deficient Th2 
effector cells hardly produced Th2 cytokines or IL-10. In these Th2 effector cells, both 
GATA3 and SATB1 proteins were present at apparently normal levels and T-bet, the 
transcription factor that is critical for Th1 differentiation was down regulated. Moreover, 
levels of Stat4 transcription, which is inhibited by GATA 3 activity (38), were low; 
indicating that in the absence of CTCF GATA 3 is still functional as a negative regulator 
of Stat4 transcription. In contrast, transcription of the three Th2 cytokine genes Il-4, Il-5 
and Il-13 was severely reduced.  
We therefore propose that CTCF plays a major role in the GATA3- and SATB1-
dependent regulation of the expression of genes within the Th2 cytokine locus.    
Our findings uncover specific CTCF-dependent pathways in T cell development, 
activation and effector function. Recently, ~14,000 genome-wide CTCF-binding sites 
were identified (13, 14). It was proposed that CTCF remains bound to these sites 
irrespective of cell type (13) and that it marks boundaries of histone methylation domains 
in human T cells (15). CTCF also mediates long-range chromatin looping in the β-globin 
locus and its deletion alters local histone modifications (10). However deletion of a CTCF 
binding site in the β-globin locus did not affect expression of the globin genes. By 
contrast, our results in T cells demonstrate an essential role for CTCF specifically in Th2 
locus expression. Hence we propose that CTCF has cell type-specific functions; it will be 
interesting to determine how CTCF performs these specific roles, while remaining bound 
to its ~14,000 cognate binding sites. Equally interesting are the questions how and which 
chromosomal interactions, both in cis and in trans, persist in the absence of CTCF. 
Importantly, our experiments in mature CTCF-negative T cells show they can proliferate 
and differentiate under appropriate conditions and it is therefore feasible to address 
these issues using CTCF knock-down or conditional targeting approaches.   
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Materials and Methods     
 
Modified Ctcf alleles and mouse models   
Human CTCF cDNA was used to screen a 129S6/SvevTac mouse PAC library (RPCI-
21) (40). PAC clones were used to isolate 6.7kb  (for 5’ end targeting) and 8kb (for 3’ end 
targeting) EcoRI subclones. For 5’ end targeting the 6.7kb EcoRI fragment was used to 
amplify 1360 bp of 5’ end homology and 5340 bp of 3’ end homology. The homologous 
arms were cloned into a vector containing the neomycin resistance gene flanked by 
loxP-sites (41). A viral thymidine kinase gene was inserted afterwards. For 3’ end 
targeting we generated a SpeI-EcoRI subclone from the PAC DNA and used its unique 
BamHI site to insert a cassette containing the puromycin resistance gene flanked by loxP 
sites, followed by splice acceptor sequences and the bacterial β-galactosidase (lacZ) 
reporter (41). Relevant parts of the different constructs were verified by DNA  
sequencing.  
 Constructs were targeted into E14 embryonic stem (ES) cells as described (41). 
DNA from resistant ES cells was analyzed with external radio-labeled probes by 
Southern blotting.  Confirmation of homologous recombination was performed using 
different 5’ end and 3’ end  probes (Fig. 1A, B) and a PCR-based assay for genotyping. 
Ctcf f/f mice were maintained on a C57BL/6 background. Ctcf f/f mice were bred to mice 
expressing chicken β-actin-Cre generating Ctcf +/- animals. T cell specific deletion of Ctcf 
was achieved by breeding to LckCre and CD4-Cre mice (25), kindly provided by Dr. C. 
Wilson (University of Washington, Seattle, USA). Cre-specific primers were used for 
genotyping.  
Mice were bred and maintained in the Erasmus MC animal care facility under 
specific pathogen-free conditions and analyzed at 6-10 weeks of age. Experimental 
procedures were reviewed and approved by the Erasmus University committee of animal 
experiments.    
 
DNA, RNA and protein analysis 
Genomic DNA was isolated, digested, and blotted onto Hybond N+ membranes 
(Amersham), and hybridized with radio-labeled probes. Ctcf probes are shown in Fig. 1. 
Total RNA was prepared using RNA-Bee RNA isolation solvent (TelTest Inc.). RNA (0.5-
1.0μg) was reverse transcribed (RT) with random and oligo-dT primers, in the presence 
of Superscript reverse transcriptase (Invitrogen). Real-time RT-PCR was performed as 
described (10) with 100ng of each primer and 0.5 units of Platinum taq DNA polymerase 
(Invitrogen). Sybr-green (Sigma) was added to the reactions and PCR was performed on 
a DNA Engine Opticon PCR system (MJ Research Inc.) and Bio-Rad MyiQ iCycler 
single-color real-time PCR detection system. Alternatively, total RNA was extracted 
using the GeneElute mammalian total RNA miniprep system (Sigma). Primers spanning 
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at least one intron-exon junction, were designed manually or using the ProbeFinder 
software  (Roche Applied Science, Indianapolis, In). Probes were either chosen from the 
universal probe library (Roche Applied Science) or designed manually (Gata3, Gapdh) 
and purchased from Eurogentec (Seraing, Belgium). Quantitative real-time PCR was 
performed using the ABI Prism 7700 sequence detection system (Applied Biosystems, 
Foster City, CA). To confirm the specificity of the amplification products, samples were 
separated by standard agarose gel electrophoresis. Threshold levels were set and 
further analysis was performed using the SDS v1.9 software (Applied Biosystems). The 
obtained Ct values were normalized to the Ct value of Gapdh or β-actin. Each PCR was 
performed at least in triplicate. Primer sequences and PCR conditions used are available 
on request.  
 Nuclear extracts were prepared as described (10) and analyzed by western blot 
(41).  Primary antibody incubation was done overnight at 4oC in Tris-buffered saline 
(TBS), containing 5% (w/v) BSA and 0.15% (v/v) NP-40. Blots were incubated with 
secondary goat anti-rabbit or -mouse antibodies, coupled to horseradish peroxidase (GE 
Healthcare UK Ltd:  1:50000). Signal detection was performed using ECL (Amersham). 
CTCF-specific (N3) antibodies, generated as described (42) using a GST-linked chicken 
CTCF (amino acids 2267) fusion protein, were used in a 1:300 dilution. DNMT1 (Abcam) 
and UBF (Santa Cruz Biotechnology) mAbs were used 1:100. Western blots were 
scanned and the levels of CTCF, UBF and DNMT1 were quantified using the gel macro 
function in ImageJ (Rasband, W.S., NIH, http://rsb.info.nih.gov/ij/). The amount of CTCF 
was normalized to DNMT1 in the same sample. 
 
Flow cytometric analyses  
Preparation of single-cell suspensions, FDG-loading, mAb incubations for four-color 
cytometry have been described (43). All mAbs were purchased from BD Biosciences 
(San Diego, CA), except for PE-conjugated anti-Granzyme B (GB12; Caltag 
Laboratories, Burlingame, CA) and anti-GATA 3 (Hg-3-31; Santa Cruz Biotechnology, 
CA). For intracellular detection of cytokines, cells were re-stimulated with plate-bound 
antiCD3 (10 μg/ml in PBS; 145-2C11) or phorbol 12-myristate-13-acetate (PMA; 50 
ng/ml; Sigma) plus ionomycin (500 ng/ml; Sigma) in the presence of GolgiStopTM (BD 
PharMingen) for 4h. Cells were harvested and stained extracellularly with PCP-
conjugated anti-CD4 or FITC-conjugated anti-CD8 (53-6.7), followed by standard 
intracellular staining with anti-IL4-PE (BVD4-1D11) or anti-IFN-γ-APC (XMG1.2), using 
paraformaldehyde and saponin.   
 For cell cycle profiles of thymic subsets, cells were first stained for surface 
markers, fixed with 0.25% paraformaldehyde and permeabilized with 0.2% Tween20.  
Next, 7-AAD was added to a final concentration of 15 μg/ml in PBS. Cell cycle status of T 
cell cultures was determined after fixing in ice-cold ethanol and subsequent staining in 
 143
PBS, containing 0.02mg/ml propidium iodide, 0.1% v/v Triton X-100 and 0.2 mg/ml 
RNAse. Doublet cells were excluded by measuring peak area and width.  
CFSE-labeling of cells was performed as described (44). Samples were 
acquired on a FACSCaliburTM flow cytometer and analyzed using CellQuestTM (BD, 
Sunnyvale, CA) or FlowJoTM (Tree Star Inc., Ashland, OR) research software. Statistical 
evaluations were done by students t-test.  
 
In vitro T cell cultures  
For in vitro T cell stimulations and Th1/Th2 polarization cultures, naive CD62L+ CD4+ or 
CD8+ T cells were purified by cell sorting using a FACSVantage VE equipped with Diva 
Option and BD FACSDiva software (BD Bioscience). Purity of obtained fractions was 
>98%. T cells were cultured at a concentration of 1 x 106 cells/ml in Iscoves modified 
Dulbeccos medium (IMDM) (Bio Whittaker, Walkersville, MD) containing 10% heat-
inactivated FCS, 5x10–5M β-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml 
streptomycin. Stimulation was with plate-bound anti-CD3 (145-2C11) and anti-CD28 
(37.51) mAbs (coated at 10 μg/ml each at 4oC overnight), or PMA (50ng/ml) plus 
ionomycin (300ng/ml). 
 For Th1-polarizing conditions, anti-IL-4 (10 μg/ml; 11B11) plus IL-12 (10 ng/ml) 
was added to the medium. Th2-polarizing cultures included anti-IFN-γ (5 μg/ml; R4-
6A2,), anti-IL-12 (5 μg /ml; C17.8) and IL-4 (10ng/ml). For Th0 conditions, no cytokines 
or mAbs were added. For differentiation of CD8+ effector T cells, only recombinant IL-2 
(5ng/ml) was added to the medium. On day 3 after activation, T cell cultures were further 
supplemented with recombinant IL-2 (5ng/ml). Both CD4+ and CD8+ T cells were 
expanded up to 7 days under the same cytokine conditions as the primary cultures. 
Cytokines were from R&D Systems Inc., Minneapolis, MN.     
Stimulation of OT-II transgenic CD4 + T cells was carried out in the presence of 
bone marrow derived dendritic cells (BM-DC). Briefly, BM single cell suspensions were 
prepared from C57BL/6 femurs and seeded at 2 x 106 per petri dish in complete IMDM 
and 200ng/ml murine rGM-CSF (Biosource). On days 3 and 6, 200ng/ml murine 
recombinant GM-CSF was added in 10 ml of fresh IMDM. On day 8, the non-adherent 
cells consisting of immature and mature BM-DC were harvested. For in vitro T cell 
proliferation studies 2x106 CFSE labeled OT-II transgenic naive CD4+ T cells were co-
cultured with 2x106 BM-DC previously pulsed with OVA peptide 323-339 (50 μg/ml, 
manufacturer) in complete IMDM. At day 4, cultured T cells were harvested for 
proliferation analysis.  
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Analyses of serum Ig and in vivo immunizations 
Total serum Ig levels were determined by subclass-specific sandwich ELISA, as 
described; IgE was induced by i.p. injection of 10 μg TNP-KLH  precipitated on alum 
(45).   
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Supplementary Data 
 
Figure S1. Flow cytometric analysis of GPF-CTCF protein expression 
GPF-CTCF protein was analyzed, in conjunction with cell surface markers, in cell 
suspensions from thymus and spleen from mice carrying a green fluorescent protein (GFP)-
Ctcf knock-in allele (CtcfGFP, H.H. et al., manuscript in preparation, for targeting strategy see 
(Akhmanova et al., 2005). The indicated cell populations were gated and expression data are 
displayed as histogram overlays of GFP-CTCF (green) on top of background signals in WT 
mice (black). 
 
 
 
Figure S2. Flow cytometric analysis of lacZ expression in CTCF conditionally deleted 
mice 
LacZ expression was analyzed in conjunction with cell surface markers. The indicated cell 
populations were gated and lacZ expression data are displayed as histogram overlays of Lck-
Cre Ctcf f/f or CD4-Cre Ctcf f/f mice (green) on top of background signals in WT mice (black). 
High lacZ expression, reflecting almost complete deletion of the Ctcf gene is present in 
DN2/DN3 for Lck-Cre Ctcf f/f mice and in ISP for CD4-Cre Ctcf f/f mice. 
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Figure S3. CTCF deletion does not affect DNA methylation or nucleolar organization 
A) Methylation status of ribosomal DNA (rDNA) repeats. Southern blot analysis of genomic 
DNA from thymus and spleen of the indicated mice was digested with EcoRI (lanes 1), EcoRI 
and HpaII (lanes 2), or (3) EcoRI and MspI (lanes 3) and hybridized with the unstable 5’ 
external transcribed spacer probe (Akhmanova et al., 2000). 
B) FISH analysis of nucleolar organization in FACS-sorted naive CD62L+ peripheral T cells 
from the indicated mice. Slides were hybridized with a DIG-labeled rDNA probe (green) 
containing non-transcribed rDNA (Akhmanova et al., 2000). Cells were counterstained with 
DAPI (blue). 
C) RT-PCR analysis for CTCF-L/BORIS expression in sorted naive peripheral CD62L+ CD4+ 
and CD8+ T cell fractions from wild-type (1,2) and CD4-Cre Ctcf f/f (3,4) mice. RNA was 
reverse transcribed, serially diluted, and used as a template for amplification. Amplification of 
testis cDNA samples (Te) and RNA samples without RT (-) were performed as controls. 
Products were fractionated by gel electrophoresis and detected with ethidium bromide. 
M=molecular weight marker. 
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Figure S4. Arrest at the ISP to DP transition in Lck-Cre Ctcf f/f mice 
A) Quantification of forward scatter values of the indicated thymocyte subpopulations in WT 
(gray bars) and Lck-Cre Ctcf f/f mice (red bars). Data are average values ± SEM from 5-8 mice 
per group. 
B) Flow cytometric analyses of HSA, CD3, TCR, CD5 and CD69 in the indicated thymocyte 
sub-populations, displayed as overlays of WT mice (black histograms) and Lck-Cre Ctcf f/f 
mice 
(red histograms). Data shown are representative of 5-8 mice per group. 
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Figure S5. The arrest of CTCF-deficient thymocytes is independent of TCR α 
rearrangement 
Providing Lck-Cre Ctcf f/f mice with a pre-rearranged TCRαβ transgene does not correct the 
developmental arrest of DP cells. 
A) The OTII TCRαβ recognizes the OVA323-339 peptide in the context of C57BL/6 MHC 
class II. OTII TCR transgenic thymocytes are positively selected towards the CD4 lineage 
(Barnden et al., 1998). 
B) The MHC class I-restricted HY TCRαβ recognizes a male-specific HY antigen peptide and 
in the C57BL/6 H-2b class I female background (Kisielow et al., 1988); HY-specific 
thymocytes are positively selected towards the CD8 lineage. (A, B) Flow cytometric profiles of 
CD4/CD8 and CD3/TCRγδ in the indicated tissues are shown as dot plots; percentages of 
cells within quadrants or regions and total thymic cell numbers are given. The expression 
profiles of total TCRβ (A) or HY idiotype-specific T3.7 TCR (B). The indicated cell populations 
are shown on the right as histogram overlays of TCR Tg Lck-Cre Ctcf f/f mice (bold lines) on 
top of profiles of TCR Tg wild-type littermates (gray filled histograms). 
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Figure S6. The arrest at the ISP to DP transition is also present in anti-CD3-treated 
CTCF/RAG2-deficient mice 
Flow cytometric analyses of the thymus of the indicated mice, which were either untreated or 
injected with 50 µg of rat anti-CD3ε antibodies in vivo. CD4/CD8 expression profiles, 3d after 
injection, are shown as dot plots (upper part). DN cell populations were gated and analyzed 
for CD25 and CD44 (lower part). Data are shown as dot plots and the percentages of cells 
within the quadrants are given. 
 
 
Figure S7. Selective advantage of TCR γδ cells in anti-CD3/CD28-stimulated cultures of 
Lck-Cre Ctcf f/f mice 
A) Flow cytometric analysis of TCRγδ expression in T cell cultures from wild type (WT) and 
Lck-Cre Ctcf f/f mice. Lymph node fractions were stimulated by anti-CD3/CD28 and cultured 
for 7 days. The percentages represent the fractions of TCRγδ+ T cells. The proportions of γδ+ 
T cells in the T-cell enriched cell suspensions before culture was <2% in WT and ~30% in 
Lck-Cre Ctcf f/f mice (see also Figure 2C). 
B) Flow cytometric analysis of CD4, CD8 and TCRγδ expression in mixed T cell cultures from 
wild-type and Lck-Cre CTCF f/f mice. Lymph node cell fractions were enriched for CD4 and 
CD8 cells and depleted for TCRγδ+ T cells, stimulated by anti-CD3/CD28 and cultured for 7 
days. 
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C) Western blotting, showing the absence of CTCF protein in mixed T cell cultures from Lck-
Cre Ctcf f/f mice. Fibrillarin was used as a loading control. Molecular weight markers are 
indicated in kD. 
 
 
 
 
Figure S8. CTCF-deficient CD4+ or CD8+ T cells do not have a defect in IL-2 production 
Analysis of IL-2 expression in anti-CD3/CD28 and PMA/ionomycin-stimulated cultures of 
sorted CD62L+ CD4+ and CD8+ T cell fractions from wild-type and CD4-Cre Ctcf f/f mice. At 
day 3, cells were re-stimulated for 4 hours prior to intracellular flow cytometric analysis. Total 
living cells were gated and CD4/IL-2 and CD8/IL-2 profiles are displayed as dot plots and the 
percentages of cells within quadrants are given. Data shown are representative of 4 mice per 
group. 
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Figure S9. Analysis of defects in the CD8 compartment of CD4-Cre Ctcf f/f mice 
A) Expansion of CD8+ T cell cultures 7 days after stimulation with αCD3/αCD28 or 
PMA/ionomycin. Symbols represent expansion values of cultures from individual mice, 
whereby cell numbers at the start of the culture were set to one. Lines indicate average 
values. 
B) Flow cytometric analysis for intracellular expression of IFNγ and granzyme B in the 
indicated CD8+ T cell cultures. CD8+ T cells were gated and expression profiles are displayed 
as dot plots. 
The percentages of cells within the quadrants are given. 
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Figure S10. Defective expansion and cytokine production in CTCF-deficient αCD3/ 
αCD28 stimulated Th cells 
 
A) Expansion of Th0, Th1 and Th2 cultures 7 days after stimulation with αCD3/αCD28. 
Symbols represent the expansion values of cultures from individual mice, whereby cell 
numbers at the start of the culture were set to one. Lines indicate average values. 
B) Flow cytometric analysis for intracellular expression of IFNγ and IL-4 in the indicated T cell 
cultures after αCD3/αCD28 stimulation. CD4+ T cells were gated and expression profiles are 
displayed as dot plots. The percentages of cells within the quadrants are given. Mean 
fluorescence values for IL-4 were 134 and 70 for wild-type and CD4-Cre Ctcf f/f IL-4+ Th2 
cells, respectively. 
C) Flow cytometric analysis for intracellular GATA3 protein expression in αCD3/αCD28- 
stimulated T cell cultures. CD4+ T cells were gated and for the indicated mice expression 
profiles are displayed as histograms overlays of Th1 (gray filled histograms) and Th2 cultures 
(bold lines). 
D) Quantitative RT-PCR analysis of GATA 3 and STAT4 expression in different T effector cell 
cultures. Expression levels were normalized for GAPDH and are expressed as arbitrary units, 
whereby expression in wild-type Th1 cells (STAT4) or Th2 cells (GATA 3) was set to 1. Mean 
values and SD are given for 4 mice analyzed per group. 
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Experimental Procedures 
 
Fluorescent in situ hybridization (FISH) 
 
FACS sorted CD4+ and CD8+ T cells were allowed to attach to glass slides for 30 min 
and fixed for 10 min with 4% PFA/PBS. Slides were stored in 70% EtOH until further use. 
For DNA-FISH, cells were pretreated by two PBS wash-steps followed by a 
permeabilization step of 4 min incubation in 0,1% pepsin in 0,01M HCl at 37 °C. 
Slides were washed once in PBS on ice and fixed again for 5 min in 4% PFA/PBS. 
Slides were washed twice in PBS and dehydrated. Denaturation was done for 2 min at 
80°C in denaturing solution (70% formamide; 2xSSC; 10 mM phosphate buffer, pH 7), 
after which the slides were cooled in 70% EtOH, dehydrated and hybridised as described 
(Gribnau et al., 2005). The rDNA probe (an 11.8kb SalI fragment of a murine rDNA 
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cosmid which contains non transcribed rDNA only (Akhmanova et al., 2000) was DIG 
labelled by nick translation (Roche). We used a Zeiss Axioplan 2 microscope for image 
acquisition and cell counting. Cells were counted without knowledge of the genotype. 
Statistical significance was tested with the chi-square tool (Excel), with a p-value of 
0.005. 
 
Magnetic Bead Purification of TCR αβ T cells 
CD4+ and CD8+ TCRαβ T cells were enriched (Figure S9) from spleen and lymph node 
cell suspensions through incubation with biotinylated mAbs to CD11b (M1/70), Gr-1 
(RB6-8C5), Ter119 (Ly-76), TCRγδ (GL3), B220 (RA3-6B2), NK1.1 (PK136), followed by 
streptavidin-conjugated microbeads and autoMACS depletion according to the 
manufacturer’s instruction (Milteny Biotec, Bergisch Gladbach, Germany). The purity of T 
cells was confirmed to be >90%. 
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Summary 
 
CTCF, an 11 Zn-finger protein, is involved in long-range chromatin interactions, 
imprinting and transcriptional regulation. Recent genome-wide analyses have revealed 
~14000 CTCF-binding sites, which mark boundaries of histone modifications and might 
partition the genome in expression domains, indicating that CTCF acts as an insulator 
protein. Analyses using antibodies against CTCF mostly show CTCF in a speckled 
pattern in the interphase nucleus. Furthermore, CTCF remains associated with mitotic 
chromosomes. Here, we analyse the dynamic behaviour and localization of GFP-tagged 
CTCF. We show that this fusion protein is functional since: 1) it binds to cognate sites in 
the genome, 2) it localizes similar to endogenous CTCF, and 3) it functionally substitutes 
for CTCF in ES cells. We have generated a knock-in allele (Ctcfki) encoding GFP-CTCF 
instead of CTCF. Homozygous Ctcfki/ki mice die at birth, due to the reduced expression of 
GFP-CTCF. Heterozygous Ctcfki/+ mice are viable and fertile. We show that GFP-CTCF 
is expressed in spermatogonia, spermatocytes and Sertoli cells of intact seminiferous 
tubules, but it is not detectable in spermatids. Fluorescence-based analysis 
demonstrates that ~200,000 molecules of CTCF are present in a fibroblast nucleus, 
which are partitioned into mobile and highly immobile fractions. A similar dynamic 
behaviour of GFP-CTCF is observed in fibroblasts, ES cells and male germ cells. Thus, 
CTCF behaves independently of the epigenetic state of a cell. As the number of 
immobile CTCF molecules within a nucleus is about five-fold higher than the number of 
reported binding sites, we propose that CTCF is has additional roles besides acting as 
an insulator protein. 
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Introduction 
 
The highly conserved DNA binding protein CTCF (CCCTC-binding factor) was 
first identified as a transcriptional regulator of the chicken c-myc gene (Lobanenkov et 
al., 1990) and, independently, as the Negative Protein 1(NeP1), a chicken lysozyme 
gene silencer binding protein (Baniahmad et al., 1990). Although the name might 
suggest differently, CTCF is known to bind to sequences with a loose consensus. The 
flexibility in binding is caused by differential use of the 11 zinc fingers present in CTCF 
(Ohlsson et al., 2001). 
A major breakthrough in the functional analysis of CTCF came with the 
identification of a CTCF-binding site within the DNA hypersensitive site 4 (5’HS4) of the 
chicken beta-globin insulator (Bell et al., 1999). An insulator is defined as a DNA element 
that prevents inappropriate gene activation or repression by neighbouring chromatin, by 
blocking access of flanking elements (such as enhancers or repressors) to a given 
promoter. The CTCF binding site of the chicken beta globin insulator is essential and 
sufficient to function as an enhancer blocker. Using chromatin-conformation-capture (3C) 
technology to investigate the three dimensional conformation of the chromatin fibre, it 
was discovered that the beta-globin locus forms an active chromatin hub (ACH) in which 
three CTCF binding elements (5’ and 3’ HS and the LCR HS) aggregate (Palstra et al., 
2003). We have shown that CTCF is important for the 3D conformation of the hub and 
that absence of CTCF causes local histone modifications (Splinter et al., 2006). 
Interestingly, we have found that CTCF remains bound to specific binding sites in 
mitosis, suggesting that higher order chromatin structures need to be maintained during 
cell division (Burke et al., 2005). 
The discovery that CTCF could function as an insulator protein, when present 
between enhancer and promoter, prompted groups to search for CTCF binding sites 
within the imprinted H19/IGF2 locus. This locus, which contains the paternally 
transcribed Igf2 gene and the maternally transcribed H19 gene, has been used as a 
paradigm for enhancer blocking. An element upstream of H19, known as the Imprinting 
Control Region (ICR), is essential for blocking enhancers, located downstream of the 
H19 gene, from activating the Igf2 gene. The ICR can only inhibit Igf2 transcription in its 
maternally inherited form, free of DNA methylation. Several groups simultaneously 
identified multiple CTCF binding sites within the ICR and showed that on the maternally 
inherited chromosome CTCF binds the ICR, yielding an explanation for the enhancer 
blocked and silent Igf2 gene (Bell and Felsenfeld, 2000; Hark et al., 2000; Kanduri et al., 
2000; Szabo et al., 2000). Methylation of the paternal ICR inhibits CTCF binding, thereby 
allowing the enhancers to activate Igf2. Using 3C analysis the enhancer blocking activity 
of the CTCF-bound ICR has been explained by invoking differential types of looping in 
the maternal and paternal loci (Murrell et al., 2004). This looping model shares 
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characteristics with the ACH of the globin locus, as in both models CTCF binds to the 
elements that aggregate into a hub. However, in the beta-globin locus removal of a 
CTCF binding site destabilizes long-range interactions and causes local loss of histone 
acetylation and gain of histone methylation, but it does not lead to loss of globin 
expression (Splinter et al., 2006). Together the data positively link CTCF to chromatin 
architecture. This is supported, among others, by the observation that the nuclear matrix 
protein nucleophosmin is a CTCF binding partner and can tether CTCF-bound elements 
to the nucleolus (Yusufzai et al., 2004). 
A recent screen for CTCF binding sites in the human genome has yielded 
13,804 sites in primary human fibroblasts (Kim et al., 2007). All binding sites were 
postulated to be potential insulators. Notably, most sequences are located far from 
transcriptional start sites, yet their distribution is strongly correlated with the presence of 
genes on a given chromosome. CTCF localization was suggested to be similar in 
different cell types (Kim et al., 2007). Strikingly, the 20-bp consensus motif found in the 
majority of the sites (Kim et al., 2007) is virtually identical to a consensus sequence 
(LM2*) bound by CTCF and found in ~15,000 conserved non-coding elements in the 
human genome (Xie et al., 2007). High-resolution profiling of histone methylation in the 
human genome showed that CTCF marks boundaries of histone methylation domains 
(Barski et al., 2007). All these data are consistent with a role for CTCF as an insulator 
protein. 
In 2002 a paralogue of CTCF, named CTCF-L, or BORIS (Brother Of the 
Regulator of Imprinted Sites), was identified (Loukinov et al., 2002). Both proteins 
contain 11 zinc fingers (71% identical at the amino acid level) and can bind the same 
DNA. Interestingly, CTCF-L expression is restricted to testis. Antibody staining studies 
indicated that CTCF-L-positive spermatocytes stain negative for CTCF (Loukinov et al., 
2002), raising the hypothesis that CTCF-L could fulfil an essential function in the 
absence of CTCF. It was hypothesized that the switch from CTCF to CTCF-L expression 
corresponded with the erasure of the bulk of DNA methylation (Loukinov et al., 2002). 
Thus, CTCF and, in testis, CTCF-L, play a key role as transcriptional silencing and 
activating factors, as well as organizers of (epigenetic) chromatin domains. 
CTCF has been shown to localise to the nucleus in a speckled pattern. In 
specific cell types and/or under unusual conditions, CTCF accumulates on centrosomes 
and midbody (Zhang et al., 2000), in nucleoli (Torrano et al., 2006), adjacent to nucleoli 
(Yusufzai et al., 2004), or in other sub-nuclear structures (Kantidze et al., 2007). 
However, no dynamic analysis of CTCF has been reported yet.  
 
To examine the dynamic behaviour of CTCF in vivo we have generated mice 
and cell lines in which GFP-CTCF is expressed instead of CTCF. Contrary to published 
data we show that CTCF is expressed in spermatocytes. Furthermore, we show that 
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CTCF partitions into two fractions: a mobile pool (~30% of the protein) and an immobile 
pool (~70 %). Significantly, our data supports the localisation of CTCF on mitotic 
chromosomes (Burke et al., 2005) and reveals a proportion non-bound CTCF protein is 
retained in mitotic cells and divided between the two daughter cells during cytokinesis. 
Our data indicate that CTCF is a stable protein. The number of CTCF molecules, as 
measured by FCS and the dynamics of the protein imply the number of proposed CTCF 
binding sites is underestimated.  
 
Results 
 
Characterization of the Ctcfki allele 
To analyse the dynamic behaviour of CTCF we generated a Ctcfki allele in which 
GFP-CTCF is expressed instead of CTCF (Fig. 1A). We have used a similar strategy 
before to generate knock-in mice expressing GFP-CLIP170 (Akhmanova et al., 2005). 
Southern blot (not shown) and PCR analysis (Fig. 1B and data not shown) demonstrated 
correct targeting of the Ctcf gene and, after the action of Cre recombinase, correct 
removal of the neomycin resistance gene and one loxP site. We derived mouse 
embryonic fibroblasts (MEFs) from wild type, heterozygous and homozygous Ctcfki E13.5 
day embryos. Western blot analysis on nuclear extracts from these cells demonstrated 
that GFP-CTCF is expressed, albeit at reduced (~20 %) levels compared to endogenous 
CTCF (Fig. 1C). Similar results were obtained in Ctcfki/+embryonic stem (ES) cells, as 
well as in kidney, testis and brain extracts from adult Ctcfki/+ mice (data not shown). We 
conclude that we have replaced endogenous CTCF with GFP-CTCF, but that this results 
in reduced expression of GFP-CTCF from the modified Ctcf allele. 
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Figure 1. Characterization of the Ctcfki knock-in allele 
A) Scheme of the Ctcfki knock-in allele. The top line represents the targeting construct, with 
Ctcf exon 3 (which contains the translation initiation codon (ATG)) indicated by a box. Double-
headed arrows indicate the 5’end (3.5 kb) and 3’end (3.0 kb) homologous arms of the 
targeting construct. The insertion cassette contains GFP, loxP sites (red) and a neomycin 
resistance gene driven by the pMC1 promoter and containing a polyadenylation sequence 
(neo-pA, green). The neo gene is transcribed antisense to the Ctcf gene. Homologous 
recombination generates a CtcfKI-neo allele. Cre-mediated excision leaves GFP and one loxP 
site. As these are in-frame with CTCF encoding sequences, the Ctcfki allele is generated. 
Positions and direction of PCR primers are indicated. 
B) PCR analysis of genomic tail DNA. PCR demonstrates the presence of a homologously 
targeted Ctcfki allele in ES cells (indicated with GFP allele).  
C) Western blot analysis. Nuclear extracts of wild type (WT), heterozygous (KI/+) and 
homozygous (KI/KI) Ctcfki MEFs were analysed with antibodies against CTCF (left panel) and 
GFP (right panel). In the heterozygous MEFs both CTCF and GFP-CTCF are present, but the 
latter protein is expressed at reduced levels. 
 
Ctcfki/ki mice are not viable 
Attempts to generate homozygous Ctcfki/ki mice failed: only 1 homozygous 
Ctcfki/ki animal was obtained out of 132 offspring from Ctcfki/+ x Ctcfki/+ matings (Fig. 2A). 
This homozygous knock-in animal was much smaller than an age-matched wild type 
mouse (Fig. 2B), and it died after 3 weeks. These data show that Ctcfki/ki mice are not 
viable. In fact, the Ctcfki/+ x Ctcfki/+ crosses yielded equal percentages of wild type and 
heterozygous Ctcfki/+mice (Fig. 2A), whereas this ratio should have been 1:2. These data 
indicate that heterozygous Ctcfki/+ mice are also present in less than expected numbers. 
A similar result was obtained after crossing wild type and heterozygous Ctcfki/+ mice (Fig. 
2A), i.e. twice as many wild type animals were generated than Ctcfki/+ mice (expected 
ratio 1:1). These data raise the question of whether GFP-CTCF is a functional protein. 
However, when we analysed the genotypes of embryos at mid- to late gestation (Fig. 2A) 
the percentage of wild type, Ctcfki/+ and Ctcfki/ki embryos was ~21 % (n=20), ~60 % (n=58) 
and ~19 % (n=18), respectively. Combined these data indicate that the Ctcfki allele is 
transmitted normally and is not deleterious for embryonic development, but that once 
mice are born the Ctcfki allele causes a selective disadvantage. 
We next tested the proliferation capacity of wild type, heterozygous and 
homozygous knock-in MEFs, to examine whether presence of GFP-CTCF adversely 
affects cell growth. As shown in Fig. 2C wild type MEFs grow faster than Ctcfki/ki 
fibroblasts. The fact that Ctcfki/+ MEFs grow faster than Ctcfki/ki fibroblasts, but slower than 
wild type MEFs, indicates that a proper amount of CTCF is required for cell proliferation, 
but argues against GFP-CTCF having a dominant negative function. 
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Figure 2. Inheritance and properties of Ctcfki alelle 
(A) Inheritance of Ctcfki allele. Heterozygous Ctcfki/+ mice were either interbred or crossed to wild 
type animals. Offspring were counted after birth (upper panel), or at mid-gestation (lower panel). 
(B) Impaired development of homozygous Ctcfki/ki mice. The only homozygous Ctcfki/ki mouse 
surviving to 3 weeks is shown. It is smaller than an age-matched mouse and had apparent 
neuronal defects (shaking). 
(C) Proliferation assay. The proliferation capacity of homozygous Ctcfki/ki and heterozygous Ctcfki/+ 
MEFs was compared to that of wild type MEFs. Homozygous Ctcfki MEFs have a reduced rate of 
proliferation. 
 
 
GFP-CTCF is a functional protein 
To examine whether GFP-CTCF is functional, we performed three experiments. 
First, in MEFs we showed complete colocalization of CTCF and GFP-CTCF (data not 
shown), indicating that the fusion protein distributes normally. Second, we generated 
embryonic stem (ES) cells carrying conditional Ctcf knock-out alleles (Heath et al., 
2007). When treated with Cre recombinase these cells will delete CTCF and, as a 
consequence, they die (data not shown). We co-transfected these ES cells with GFP-
CTCF and CTCF-GFP and picked clones that survived Cre treatment. We examined 
three independent ES cell lines for CTCF and GFP-CTCF expression. Clearly in all three 
clones only the fusion protein is expressed (Fig. 3A). These data demonstrate that GFP-
CTCF can functionally substitute for CTCF in a cell survival assay. Interestingly, in all 
three clones the level of GFP-CTCF is highly similar to that of CTCF, strongly suggesting 
that cells can only grow well when appropriate amounts of CTCF are present. 
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The GFP-CTCF expressing ES cells were allowed to form small aggregated 
colonies. Under such conditions the normally round ES cell nucleus becomes highly 
irregular in shape (Fig. 3B). In most cells GFP-CTCF is localized in a speckled pattern 
throughout the nucleus and expression is reduced in the nucleolus. This distribution is 
similar to that reported for other cell types. Interestingly, we also captured images of an 
ES cell going through mitosis and could show GFP-CTCF on mitotic chromosomes, as 
reported before (Burke et al., 2005).  
 
 
Figure 3. Functionality of GFP-CTCF 
Western blot analysis of ES cells.  
(A) Wild type ES cells expressing endogenous CTCF (wt, clone 9B2) are compared to three 
independent ES cell lines that express GFP-CTCF instead of endogenous CTCF (4F1, 3G1, 
3D1). Notice that GFP-CTCF migrates at a higher position. Expression levels of GFP-CTCF 
and endogenous CTCF are similar. 
The distribution of GFP-CTCF in ES cells.  
(B) GFP-CTCF expression was imaged using confocal microscopy (three still images of a 
time-lapse movie are shown) (3B). For clarity the nuclei of two ES cells are outlined. One cell 
of the colony is going through mitosis. GFP-CTCF is seen on the mitotic chromosomes at the 
metaphase plate (arrow in left image), and moves with the chromosomes at telophase (arrows 
in middle and right images) to the daughter cells. 
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C) Chromatin immunoprecipitation (ChIP) analysis. The binding of CTCF and GFP-CTCF in 
wild type, heterozygous Ctcfki/+, and homozygous Ctcfki/ki fetal liver cells to the beta-globin-
locus was analysed by ChIP using anti-CTCF antiserum. 
 
 
Our third approach to demonstrate functionality of GFP-CTCF was to analyse 
binding of the fusion protein to established sites in the mouse beta-globin locus (Splinter 
et al., 2006). Chromatin immunoprecipiation (ChIP) indeed showed binding of CTCF 
and/or GFP-CTCF to the 3’ hypersensitive site (3’HS1) site in fetal livers derived from 
wild type, heterozygous Ctcfki/+, and homozygous Ctcfki/ki embryos (Fig. 3C). GFP-CTCF 
not only binds to this cognate site but was also shown to ChIP other sites in the globin 
locus (data not shown). We conclude that GFP-CTCF is a functional protein. 
 
 
In vivo distribution of CTCF 
It has been reported that CTCF and CTCF-L are expressed in a mutually 
exclusive manner in male germ cells (Loukinov et al., 2002). To visualize GFP-CTCF in 
live germ cells, we dissected testis tubules (with Hoechst to mark nuclei) and examined 
these at 33oC with a confocal/multiphoton set up. Previously we used this set-up to 
document expression of GFP-CLIP170 in the testis (Akhmanova et al., 2005). The 
distribution of GFP-CTCF was examined, tubules were scanned longitudinally, and 
optical sections acquired through the tubule. We observed GFP-CTCF-positive cells 
throughout the seminiferous tubule (Fig. 4A-F). In combination with Hoechst nuclear 
staining we identified cell types. Our data show that GFP-CTCF is expressed in 
spermatogonia, spermatocytes and Sertoli cells. By contrast, we could not detect GFP 
signals closer to the lumen of the tubule, in round and elongating spermatids. These 
results are in stark contrast to immunocytochemistry-based data (Loukinov et al., 2002). 
We conclude that CTCF localizes in all cells of the testis, except at later stages of 
spermatogenesis. 
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Figure 4. In vivo distribution of GFP-CTCF, GFP-CTCF expression in seminiferous tubules of 
the testis 
GFP-CTCF expression (green) is shown in conjunction with Hoechst (red), a vital DNA stain 
that was injected into the testis and which stains nuclei on the inside of the blood-testis 
barrier. In panels A-C a surface staining of CTCF is shown. In panels C-F a cross section of 
cells within the tubule is shown. Notice that GFP-CTCF protein is expressed in all nuclei, 
including those of Sertoli cells (recognizable in panels A-C by the large Hoechst-positive dot 
inside the nucleus). However, GFP-CTCF is notably absent from round spermatids (panels D-
F, small nuclei, again recognizable by the large Hoechst-positive dot). 
 
 
Dynamic behaviour of CTCF 
Using fluorescence recovery after photobleaching (FRAP) and fluorescence 
correlation spectroscopy (FCS) approaches (Bacia et al., 2006), we next analysed the 
dynamic behaviour of GFP-CTCF in cultured cells (Fig. 5) and in intact seminiferous 
tubules of the testis (data not shown). Both approaches revealed that a large percentage 
of CTCF (60-70 %) is immobile. Using FCS we calculated a concentration of ~200nM of 
GFP-CTCF inside a fibroblast nucleus. Given the fact that GFP-CTCF is expressed at 
~20% of endogenous CTCF, this corresponds to about 200,000 molecules of CTCF 
inside a fibroblast nucleus. 
With FRAP similar patterns of recovery were observed in homozygous and 
heterozygous knock-in MEFs (Fig. 5B), suggesting that the presence of endogenous 
CTCF does not affect the dynamic behaviour of GFP-CTCF. Furthermore, a similar 
behaviour was detected in MEFs and ES cells (Fig. 5) and in cells of the seminiferous 
tubule (data not shown). These data suggest that the dynamic behaviour of CTCF is not 
affected by epigenetic state of the cells. 
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Figure 5. FRAP analysis 
FRAP in MEFs. Heterozygous Ctcfki/+ and homozygous Ctcfki/ki MEFs were analysed by FRAP. In 
(A) the GFP-CTCF distribution is in MEFs shown, notice the granular staining pattern and the 
apparent exclusion from the nucleolus. The crosshair indicates the position of the bleach.  
In (B) fluorescent recovery of GFP-CTCF is shown in heterozygous Ctcfki/+ (red) and homozygous 
Ctcfki/ki (green) MEFs. Approximately 70% of the total pool of GFP-CTCF does not recover within 
the time frame of the experiment. FRAP in ES cells.  
(C, D) Two ES cell lines expressing GFP-CTCF were analysed by FRAP. Approximately 60 % of 
the total pool of GFP-CTCF remains immobile for the duration of the experiment. 
 
 
Discussion 
Here, we have analysed the dynamic behaviour and in vivo distribution of CTCF, 
tagged with GFP. We wanted to address three questions. First, CTCF was reported to be 
absent from spermatocytes and was not detected in Sertoli cells (Loukinov et al., 2002). 
However, the latter is very odd given the essential function of CTCF in virtually all cell 
types. Using the GFP-CTCF knock-in mice we wanted to address this issue. Second, 
recent reports emphasize a role for CTCF as an insulator (Barski et al., 2007; Kim et al., 
2007; Xie et al., 2007), however, nothing is known about its dynamic behaviour. Third, 
we wished to calculate the number of CTCF molecules present in a nucleus.  
Based on the successful analysis of GFP-CLIP170 knock-in mice (Akhmanova 
et al., 2005), we decided to use a similar strategy to generate GFP-CTCF expressing 
knock-in animals. However, we found that the amount of GFP-CTCF in knock-in cells 
and tissues was reduced to approximately 20 % of the level of endogenous CTCF based 
on western blot data. Western blot analysis was performed using a CTCF antibody with 
an N-terminus epitope. Although recognition of GFP-CTCF protein could be sub-optimal 
due to the antibody used, and therefore indicate lower expression than actual levels, we 
show other phenotypes that suggest low expression of CTCF occurs. CTCF has been 
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described to function in a dose-dependent manner in T-cells in vivo (Heath et al, 
manuscript in preparation). Heterozygous GFP-CTCF MEFs have reduced rates of 
proliferation compared to WT, but undergo greater expansion than homozygous GFP-
CTCF MEFs. Interestingly, the inheritance of GFP-CTCF alleles in mice is strikingly 
similar to that of a CTCF knock out allele (Fig 2a, H Heath unpublished observations). 
Northern blot data suggest reduced levels of GFP-CTCF protein is not due to a reduction 
in the level of GFP-CTCF encoding mRNA (not shown). Thus, either GFP-CTCF is less 
stable than CTCF, or the fusion protein is produced less efficiently. Further research is 
required to distinguish between these options. 
Ctcfki/ki mice are not viable. We think this is largely due to the fact that GFP-
CTCF is present in reduced amounts. Alternatively, GFP-CTCF may have a dominant 
negative effect. However, the fact that GFP-CTCF can fully substitute for CTCF in ES 
cells argues against such a scenario. Furthermore, out of 24 backcrosses of 
heterozygous Ctcf+/- knockout mice (Heath et al., 2007) to C57Bl6 wild type mice we 
obtained 101 wild type offspring and 74 Ctcf+/- knockout offspring (H. Heath, unpublished 
observations). Thus, also when the Ctcf gene is deleted heterozygous animals are 
apparently at a selective disadvantage. These data strongly suggest that the amount of 
CTCF is important for normal animal survival. 
 Using heterozygous Ctcfki/+ knock-in mice we analysed expression of GFP-
CTCF in seminiferous tubules of the testis. We detected GFP-CTCF in all cells of the 
tubule, except in germ cells undergoing spermiogenesis (i.e. from the round spermatid 
stage onward). We believe this localization pattern reflects the true distribution of CTCF, 
as we did not fix tissues and did not have to employ antibodies to examine localization. A 
distribution of CTCF as described here is logical: CTCF is necessary in all cells of the 
body, including Sertoli cells and spermatogonia. However, in cells that start to actively 
compact their DNA and undergo replacement of their histones first with transition 
proteins and, subsequently, with protamines, CTCF is not required. Thus, the mutually 
exclusive expression of CTCF and CTCF-L is incorrect – however, the hypothesis that 
these proteins compete for binding sites on the DNA of male germ cells may still be 
correct. 
 Our live analysis in ES cells showed that CTCF is indeed localized on mitotic 
chromosomes, as previously reported (Burke et al., 2005). However, we did not detect 
GFP-CTCF on centrosomes (Zhang et al., 2004); this may be a special localization of 
CTCF in immortal cell lines. Furthermore, unlike in K562 cells (Torrano et al., 2005), we 
did not detect enrichment of CTCF on nucleoli of ES cells. Instead, in all cells tested, 
CTCF distributed in a speckled pattern. We could distinguish two fractions: ~30 % of 
CTCF was mobile, whereas ~70 % of the protein was immobile. The latter behavior 
explains the difficulties investigators might have in isolating the protein from nuclear 
extracts. 
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The number of CTCF molecules inside a fibroblast nucleus is ~200.000. Recent 
genome-wide analyses have revealed ~20,000 binding sites for CTCF within the human 
and mouse genomes (Kim et al., 2007; Xie et al., 2007). Thus, the number of CTCF 
molecules largely exceeds the number of binding sites (~40,000 in a diploid cell). In 
future experiments we will specifically investigate two possible explanations for this 
discrepancy. First, it is possible that the 20,000 binding sites that were reported are only 
a subset of the total number of CTCF binding sites. However, it appears unlikely that 
there are five times more sites. The second possibility is that CTCF has additional roles 
besides acting as an insulator. It will be interesting to determine whether the mobile and 
immobile pools of CTCF have different roles or that these pools do exchange but at very 
low rates. It is striking that the dynamic behavior of CTCF is so independent of 
epigenetic state of the cell. This observation also requires further research. 
 
Materials and Methods 
Molecular biology and antibodies 
DNA, RNA and protein isolations were essentially performed according to standard 
procedures (Sambrook et al., 1989). Southern, northern and western blot analyses were 
performed as described (Hoogenraad et al., 2002). PCR analysis was using oligos as 
described in figure 1. Chromatin immunoprecipiation (ChIP) protocols have been 
described (Splinter et al., 2006). Antibodies against CTCF are published elsewhere 
(Heath et al., 2007). Anti-GFP antibodies were purchased from Abcam. Secondary 
antisera were alkaline phosphatase-labeled anti-rabbit and anti-mouse antibodies 
(Sigma). 
 
Generation of GFP-CTCF knock-in allele, mice and mouse embryonic fibroblasts 
Based on a previously published strategy (Akhmanova et al., 2005) we generated the 
Ctcfki allele, in which GFP-CTCF is expressed instead of CTCF. The same mouse PAC 
clones from female 129S6/SvevTac mouse spleen genomic DNA (Osoegawa et al., 
2000) as previously used to generate the Ctcf knockout constructs (Heath et al., 2007) 
were now used to insert a GFP-lox-neo-lox casette into the ATG translation initiation 
codon on Ctcf exon 3. Targeting of embryonic stem (ES) cells, and selection and 
identification of the positive clones was performed as described previously (Hoogenraad 
et al., 2002). One targeted ES cell clone with the correct karyotype was chosen to 
convert the knockout allele into a GFP-CTCF knock-in allele by Cre-mediated 
recombination in ES cells. Heterozygous GFP-CTCF knock-in ES cells were injected into 
C57Bl/6 blastocysts. Chimeric males were mated to C57Bl/6 females to obtain germ line 
transmission of the modified allele. Mouse genotyping was routinely performed by PCR. 
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Generation of GFP-CTCF expressing ES cells 
ES cells with a floxed Ctcf allele were derived from female conditional Ctcf knockout 
mice (Heath et al., 2007). These cells were infected with a lentivral construct expressing 
Cre recombinase in combination with GFP-CTCF (F. Sleutels, manuscript in 
preparation). Thus, while the endogenous Ctcf allele is deleted cells can be rescued by 
expressing “transgenic” GFP-CTCF. Several ES cell lines were isolated and analyzed. 
 
Time lapse imaging 
The fluorescence live imaging of cultured somatic cells and of testis tubules was 
performed as described (Akhmanova et al., 2005). When required, 5 μg/ml Hoechst 
33342 (Molecular Probes) was added. In this incubation system, the Hoechst stain is 
taken up only by nuclei on the basal side of the Sertoli cell barrier (also called “blood-
testis barrier”). This allows for identification of all cells on the basal side of this barrier: 
peritubular cells, Sertoli cells, spermatogonia, and preleptotene spermatocytes. When 
applicable, the testis was injected through the rete testis with Hoechst 33342 and Trypan 
blue (Sigma) in 3-5 μl PBS, one hour prior to testis dissection, to allow spreading of the 
vital DNA stain throughout the adluminal compartment of the testis tubules and uptake 
by nuclei on the adluminal side of the Sertoli cell barrier.This method makes it possible to 
identify the germ cell types that have migrated through the Sertoli cell barrier. The testis 
tubules were examined at 330C, using a Zeiss LSM510NLO confocal/multiphoton set up, 
to allow simultaneous acquisition of phase-contrast, GFP and Hoechst images. 
 
Fluorescence-based biophysical measurements 
Fluorescence recovery after photobleaching (FRAP) was carried out with the 63x 
planapochromat (1.4 NA) oil immersion lens as described (Akhmanova et al., 2005). 
Bleaching of an outlined region of interest (ROI) was done with several iterations of the 
488 nm laser at full transmission (2.6 mW). Prior to and after bleaching the laser was set 
at 2% transmission (55 µW). The Zeiss LSM software was used to measure pixel 
intensities inside different ROIs. Recovery values were normalized to the prebleach 
values for each ROI. Values were imported into Aabel (Gigawiz) for graphical 
representation and statistical analysis. 
Fluorescence correlation spectroscopy (FCS) measurements were conducted 
as described previously (Drabek et al., 2006) in MEFs expressing GFP-CTCF. For these 
FCS experiments we used the LSM 510-Confocor II (Zeiss) and the 488nm Ar-laser 
(beampath: HFT488-Mirror-BP505-550). The system was calibrated with rhodamine 6G 
(diffusion coefficient: 28x10-10 m2/s at 20 ºC). 
Using FCS we calculated that approximately 20 molecules of GFP-CTCF are 
present in the FCS measurement volume of 0.25 fl. To calculate the total number of 
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CTCF molecules in a nucleus we assumed that GFP-CTCF is expressed at about 20 % 
of the level of CTCF and that a nucleus has a radius of 5 micrometeres. 
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Chapter 7: General discussion and future directions 
 
What does CTCF do and what have we learnt? 
 
The CTCF protein is known to be required for embryonic development, cell cycle 
progression, regulation of transcriptional activity, imprinted gene expression and X-
inactivation in conjunction with its role as a mediator of chromatin structure, histone 
modifications, chromatin interactions in cis and chromosome interactions in trans. The 
fact that one single protein has such diverse functional roles makes it difficult to tease 
out its function in distinct cellular events.  
In this thesis we focused upon studies where the Ctcf gene has been deleted in 
a spatial and temporal manner from two different cell lineages. Such studies have not yet 
been reported. By conditional deletion analysis, we show that cellular expansion and 
differentiation in vivo is CTCF dependent. Surprisingly, our studies have revealed several 
key cellular processes that do not appear to require CTCF. We also address questions 
regarding levels of CTCF protein within the cell and suggest that a critical level of CTCF 
is required for development and cellular function.  
 
CTCF as a tumour-suppressor gene 
 
The current information regarding the potential tumour-suppressor function of 
CTCF comes from analysis in human cells. CTCF maps to the long arm of chromosome 
16, in a region frequently deleted in sporadic breast and prostate tumours, 16q22.1 
(Filippova et al. 1998). The binding of CTCF to promoter regions of tumour suppressor 
genes Brac1 and retinoblastoma (Rb) prevents the acquisition of methylation and 
repression (De La Rosa-Velazquez et al. 2007, Butcher et al. 2004). However, several 
studies have failed to ascertain correlations between the loss or aberrant expression of 
CTCF and tumour progression (reviewed in Recillas-Targa et al. 2006). To date, it is 
unknown if CTCF has the same potential function in mice. In our studies, we found no 
evidence of obvious tumours in heterozygous CTCF mice, nor the development of 
lymphoma in mice with CTCF depleted T-cells. CTCF is expressed in both mouse and 
human tumour-cell lines (MEL cells and HeLa cells), however it is not known if CTCF still 
interacts with critical target sites, such as PIM1, p16INK4a, Rb. ChIP experiments to 
determine CTCF interaction with these loci would be very interesting. Changes in DNA 
methylation may occur at promoter regions in the mouse genome as have been 
demonstrated in human cells. Preliminary experiments suggest that global patterns of 
DNA methylation (rDNA locus, H. Heath unpublished observations) do not change in 
CTCF deficient murine cells. Bisulphate sequencing of specific loci would allow a more 
sensitive detection of potential changes in methylation patterns.  
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In mice, especially in lymphoid cells, the proto-oncogene c-myc requires tight 
regulation. Transgenic mice over-expressing c-myc are susceptible to both B- and T-cell 
lymphomas, whereas T-cell specific deletion of c-myc induces developmental arrest at 
the DN3 stage (Adams et al. 1985, Spanopoulou et al.1989, Stewart et al 1993).  CTCF 
was originally identified as a transcriptional repressor of c-myc (Lobanenkov et al. 1990) 
and increased expression of CTCF in WEHI 231 B-cell lymphoma cultures induced the 
down-regulation of c-myc expression (Qi et al, 2003). Significantly, in T-cells where the 
CTCF gene had been conditionally deleted, we saw no evidence of lymphoma in aged 
mice (45 weeks) or mis-regulated c-myc expression. CTCF binding sites in c-myc 
regulatory regions are conserved between human and mice. It is not known if these 
binding sites acquire methylation in the absence of CTCF, or indeed if CTCF remains 
bound when c-myc is activated and therefore transcriptional regulation could be 
mediated by co-activating/repressing complexes together with CTCF. Importantly, 
inducible activation of lck-c-mycER in transgenic mice indicated no significant alterations 
in the proportions of thymocyte subsets comparing mice treated or not with 4-hydroxy-
tamoxifen (4-OHT). This indicates the consequences of c-myc activation in T-
lymphocytes may be a reflection of the effects on c-myc target genes following 
constitutive over-expression of c-myc that manifest as malignancies (Rudolph et al. 
2000). Lck-Cre-mediated deletion of CTCF in T-cells induced a developmental block at 
the ISP stage due to an arrest at G1, and in vitro proliferation of peripheral T-cells was 
impaired in cells derived from CTCFlox/loxCD4Cre mice. This does not correlate with de-
repression of c-myc, a growth-promoting factor. On the contrary, inhibition of c-myc is 
known to prevent lymphocytes entering S-phase (Heikkila et al. 1987). Taken together 
this suggests that in T-cells at least, the loss of CTCF does not directly activate c-myc 
mRNA expression, nor induce T-cell lymphomas. It will be interesting to see if c-myc 
expression is mis-regulated in the absence of CTCF in other conditional systems that by-
pass the use of transformed cell lines. Mouse embryonic fibroblasts derived from 
CTCFlox/lox mice infected with Cre-expressing lenti-virus also fail to proliferate and do not 
have increased expression of c-myc (F. Sleutels and S. vd Nobelen unpublished 
observations).  
Mutations in p53 and the cyclin-dependent kinase (CDK) inhibitor p27 
(CDKN1B) are also associated with tumour progression in mice (Philipp-Staheli et 
al.2004). The down-regulation of nuclear p27 or cytosolic sequestering is frequently 
associated with tumours, particularly in conjunction with the loss of p53. In the absence 
of CTCF, no significant effect on p53 mRNA expression was observed in thymocytes and 
expression of both p27 and p21 increased compared to wt cells. The expression of p27 
and p21 is high in normal quiescent T-cells and must be down-regulated to allow 
transition from G1 to S-phase (Tsukiyama et al. 2001, Wolfraim et al. 2004). The elevated 
expression of p27 in CTCF deficient thymocytes might inhibit the development of 
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tumours, if CTCF was to be involved in T-cell lymphoma progression. It is unknown if 
p27 or p21 expression is elevated in peripheral T-cells and it remains to be seen if CTCF 
is a direct transcriptional repressor of p27 in thymocytes. CTCF expression is increased 
in activated/proliferating cells (Herblot et al. 1999), which could indicate the up-regulation 
of CTCF potentially controls p27 expression, perhaps via recruitment of repressive 
chromatin modifying complexes. CTCF has been reported to interact with histone 
deacetylases, although this has not been verified in T-cells. Alternatively, CTCF could 
initiate/promote the degradation of p27 by triggering appropriate pathways, however this 
is merely a suggestion as there is currently no evidence of CTCF-mediated degradation 
of any proteins. The related CDK-inhibitor p21 is a transcriptional target of p53 also 
associated with tumour-suppressor activity although to a lesser extent that p27. In 
contrast to T-cells, p27 expression is not elevated in CTCF deficient MEFs, although p21 
expression is up-regulated consistent with a proliferation defect in these cells (S. vd 
Nobelen unpublished observations). This could indicate differential regulatory pathways 
in these distinct cell types. Cell-cycle inhibition of p21 and p27 occurs via binding of 
cyclin/CDKs preventing cell-cycle progression. An increased level of p21 mRNA 
expression is an effect most often mediated by low levels of c-myc. However, it is not 
likely that increased expression of p21 reflects decreased c-myc expression in the 
absence of CTCF as no dramatic effect on c-myc mRNA expression was detected in 
CTCF deficient thymocytes by RT-PCR. A genome-wide analysis of CTCF binding sites 
in human cells revealed four sites around the p21 promoter (Barski et al. 2007). The 
corresponding region in MEFs also binds CTCF as indicated by ChIP (S. vd Nobelen 
unpublished observations). These data indicate that the p21 gene is a direct target of 
CTCF. 
 
 
Cell proliferation, differentiation and locus-specific gene expression in the 
absence of CTCF 
Data presented in this thesis show that CTCF is a key regulator of chromatin 
structure at the β-globin locus and is necessary for cellular expansion, cytokine 
expression and the functional capacity of T-cells in vivo. However a number of key 
regulatory processes apparently occur in a CTCF-independent manner. 
 
Normal expansion of T-cells in the thymus requires CTCF 
 
CTCF is expressed at every stage of T-cell development, as determined by GFP 
expression from heterozygous knock-in mice. In CTCFlox/loxLck-Cre mice, defective 
thymocyte differentiation is evident by a dramatic decrease in the total number of 
thymocytes, an increased number of cells at the DN-to-ISP stage and a significant 
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reduction in DP cells. The transition between DN and DP cells proceeds through the ISP 
intermediate, which requires correct preTCR expression and signaling, functional 
rearrangement of Tcrβ genes (β-selection), rapid proliferation, and - in mice - activation 
of Cd8 expression.  Each of these regulatory events is mediated by changes in 
chromatin remodeling and histone modifications, DNA methylation and even dynamic 
positioning of chromatin in nuclear space (Krangel, 2007). Careful analysis of these 
processes revealed no apparent defects in the absence of CTCF - determined by RT-
PCR - with the exception of proliferative capacity. Tcr genes are formed by somatic 
recombination of different gene segments and expression of the four different Tcr types 
requires developmental coordination. CTCF-dependent and independent insulator 
sequences are present on the Tcrα/δ locus (Magdinier et al. 2004). The expression of 
neither Tcrα nor δ genes is aberrantly regulated in the absence of CTCF, suggesting 
other unknown proteins are responsible for spatial and temporal coordinated expression 
of this locus.  
Subsets of thymocytes (DN, ISP, DP/CD4+SP) analysed by RT-PCR revealed 
elevated expression of p21 and p27 mRNA in CTCF-/- ISP cells, consistent with the 
observed arrest in G1. Interestingly, a number of other studies have highlighted 
phenotypes similar to CTCF deficiency in T-cells. The bHLH factor HEB and Lsh1, a 
member of the SNF2 family of chromatin remodeling factors, are both required for the 
DN-to-DP transition (Barndt et al. 2000, Geiman et al. 2000). The phenotypic similarities 
between these mutants and CTCFlox/loxLck-Cre mice are suggestive of a role for CTCF in 
mediating the expression or functional capacity of these proteins. However there is 
currently no evidence for this. Interestingly, TCF1, a T-cell specific HMG box protein, has 
been identified in CTCF-biotin tagged pull-downs using nuclear extracts from thymus (S 
vd Nobelen unpublished observations). The functional significance of this interaction 
remains to be verified and analysed in vivo. TCF1 is important for expression of Tcrα 
genes (Roberts et al. 1997), however Tcrα gene expression is not impaired in the 
absence of CTCF. These studies indicate that an intricate network of factors function 
coordinately to regulate T-cell differentiation. Importantly, it also suggests T-cell 
differentiation and gene regulation in T-cells requires more than CTCF per se and CTCF 
is not able to rescue or compensate for defects in factors such as HEB or Lsh1 assuming 
CTCF is unaffected in these mutants. 
Despite the profound developmental block at the ISP stage, T-cell development 
can proceed in CTCFlox/loxLck-Cre mice and cells can migrate from the thymus and 
populate the peripheral lymphoid tissues, albeit in very low numbers. CTCF mRNA was 
strongly reduced in a pool of all DN stages and absent in CTCF-/- thymocytes by the ISP 
stage. However we have observed that loss of CTCF protein as detected by western blot 
occurs only 3-4 days after initiation of recombination, therefore CTCF is a highly stable 
protein. It is possible that residual CTCF remains in developing thymocytes long enough 
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to support progression through the various checkpoints in the thymus (chapter 5). 
Importantly, the presence of mutant mature cells in the periphery indicates CTCF is not 
required for survival of these cells.  
The Cd4 and Cd8 loci require coordinated and dynamic changes in chromatin 
modifications to allow the correct expression of the genes that characterize the different 
developmental stages of thymocyte development. Significantly, the expression of neither 
Cd4 nor Cd8 appears to be mis-regulated in the absence of CTCF. The Runx1 and 
Runx3 transcription factors are highly implicated in the regulation of Cd4 expression 
(Taniuchi et al. 2002). Interestingly, Runx factors mediate silencing of Cd4 through 
binding to the nuclear matrix and attracting repressive histone modifying complexes in a 
manner similar to CTCF.  CTCF is not known to interact with or regulate the expression 
of Runx factors, nor interact with enhancers required for Cd8 expression (Sato et al. 
2005). CTCF binding sites within the Cd4 and Cd8 loci have not been identified. 
 
 
CTCF is required for TH2-mediated responses in vivo and distinct activation 
pathways and cytokine expression in vitro 
 
Recombination of Ctcf after β-selection increased the numbers of CTCF-/- cells in the 
periphery, presumably because CTCF is necessary for the highly proliferative stages of 
thymocyte development around β-selection, but may not affect the less proliferative later 
stages. We analysed the functional capacity of CTCF-/- peripheral CD4+ cells by ELISA, 
measuring the concentration of T-helper dependent immunoglobulins (IgGs) in serum. 
Levels of the Th-2 dependent IgG1 were significantly reduced and levels of the Th-1 
dependent IgG2a was slightly lower in CTCF mutant mice. This strongly suggested Th-2 
cells in particular were not functional. Th-2 cells are key mediators of humoral immunity 
that requires activation of B-cells and regulates the response to allergens. Induction of 
an allergic response as measured by serum levels of IgE following immunisation with 
TNP-KLH was defective in the absence of CTCF. Further analysis of CTCF deficient 
mice is required to ascertain the specific defects presented. It would be of interest to 
challenge CTCF mutant mice with Th-1 inducing pathogens as IGg2a levels were also 
slightly reduced in the ELISA, and expression of Th-1 dependent factors STAT4, T-bet 
and Ifn-γ are also reduced.  
 
 The differentiation of naïve T-cells into distinct effector cells is characterized by 
restricted transcription factor expression profiles, DNA methylation and changes in 
chromatin structure. Histone modification patterns reveal the restricted expression profile 
of Il4 is set in the thymus in conjunction with CD4+/CD8+ lineage choice. It is not clear if 
the correct epigenetic modifications are made in CTCF -/- thymocytes, and whether or 
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not CD8+ cells can express IL-4. T-helper cells are characterized by differential cytokine 
expression. In CTCF depleted T-helper cells, the expression of signature Th-2 cytokines 
is almost absent and Th-1 cells express reduced levels of Ifn-γ. Differentiation of naïve 
CD4+ cells into Th-2 cells is accompanied by replication-dependent demethylation of 
CpG sites within the Il4/Il13 locus (Lee et al. 2002). The DNA-binding capacity of CTCF 
is methylation sensitive, therefore if CTCF interacts directly with the promoters of Th-2 
cytokine genes, this would occur as a result of activation. Demethylation may be 
triggered by or require IL-4R signaling, as DNA methylation is retained in both primary 
CD4+ and CD8+ cells activated in non-polarising conditions. DNA methylation is a critical 
epigenetic mediator of cytokine expression. Both CD4+ and CD8+ cells express IL-4 in 
the absence of Dnmt1 (Makar et al. 2003). In the absence of CTCF both Th-1 and Th-2 
cells fail to proliferate efficiently in vitro when activated by anti CD3/anti CD28.  It is 
possible that the Il4/Il13 locus in CTCF -/- cells remains methylated due to reduced 
replication-dependent demethylation. In this case, the activation of Il4, Il5 and Il13 may 
not be directly dependent on CTCF. Proliferative signals perhaps mediated by CTCF 
may trigger demethylation of the locus.  
 
The molecular basis for CTCF-mediated cytokine expression remains elusive. 
The particular T-helper defects may reflect specific CTCF-protein complexes or target 
genes not required at earlier stages. GATA3 is a key regulator of both direct 
transcriptional activation and chromatin structure of the Il4/Il13 locus. In the absence of 
CTCF, GATA3 protein was not induced. It is unlikely that CTCF directly activates Gata3 
transcription given that expression of Gata3 mRNA was not significantly different 
comparing WT and knock out cells. When stimulated by αCD3ε/αCD28, which mimics 
TCR signaling, elevated levels of STAT4 repressed the expression of GATA3 possibly 
via T-bet. However, when PMA/ionomycin was used the induction of GATA3 recovered. 
This situation is similar to effects seen when T-bet is ectopically expressed in Th-2 cells. 
Activation by PMA/ionomycin induced a strong increase in T-bet-mediated Ifn-γ 
production but Ifn-γ expression was only weakly increased when stimulating with IL-12-Il-
18 or OVA/APC (Afkarian et al. 2002). PMA therefore bypasses the effect of a factor in 
either TCR or cytokine-induced pathways. Antigen-APC or cytokine stimulation induces 
STAT4 dependent Ifn-γ production, whereas PMA/ionomycin induces STAT4 
independent Ifn-γ production. In a similar model, PMA/ionomycin could circumvent the 
need for STAT6 activation of GATA3.  
Importantly, even in the presence of GATA3, the expression of Il-4, -5 and -13 
remained low in CTCF deficient cells. This suggests that factors besides GATA3 are 
required for cytokine expression in the absence of CTCF. GATA-3 and STAT6 are 
known to regulate chromatin interactions in cis at the Il4/Il13 locus that mediate cytokine 
expression. SATB1 also forms chromatin loops along this region, and is required for 
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cytokine transcriptional activity (Cai et al. 2006, Spilianakis et al. 2004). The study by Cai 
et al suggest GATA3/STAT6 looping reflects a poised chromatin state that is insufficient 
to induce expression of cytokines, and instead propose that SATB1-mediated c-Maf 
expression directs the transcription of Il4, Il5 and Il13. The higher order transcriptionally 
active chromatin configuration at this locus requires SATB1, c-Maf and RNA pol II. In 
CTCF -/- PMA/ionomycin stimulated Th-2 cells, SATB1 is expressed as revealed by 
western blot. However we do not know if SATB1-mediated loops are retained or if 
SATB1 is functional in CTCF deficient cells. SATB1 is required for c-Maf activity, and 
although we have not demonstrated this, it is unlikely that c-Maf is not induced in the 
presence of SATB1. CTCF itself is necessary for the formation of chromatin loops in cis, 
although CTCF is not yet known to be necessary for chromatin loops at this locus. 
Database analysis of CTCF binding sites at the Il4/Il13 locus in humans reveals strong 
binding sites flanking the locus, but only weak if any potential binding sites within the 
locus, including the Th-2 LCR (figure 7.1). It is reasonable to suggest this pattern of 
binding sites is also present in mice, but this remains to be verified by chromatin 
immunoprecipitation.  
 
 
 
 
Figure 7.1: A schematic representation of predicted CTCF and SATB1 binding sites in 
the TH2 locus. 
 
Transcriptional orientation is indicated by horizontal arrows. Vertical arrows indicate SatB1 
binding sites (see text for details). Vertical lines indicate potential CTCF binding sites. The 
height of vertical lines is indicative of the confidence CTCF will bind at that position (Barski et 
al. 2007). Position of the binding sites is approximate. Position of CTCF-binding sites was 
obtained from human T cells (Barski et al. 2007), whereas SATB1-binding sites were obtained 
from mouse T cells (Cai et al. 2006). 
 
The different effects of stimulation via the TCR or bypassing the TCR with 
PMA/ionomycin suggests signaling from the TCR is impaired in the absence of CTCF. It 
is not clear if this is a question of thresholds and whether CTCF -/- cells could respond to 
TCR-derived signals if the intensity of this was increased. The expression of TCRβ and 
CD3 is equivalent in WT and CTCF deficient cells as measured by FACS. This suggests 
there is no obvious discrepancy regarding the number of TCRs present on the cell 
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surface. RT-PCR analysis of signaling molecules required immediately downstream of 
the TCR indicated no significant difference in expression between control and CTCF 
mutant CD4+ cells. Signal cascades are often mediated by phosphorylation, and it 
remains unknown if this occurs in the absence of CTCF. Western blot analysis of CTCF 
deficient cells with phosphorylation-specific antibodies would be required to analyse this.  
 
 
Figure 7.2: A simplified scheme of TCR-mediated intracellular signaling.  
Based on (Janeway et al. Immunobiology 6th edition, Garland Science Publishing 2005).  
 
Preliminary experiments suggest a solo effect of ionomycin-derived signals is sufficient 
to ‘rescue’ cell division and GATA3 expression in the absence of CTCF. Stimulation of 
CTCF knock out cells with αCD3ε/PMA did not support proliferation or GATA3 
expression. PMA and ionomycin activate the Ras/MAPk pathway and calcium signals 
respectively (fig 7.2). Importantly, within a cell, pathways as depicted in figure 7.2 will not 
work independently, but invariably will share regulatory factors and influence each other. 
Ionomycin induces calcineurin/NF-AT -regulated transcription factors, which are probably 
responsible for chromatin remodeling and/or GATA3 induction in the absence of CTCF 
and possibly in the absence of STAT6 signals, although this remains to be verified. Ras-
Erk signals are required for the DN-DP transition that is impaired in the absence of 
TCR activation
        Tyrosine-P Lck/Fyn 
          Activation of ζ-chain assoc protein Zap-70 
Zap-70 phosphorylates LAT and SLP-76 
SLP-76 activates phospholipase C-γ (PLC- γ),                               
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CTCF. However, in human corneal epithelial (HCE) and myeloid cells, CTCF is activated 
by Erk signals and down-regulated by cellular stress such as UV irradiation or hyper-
osmotic stress (Li. 2007). Stress-induced activation of NFκB is proposed to regulate the 
repression of CTCF as this is reversed in the presence of NFκB inhibitors. The 
interleukin 1 receptor-associated kinase (IRAK) family activate NFκB via Toll-like 
receptors. The only lymphoid specific factor known to be a direct target of CTCF is Irak2 
(Kuzmin et al. 2005). CTCF was shown to bind to the Irak2 promoter and directly activate 
Irak2 transcription in human cells. Preliminary analysis by quantitative RT-PCR indicates 
this function of CTCF is conserved in mice (H. Heath unpublished observations). The 
IRAK family of proteins are important regulators of immune responses; IRAK4 is a critical 
regulatory factor of innate and acquired immunity (Suzuki et al. 2006). CTCF binding 
sites in the IRAK4 promoter remain to be established. The link between CTCF and Irak2 
could suggest CTCF may be involved in signaling for the activation of NFκB but not NF-
AT and explain why CTCF deficient T-cells respond to ionomycin but not PMA activation. 
A comparison of NFκB and NF-AT expression in WT and CTCF deficient CD4+ cells by 
western blot is required in the first instance. The significance of CTCF-mediated down 
regulation of Irak2 in mice is currently unknown. Irak2 induces pro-apoptotic signals via 
caspase 8 in response to Yersinia infections and LPS. It would be of interest to challenge 
CTCF mutant mice with inflammatory pathogens.  
 
 
CTCF is not required for the development and proliferation of γδ-T-cells 
 
CTCF is expressed in γδ T-cells as shown by GFP-CTCF expression and the 
Ctcf gene in γδ T-cells can be recombined in an LCK-Cre-mediated manner as 
demonstrated by lacZ expression. The LCK-Cre transgene is active at the DN1 stage 
prior to αβ/γδ fate decisions in thymus (Shimizu et al. 2001). Initial attempts to analyse 
the proliferation and cytokine expression of CTCFlox/loxLck-Cre -/- CD4+ cells in vitro 
generated cultures producing high levels of Ifn-γ even in Th-2 conditions. FACS analysis 
of these cultures after 7 days revealed a substantial proportion of γδ T-cells were 
conditionally deleted as shown by lacZ expression and western blot, despite initial MACS 
purification for CD4+ cells. In the absence of CTCF, γδ T-cells have a proliferative 
advantage over CD4+ and CD8+ cells in vitro. However the molecular mechanism behind 
this and whether CTCF deficient γδ T-cells are functional in vivo is unknown. In humans, 
γδ T-cells are sensitive to activation-induced cell death, and standard mitogen-activated 
culturing is not suitable for γδ T-cell expansion (Guo et al. 2002, Lamb et al. 2005). 
Preferential expression of the IL-15Rα opposed to IL-2Rα alters the responsiveness of 
γδ-T-cells to IL-2 mediated apoptosis. Interestingly, in mice, IL-2 is an activator of CTCF 
in vitro and in vivo (Herblot et al. 1999). Normal activation-induced cell death could be a 
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response to CTCF rather than IL-2 signalling, and in the absence of CTCF γδ T-cells may 
be protected. It would be interesting to see if CTCF deficient γδ T-cells express IL-15Rα. 
The only cell surface marker for γδ T-cells is the TCRγδ itself. This suggests that Tcr-γ 
and -δ loci rearrange in a CTCF-independent manner.  
γδ T-cells in humans and mice are important for anti-tumour 
immunosurveillance. Intradermal injections of chemical mutagens or tumour cells, or 
application of chemical carcinogens to the skin induce the development of tumours more 
rapidly in mice without γδ T-cells (Girardi et al. 2001). It is unknown whether CTCF 
deficient γδ T-cells can still mediate the progression of tumour development. In the future 
this would be an interesting experiment incorporating the functional capacity of CTCF 
deficient γδ T-cells and the tumour-suppressor function of CTCF.  
The characteristic cytokines of γδ T-cells are Ifn-γ and Il-17. Il-17 is also the characteristic 
cytokine of the proinflammatory Th-17 cells (Laurence & O’Shea. 2007).  Preliminary 
experiments suggest Il-17 can be expressed in γδ T-cells in the absence of CTCF, but 
this needs to be verified and checked with intracellular FACS. γδ T-cells were the first 
cells identified in this study to proliferate in a CTCF-independent manner. Understanding 
why γδ T-cells can proliferate in the absence of CTCF would be very important. 
Microarray analysis of γδ T-cells would be useful in terms of identifying CTCF target 
genes. However, analysis of the potential functional capacity of γδ T-cells that lack CTCF 
would be of most interest. Equally so is the question of whether Th-17 cells can be 
derived in vitro from CTCF deficient naïve CD4+ cells.  
 
 
CTCF and chromatin architecture 
 
The chromatin structure of the β-globin locus is regulated by CTCF (Splinter et 
al. 2006, this thesis). CTCF binding sites flank the locus and interact by looping out the 
intervening chromatin. In erythroid precursor cells, a transcriptionally poised but inactive 
structure is established (chromatin hub) (Palstra et al. 2003). Differentiation into globin 
expressing erythroid cells requires the incorporation of the globin genes into the hub via 
interactions between the LCR and gene promoters. Significantly, we have shown that 
CTCF-mediated ACH formation at the β-globin locus is not necessary for transcriptional 
activity. This raises the question of why this loop is formed and what is the purpose of it?  
ES cells carrying a targeted mutation of the 3’HS1 CTCF binding site could 
efficiently differentiate into erythroid progenitors (ES-EP), suggesting chromatin loops as 
defined and analysed in this study were not required for ensuring commitment to the 
erythroid lineage. Interestingly, GATA-1 expression was unaffected by the loss of CTCF 
in lenti-viral cre transfected fetal liver cells, indicating that GATA1 is not a target of 
CTCF. GATA1 in particular is necessary for erythroid differentiation from multi-potent 
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progenitor cells. The expression of GATA1 and other erythroid specific transcription 
factors such as EKLF were not analysed in ES-EPs. However deletion of 3’HS1 is known 
to have little effect on globin gene transcription (Strouboulis et al. 1992). Accordingly 
mutant ES-EPs did express globin and therefore must also express the required 
transcription factors. CTCF is not known to bind β-globin gene promoters, interact with or 
regulate GATA1, EKLF or other erythroid transcription factors. It would be of interest to 
analyse the capacity of CTCF deficient ES-cells to become ES-EPs and to measure the 
transcriptional activation of globin genes in conditionally deleted fetal liver cells. 
Importantly, LCR-gene contacts were retained in mutated ES-EPs indicating transcription 
factor recruitment is the main regulatory feature of this locus. This is consistent with the 
finding that EKLF was necessary for LCR-gene interactions (Drissen et al. 2004). How 
specific transcription factors are recruited to the β-globin locus is currently unclear. It was 
previously thought that establishment of chromatin loops would cluster regulatory regions 
close by in nuclear space, and that this clustering would attract transcription factor 
complexes. Our data suggest that the chromatin loops analysed in this study were not 
the determining factor. Additional flanking CTCF binding sites are predicted more 
external to –85 and 3’HS1 (Sleutels & vd Nobelen). It is possible that the main CTCF-
mediated regulatory loop of the β-globin locus has not yet been identified. Verification of 
CTCF binding at these external sites followed by mutational analysis will be required to 
ascertain the significance of potentially super-β-globin loops. 
Insulators are characterised by two separable functions; enhancer blocking and 
protection against chromatin position effects. The latter is CTCF-independent (Recillas-
Targa et al. 2002). The β-globin locus is embedded in a region of olfactory receptor 
genes (MOR). CTCF binding sites flanking the β-globin locus are thought to function as 
insulator sequences, preventing activation of MOR genes by the β-globin LCR. The lack 
of expression of the surrounding MOR genes in CTCF mutant cells indicate either 
additional sequences are required for enhancer (LCR)-blocking or the transcription factor 
environment in erythroid cells does not support MOR expression.  
The loss of CTCF binding from all β-globin target sites is accompanied by a 
local gain of di-meH3K9/27. It is not known if a DNA methylation gain also occurs. The 
change from H3 acetylation to repressive modifications is restricted to the CTCF binding 
site. No spreading of repressive chromatin modifications into the locus is observed. The 
association of CTCF with HAT complexes is not verified, and it is not clear why 
repressive histone modifications replace CTCF binding at this locus, as it has no impact 
on the transcriptional activity of β-globin genes.  
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GFP-CTCF knock-in mice; the dynamic behaviour of CTCF 
 
Studies mapping CTCF binding sites acknowledge the omission of repetitive 
sequences from the analysis. Consequently current data regarding CTCF binding site 
location and number does not fully represent all CTCF interaction sites and functions. 
Most analyses also use fixed chromatin material and therefore cannot accurately 
address the concentration of CTCF protein in terms of molecule number present in a 
given nucleus or give any information regarding dynamics of the CTCF protein. The 
generation of mice in which GFP is incorporated in-frame 5’ to the endogenous CTCF 
translation initiation site has circumvented many of the issues regarding fixed cells or 
chromatin. However this modification of CTCF strongly affects the survival of mice 
around birth. Increased incidences of wt mice are born, suggesting heterozygous GFP-
CTCF mice are developmentally impaired. In contrast to the complete CTCF knockout, 
GFP-CTCF homozygous embryos develop until a relatively late stage in embryogenesis. 
It is currently unclear why homozygosity of the GFP-CTCF fusion protein is detrimental 
to post-natal development; a detailed pathology of mice just before and after birth would 
be of great interest. 
The development of late-stage embryos permitted the isolation of MEFs for 
various analyses; proliferative capacity, the dynamic localisation of GFP-CTCF 
throughout the cell cycle and expression levels of GFP-CTCF. We show by western blot 
that the protein level of the GFP-modified allele is significantly lower than endogenous 
CTCF. Antibodies against CTCF were derived using the N-terminus domain. It is 
possible that the antibody used does not recognise GFP-CTCF as efficiently as a C-
terminus antibody might. Preliminary analysis of N- and C-terminus CTCF antibodies 
detecting COS-1 cells transiently transfected with GFP-CTCF and CTCF-GFP did not 
suggest either antibody detected the GFP-tagged protein with more or less efficiency. 
Furthermore, independent data reveals CTCF functions in a dose-dependent manner in 
T-cells in vivo. The effects of reduced GFP-CTCF protein levels also manifest as 
impeding the rate of cellular proliferation, which is affected in MEFs in a GFP-CTCF 
dose-dependent manner. Together these data imply that a critical amount of CTCF is 
necessary for development, but also suggests that the loss of CTCF binding to some 
sites – as is inevitable with decreased amounts of protein in the nucleus – is enough to 
impair but not block proliferation. It will be of interest to detect which binding sites retain 
CTCF in the homozygous GFP-CTCF cells. ChIP revealed GFP-CTCF binds to CTCF 
target sites within the β-globin locus in fetal liver cells. The expression of β-globin genes 
is not required for cellular proliferation. It is currently unknown if GFP-CTCF can still bind 
CTCF target sites in proliferation dependent gene loci such as c-myc.  
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A large fraction (~70 %) of GFP-CTCF is immobile as determined by FRAP 
analysis in the interphase nucleus, apparently remaining bound either to chromatin, the 
nuclear matrix or both. This is a particularly unusual feature for a transcription factor, and 
probably reflects the structural role of CTCF regarding chromatin organisation, although 
a minority mobile fraction (~30 %) of GFP-CTCF does exist. The functional distinction 
between these two pools of GFP-CTCF remains to be elucidated. It may reflect 
modifications of the CTCF protein. The treatment of GFP-CTCF cells with HDAC 
inhibitors (TSA) or transcriptional inhibitors (DRB) will be useful in understanding the 
regulation of CTCF dynamics within the nucleus.  
FRAP and FCS analyses of GFP-CTCF knock-in fibroblasts and ES-cells with 
GFP-CTCF rescue constructs both demonstrate similar dynamics and protein 
concentration within the nucleus. The concentration of GFP-CTCF as determined by 
FCS indicates there are approximately 200,000 CTCF molecules in a given nucleus. 
FCS software takes the presence of dimeric/multimeric complexes into account. When 
considering the dynamics of the protein, this equates to around 130,000 CTCF binding 
sites in the mouse genome. This is significantly more than current estimates (Vetchinova 
et al. 2006, Kim et al. 2007, Xie et al. 2007), but not necessarily an unrealistic figure 
considering there are ~22, 000 genes -averaging nearly 6 CTCF target sites per gene in 
the genome that may require regulation in one form or other by CTCF. Clear technical 
distinctions can be drawn between the current knowledge of numbers of CTCF binding 
sites and the data revealed in this thesis. The GFP-CTCF model is a direct in vivo 
analysis that is not susceptible to limiting conditions such as interpretation of arrays, 
antibodies or fixation techniques that may impede the detection of CTCF binding sites. 
Significantly, the GFP-CTCF model revealed for the first time the dynamics of the CTCF 
protein and the proportion of CTCF that is immobile compared to mobile. The fact that 
some CTCF molecules are not constitutively bound to chromatin further suggests the 
number of potential CTCF binding sites within the genome may be underestimated when 
using fixed cells. Current analyses of CTCF binding sites within the human genome have 
revealed ∼ 14 000 CTCF-associated insulator sequences (Kim et al. 2007). The data 
presented in this thesis suggests more insulator sequences exist than current estimates. 
Alternatively, CTCF binds a substantial number of sites that have no insulator function. 
 
An accumulation of CTCF at the nucleoli is observed by immunofluorescent 
analysis of CTCF in K562 cells (Torrano et al. 2005), however in primary GFP-CTCF 
MEFs or indirect immunofluorescence in primary cells, CTCF is absent from the 
nucleolus. This may highlight a difference between primary and transformed cell lines. 
Interestingly, CTCF is an interacting protein partner of two distinct nucleolar proteins, 
nucleophosmin and UBF (Yusufzai et al. 2004, S. vd Nobelen unpublished 
observations), although the functional significance of this is unknown and it remains to 
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be seen if CTCF mediates the shuttling of either of these factors between the nucleus 
and nucleoli.  Live imaging of GFP-CTCF ES cells showed that CTCF is indeed localized 
on mitotic chromosomes, as previously reported (Burke et al. 2005). However, we did not 
detect GFP-CTCF on centrosomes or the midbody (Zhang et al. 2004); this may be a 
special localization of CTCF in transformed cell lines in contrast to immortal non-
differentiated ES cells. The dynamic and specific localization of GFP-CTCF on mitotic 
chromosomes suggests CTCF is perhaps required for regulating the condensation of 
chromatin at mitosis, although mechanisms for this are unclear. Alternatively, CTCF 
interaction with mitotic chromosomes may function as an epigenetic mark, a mechanism 
of cellular memory. Interestingly, not all CTCF binding sites are occupied by CTCF 
during mitosis (Burke et al. 2005, Komura et al. 2007). It will be interesting to investigate 
if there is any correlation between the specific loci CTCF remains bound to.  Importantly, 
if CTCF is required for mitosis, the localization of GFP-CTCF on mitotic chromosomes 
raises questions of how T-cells can proliferate in the absence of CTCF. It would be of 
interest to analyse the dynamic distribution of GFP-CTCF in T-cells to confirm the same 
mitotic distribution is observed. Results presented in this thesis show a notable 
proportion of GFP-CTCF protein does not bind to mitotic chromosomes, but is retained 
and divided between the two daughter cells. The significance of this ‘free’ CTCF remains 
to be elucidated. 
We have used GFP-CTCF mice to analyse the expression pattern of CTCF 
during spermatogenesis by the live imaging of seminiferous tubules. Both male and 
female germ cells undergo the erasure and re-establishment of methylation marks. 
Loukinov et al proposed that during spermatogenesis, this stage coincided with a loss of 
CTCF expression and a concomitant up-regulation of the CTCF paralogue CTCF-L 
(BORIS) (Loukinov et al. 2002). Our live cell imaging does support this idea. We observe 
GFP-CTCF expression in all stages of spermatogenesis with the exception of mature 
spermatids, which have an altered compact chromatin structure consisting of 
protamines. The apparent conflict of data is most likely due to technicalities; indirect 
immunofluorescence of CTCF and BORIS was used to ascertain mutually exclusive 
patterns of expression in testis (Loukinov et al. 2002). GFP-CTCF imaging reflects the 
live in vivo dynamics of the protein and is not susceptible to fixation conditions or protein 
conformations. Importantly, studies by Szabo et al have eliminated the suggestion of a 
CTCF-BORIS reciprocal expression pattern in male and female germ cells to regulate 
methylation imprints (Szabo et al. 2004). Although global methylation in germ cells may 
still require BORIS, we suggest this does not happen independently of CTCF.  
 
It is clear that studies presented in this thesis have revealed more surprises and 
raised more questions than first anticipated. The generation of mice carrying conditional 
Ctcf alleles has allowed the first in vivo analysis of CTCF and is a very powerful model 
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for investigating the functional capacity of cells and cellular systems in the absence of 
CTCF. The precise function of CTCF remains elusive, and I do not agree with a single 
function existence. CTCF continues to present as a multi-faceted protein and the 
consequences of deletion as a function of the cell type, specific locus and stage in 
development investigated. The generation of GFP-CTCF knock in mice has been a 
useful model to approach the idea of function from a different perspective, and has 
presented novel insights to both the activity of CTCF and the expression levels of CTCF 
required to support development and proliferation. Several key processes can still occur 
in the absence of CTCF. Hence the data generated in these studies and presented in 
this thesis have enhanced our understanding of the complexities behind gene regulation 
and cellular survival and the contribution of CTCF in these areas. The data presented in 
this thesis demonstrate that the original characterization of CTCF as a transcription 
factor is valid, as long as we conclude transcription factors also have other functions 
within the nucleus. 
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Summary 
 
The genetic information used in each cell type is different. Differential gene 
expression generates cellular diversity and mediates the development of a multi-
cellular body. The molecular mechanisms behind this are of great interest. 
Substantial advances in the understanding of gene regulation and function have 
been made based on the approaches of analysing gene expression, knocking 
individual genes out in various model organisms and trying to ascertain functions 
based on the obtained phenotype, and by examining the localization and behaviour 
of proteins encoded by these genes. In doing this we have hoped to understand 
from the bottom-up fundamental components of aspects of multi cellular existence*. 
Spatial and temporal expression of genes is mediated co-ordinately by direct 
modifications of chromatin, modifications of the DNA and interaction of the DNA with 
numerous general and cell type specific proteins, some of which function to remodel 
the chromatin structure. I have described these processes in chapter 1. 
Ascertaining functions of genes (or the proteins they encode) becomes 
particularly problematic when genes are expressed in many different cells at 
different stages of an organism’s development, and deletion of such genes is 
detrimental to cell viability. This is the case for the Ctcf gene, which encodes an 11-
zinc-finger protein. CTCF binds DNA with a loose consensus and has multiple 
interaction partners. It was the first vertebrate protein identified to have enhancer 
blocking activity and was proposed to regulate the transition between 
transcriptionally active and repressed chromatin domains. CTCF is in fact a multi-
functional protein shown to regulate transcriptional activation, mediate histone 
modifications, chromatin looping in cis and chromosomal interactions in trans. The 
current knowledge regarding CTCF was detailed in chapter 2. 
To better understand the role of this protein in vivo, we have generated 
conditional Ctcf knockout mice in order to choose both the time during development 
and the specific cell type where deletion of the Ctcf gene occurs. Embryonic 
development in mice is severely impaired in the absence of CTCF, which precluded 
the analysis of a complete knockout of CTCF during late stages of development. 
However, by conditional deletion of the Ctcf gene we have been able to analyse the 
role of CTCF in hematopoietic tissues. The haematopoietic system consists of many 
different cell types, each with distinct functional capacities. Erythropoiesis and the 
development of T-lymphoid cells are well-characterised examples of cellular 
differentiation pathways that require tight regulation of sequential proliferation and 
differentiation. These aspects were discussed in chapter 3. 
                                                 
* From The Music of Life; Biology Beyond the Genome. Noble, D. Oxford University Press, 2006. 
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The transcription of β-globin genes is restricted to erythroid cells. Previous 
studies have revealed that the chromatin structure of the β-globin locus in mice is 
organised into a chromatin hub in erythroid precursor cells. Activation of β-globin 
genes occurs via the recruitment of specific transcription factors and contacts 
between the Locus Control Region (LCR) and genes that are mediated by chromatin 
looping. We have demonstrated that the chromatin configuration of the mouse β-
globin locus is dependent on CTCF-mediated clustering of DNA hypersensitive sites 
that flank this locus. The binding of CTCF to the β-globin locus also prevents the 
gain of repressive histone modifications to CTCF binding sites. The significance of 
defined chromatin domains and looping however is brought into question as we 
show β-globin gene transcription occurs in the absence of a normal ACH formation. 
The results of this study were presented in chapter 4. 
When CTCF protein levels are specifically depleted in T-cells, we show that 
the expansion of T-cells within the thymus is very sensitive to the level of CTCF. In 
the absence of CTCF, T-cell differentiation in the thymus is impaired and an 
accumulation of ISP cells occurs. CD4+ cells leaving the thymus do differentiate into 
effector T-helper cells in the periphery. However, when tested for their efficacy, Th2 
cells are completely incompetent to mediate an allergic response. T-helper cells 
express characteristic cytokine genes that are arranged in a chromatin configuration 
similar to the β-globin ACH. Our studies indicate that despite the presence of key 
regulatory proteins such as GATA3 and SatB1, transcriptional activation of cytokine 
genes is impaired in the absence of CTCF. We also show that the activation of T-
cells in vitro via signals through the T cell receptor require CTCF. Interestingly, in the 
presence of the calcium ionophore ionomycin CTCF-deficient cells can divide, 
indicating that CTCF is not necessarily required for cell proliferation. The data were 
detailed in chapter 5. 
In chapter 6, I have described the generation and analysis of a GFP-CTCF 
knock-in allele. This allele allowed analysis of the localisation and activity of the 
CTCF protein in vivo. A previous publication indicated that a window of CTCF-
negative germ cells occurs during spermatogenesis. Our data actually show that 
CTCF is ubiquitously expressed during spermatogenesis, with the exception of 
spermatids when DNA is further compacted. We used intact seminiferous tubules 
from the GFP-CTCF knock-in mice, mouse embryonic fibroblasts (MEFs) from GFP-
CTCF knock-in embryos, and embryonic stem (ES) cells expressing CTCF tagged 
with GFP, to study the dynamics of the CTCF protein. This data revealed two distinct 
dynamic populations of CTCF within the nucleus and suggest that the number of 
binding sites for CTCF in mice exceeds current predictions. 
The studies addressed in this thesis have provided novel insight into the 
significance of CTCF acting in different cells and differentiation pathways. I have 
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discussed the findings of our experiments and their significance with regard to 
published observations of CTCF function in the final chapter 7. Two conclusions 
stand out, namely that CTCF is not absolutely required for T cell proliferation (see 
chapter 5), and that the protein is only essential for some cell-specific and perhaps 
locus-specific programs (chapters 4 and 5). Given the ubiquitous expression of 
CTCF and its presumed essential role, these findings are surprising and warrant 
further detailed analysis. 
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Samenvatting 
 
Alhoewel vrijwel elke cel in ons lichaam precies dezelfde genetische 
informatie bevat, wordt die per celtype verschillend afgelezen. Deze verschillen in 
genexpressie patronen zijn mede verantwoordelijk voor de diversiteit in cel typen. 
Het is belangrijk om uit te vinden wat nu de onderliggende moleculaire 
mechanismen zijn. Er is goede vooruitgang geboekt in ons begrip over hoe genen 
gereguleerd worden en wat hun functie is door te kijken naar: (1) gen expressie 
patronen; (2) door genen te inactiveren in verschillende model organismen en door 
gen functie te destilleren op basis van waargenomen fenotypen; (3) door de 
intracellulaire distributie en het gedrag te bestuderen van eiwitten die door de 
desbetreffende genen worden gecodeerd. Door dit soort studies hoopten we de 
meest fundamentele componenten van het multi-cellulaire bestaan te isoleren en te 
begrijpen. 
 Een functionele analyse van een gen in een organisme (ofwel van het eiwit 
gecodeerd door dat gen) wordt bemoeilijkt als het gen in kwestie in veel cellen en in 
een groot aantal stadia van de ontwkkeling van het organisme tot expressie komt en 
als inactiverig van het gen al vroeg in de ontwikkeling zware afwijkingen tot gevolg 
heeft. Dit is het geval voor het Ctcf gen, wat codeert voor een eiwit met 11 zink 
vingers. CTCF bindt verschillende DNA sequenties en heeft meerdere interactie 
partners. CTCF was het eerste eiwit in vertebraten waarvan is aangetoond dat het 
de activiteit van een enhancer op een promoter kan blokkeren. Het eiwit lijkt ook 
betrokken te zijn bij het scheiden van actief transcriberende chromatine domeinen 
van inactieve domeinen. Vandaar dat CTCF een “enhancer-blocker” en “insulator” 
wordt genoemd. CTCF is feitelijk een multifunctioneel eiwit betrokken bij transcriptie 
activatie, histon modificaties, de vorming van intrachromosomale chromatine lussen, 
maar ook bij interchromosomale interacties. De huidige kennis omtrent CTCF heb ik 
beschreven in hoofdstuk 2. 
 Om de in vivo rol van CTCF beter te begrijpen hebben we zogenaamde 
conditionele Ctcf “knockout” muizen gemaakt. Zo konden we zelf de tijd van, en het 
cel type waarin, Ctcf deletie plaatsvond in het zich ontwikkelende organisme 
bepalen. We hebben laten zien dat de embryonale ontwikkeling van muizen zwaar is 
aangedaan in de afwezigheid van CTCF. Dit maakte de analyse van volwassen 
muizen waarin CTCF afwezig is in alle cellen onmogelijk. We konden daarentegen 
wel de rol van CTCF bestuderen in het hematopoietische (bloedvormend) systeem. 
Dit bestaat uit veel verschillende celtypen, met een specifieke functie voor elk type 
cel. Erythropoiese en T-cel lymphopoiese zijn goed gekarakteriseerde voorbeelden 
van cel differentiatie routes waarin strikt gereguleerde, elkaar opvolgende stappen 
van proliferatie en differentiatie uiteindelijke zorgen voor, respectievelijk, een 
volwassen rode bloedcel en een T cel. Deze processen zijn beschreven in hoofdstuk 
3. 
De transcriptie van de β-globine genen vindt alleen plaats in rode 
bloedcellen. Eerdere studies hebben laten zien dat al in de erythroïde voorlopers het 
chromatine in het β-globine locus georganiseerd is in een specifieke structuur van 
lussen en knopen die een “chromatin hub” wordt genoemd. De activering van de β-
globine genen gebeurt doordat specifieke transcriptie factoren worden aangetrokken 
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en doordat er intensieve contacten komen tussen het Locus Control Region (LCR) 
en de β-globine genen zelf. Dit alles wordt gecoördineert via de “chromatin hub”. Wij 
hebben laten zien dat de chromatine structuur van het β-globine locus afhankelijk is 
van CTCF en dat dit eiwit essentieel is voor de vorming van contacten tussen 
DNAse gevoelige gebieden aan beide kanten van het β-globine locus. CTCF binding 
in het β-globine locus voorkomt ook dat histonen gemodificeerd worden op een 
manier die karakteristiek is voor inactief chromatine. Een verrassend resultaat was 
dat ondanks de duidelijke rol van CTCF in deze processen de transcriptie van de β-
globine genen niet significant verminderd in de afwezigheid van een CTCF 
bindingsplaats. Dit werpt de vraag op wat nu de functie is van de “chromatin hub” in 
het β-globine locus. De resultaten van deze studies staan beschreven in hoofdstk 4. 
Als we het Ctcf gen specifiek inactiveren in T cellen van het 
immuunsysteem laten we zien dat deze cellen erg gevoelig zijn voor vermindering 
van de niveaus van dit eiwit. In afwezigheid van CTCF is de differentiatie van T 
cellen in de thymus geblokkeerd en stapelen de zogenaamde ISP cellen zich op. 
CD4-positieve T cellen kunnen de thymus verlaten en verder differentiëren naar 
zogenaamde T-helper of –effektor cellen. Wanneer deze cellen echter getest 
worden op hun effectiviteit dan blijkt dat in ieder geval de T helper 2 (Th2) cellen niet 
in staat zijn om een adequate afweer op te bouwen. Th2 cellen expresseren een 
specifieke set van cytokines, waarvan de coderende genen in een gebied liggen die 
een chromatine conformatie heeft die veel lijkt op die van het globine locus. Onze 
resultaten laten zien dat ondanks de aanweigheid van belangrijke T cel transcriptie 
factoren als GATA3 en SATB1 de activering van de cytokine genen in afwezigheid 
van CTCF geremd is. We laten ook zien dat gekweekte T cellen CTCF nodig 
hebben om een goede signaal transductie cascade vanaf de T cel receptor op te 
zetten. Een interessant resultaat is dat in aanwezigheid van ionomycine (een 
calcium ionofoor) cellen kunnen delen in afwezigheid van CTCF, wat aantoont dat 
CTCF niet perse nodig is voor cel proliferatie. Deze resultaten heb ik beschreven in 
hoofdstuk 5. 
In hoofdstuk 6 heb ik de analyse beschreven van ons zogenaamde GFP-
CTCF “knock-in” allel. In plaats van CTCF wordt van dit allel het fusie eiwit GFP-
CTCF afgeschreven, waardoor we het dynamische gedrag van CTCF in vivo kunnen 
bestuderen. Voorgaande publicaties suggereren dat er gedurende de 
spermatogenese een periode is dat CTCF niet in mannelijke kiemcellen voorkomt. 
Onze data laten zien dat dit niet waar is en dat CTCF in alle cellen van de testis 
tubuli tot expressie komt behalve in spermatiden: kiemcellen waarin het DNA nog 
verder samengebundeld wordt. We hebben intacte testis tubuli van de GFP-CTCF 
“knock-in” muizen, embryonale fibroblasten van dezelfde muizen, alsmede 
embryonale stem cellen die GFP-CTCF expresseren in plaats van CTCF allemaal 
gebruikt om het dynamische gedrag van CTCF te bestuderen. Het blijkt dat dit eiwit 
in twee fracties voorkomt, een kleine mobiele populatie en een gote immobiele 
populatie. Onze resultaten suggereren dat het aantal gepubliceerde 
bindingsplaatsen voor CTCF veel minder is dan het aantal CTCF moleculen dat 
aanwezig is in een kern. 
 De studies die in dit proefschrift zijn beschreven hebben tot een nieuw 
inzicht geleid omtrent de functie van CTCF in verschillende cel typen en 
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differentiatie routes. In het laatste hoofdstuk (7) heb ik onze resultaten vergeleken 
met die van een groot aantal publicaties over CTCF. Voor wat betreft ons werk 
noem ik nogmaals twee resultaten, namelijk dat CTCF niet echt nodig is voor cel 
proliferatie (zie hoofdstuk 5) en dat het eiwit soms wel en soms niet noodzakelijk is 
voor cel-specifieke en locus-specifeke transcriptie programma’s (zie hoofdstukken 4 
en 5). Gegeven de expressie van CTCF in vrijwel alle cellen van de muis en de 
gedachte dat dit geconserveerde eiwit essentieel is, zijn dit verrassende resultaten 
die verdere studie naar dit eiwit noodzakelijk maken. 
 
Vertaling: N. Galjart 
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